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ABSTRACT
Molecules existing in the extracellular space (ECS) make up a complicated
network of structural proteins, signaling molecules, cellular adhesion molecules and
transmembrane receptors. Many ECS molecules are implicated as active regulators of
structural and functional brain plasticity. When molecules in the ECS are improperly
expressed or degraded, cellular communication becomes disrupted and can lead to a
variety of disease pathologies. Thus, there are myriad overlapping regulatory
mechanisms that determine and maintain the composition of the ECS. Research
investigating extracellular molecule expression in the brain identified that some exhibit
cyclic, near 24-hour rhythms and may be under circadian control. Further, extracellular
molecules are hypothesized to help perpetuate the oscillations of the mammalian master
clock located in the suprachiasmatic nucleus (SCN). Our goal was to expand upon past
findings in our laboratory that implicate a pivotal role of extracellular proteases, namely
those in the plasminogen activation cascade, in gating glutamate-induced phase shifts.
Two proteases activated by this cascade are matrix metalloproteinase-2 and -9 (MMP2/9). Across the brain, MMP-2/9 catalytically cleave extracellular scaffolding molecules
like β-dystroglycan in response to increased neuronal activity. MMP-2/9-mediated
degradation of extracellular molecules is also known to facilitate changes in neuronal and
astrocytic morphology and alter N-methyl-D-aspartate receptor (NMDAR) activity.
Interestingly, a previous study of MMP-2/9 in the hamster SCN found that MMP-9 activity
exhibits a diurnal rhythm in activity, while MMP-2 does not. For this project, we aimed to
elucidate the role of MMP-2/9 by further characterizing their expression and activity in
mouse SCN tissue. We found that MMP-2/9 activity is highest during the day and that
inhibiting their activity phase shifts neuronal activity rhythms in a time dependent manner.
Further, we sought to better understand physiologic consequences of MMP-2/9 mediated
cleavage of β-dystroglycan in regulating astrocytic diurnal morphologic rhythms. We
confirmed that astrocyte morphology exhibits a day to night transition toward a highly
ramified state. Although β-dystroglycan expression is constitutive across the day and
potentially interacts with SCN astrocytes, their degradation does not appear to be
regulated by MMP-2/9 activity.
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CHAPTER I: INTRODUCTION
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The mammalian master clock regulates circadian rhythms
Nearly every organism on earth exhibits daily cycles in behavior, physiology and
metabolism. These iterative, near 24-hr patterns are called circadian (Latin;
circa=approximate, diem=day) rhythms. Examples of these rhythms in mammals include
melatonin secretion, blood pressure, body temperature and sleep-wake cycles (Refinetti
& Menaker, 1992; Schulz & Steimer, 2009; Albrecht, 2012; Bollinger & Schibler, 2014).
In mammals, the master clock is located in a brain region called the suprachiasmatic
nucleus (SCN). The SCN is a bilateral nucleus in the ventral hypothalamus that consists
of about 20,000 neurons (Van den Pol, 1980; Reiter, 1991; Moore, 1995; 2007). Not only
does this region generate endogenous circadian rhythms, but it also integrates “time of
day” information and communicates these signals to the rest of the brain to synchronize
peripheral clocks with the daily light cycle (Moore & Eichler, 1972; Stephan & Zucker,
1972).
Proper maintenance and synchronization of circadian rhythms is important for
maintaining a healthy lifestyle. However, our modern society sometimes exposes
individuals to artificial light at night or demands travel across time zones. In these cases,
our circadian rhythms experience a disruption, or phase shift, in their oscillatory patterns
(Rajaratnam & Arendt, 2001; Touitou et al., 2017). Acute phase shifting can result in
health consequences such as fatigue, jet-lag and/or increased inflammation as our bodies
entrain to the new light cycle (Scheer et al., 2009; Castanon-Cervantes et al., 2010). On
the other hand, chronic circadian rhythm disruption leads to detrimental conditions such
as depression (Lall et al., 2012; LeGates et al., 2012; Obayashi et al., 2018), shift-work
disorder (resulting from working on-call, rotating, or extended overnight shifts) (Sack et
al., 2007), metabolic disorder (Scheer et al., 2009), increased risk for neurodegenerative
diseases like Alzheimer’s Disease (Reisberg et al., 1987; Witting et al., 1990; Wulff et al.,
2010; Hastings & Goedert, 2013) or for certain cancers (Filipski et al., 2005; Costa, 2010).
In practice, clinicians can perform circadian rhythm evaluations (also called
“chronotyping”) and prescribe circadian alignment practices, like appropriate sleep
scheduling or medication to help “reset” their patient’s clocks and improve health
outcomes. (Arendt et al., 1997; Morgenthaler et al., 2007; Sack et al., 2007; SánchezBarceló et al., 2010; Bubenik & Konturek, 2011; Adan et al., 2012). Thus, understanding
2

the underlying mechanisms of the mammalian circadian clock and how it adapts to
changes in the light cycle is imperative for maximizing human health.
Studies investigating the mechanisms that underlie circadian rhythm generation
show that lesions of SCN or retinohypothalamic tract (RHT) neurons disrupt an
organism’s behavioral and physiologic rhythms (Moore & Eichler, 1972; Moore & Klein,
1974; Morin & Cummings, 1981; Moore, 1995). Remarkably, transplantation of embryonic
SCN tissue into the third ventricle, dorsal to the ablated region, restores behavioral
rhythms in SCN lesioned mammals (Drucker-Colín et al., 1984; Sawaki et al., 1984;
DeCoursey & Buggy, 1989; Aguilar-Roblero et al., 1994; Tousson & Meissl, 2004).
Certain hormonal cycles (i.e. rhythmic secretion of cortisol, adrenal hormone, and
melatonin), however, are not restored by embryonic SCN implantation (Meyer-Bernstein
et al., 1999). Although donor SCN tissue continues to produce rhythms in metabolic and
electrical activity (Aguilar-Roblero et al., 1992), transplanted embryonic tissue
encapsulated in permeable acrylic polymer tubes only restores behavioral rhythms
(Lehman et al., 1995). These studies indicate that the SCN sends efferent entrainment
signals via two distinct methods: by secretion of diffusible factors (Egli et al., 2004) and
electrically by axonal projections to regions specific for neuroendocrine function, such as
the anterior hypothalamus and the anteroventral periventricular nucleus (Watts et al.,
1987; Watson et al., 1995). Collectively, these data support that the SCN uses both
electrical and chemical outputs to synchronize behavioral and physiologic circadian
rhythms.
The molecular master clock is a transcriptional-translational feedback loop
The core molecular clock mechanism in the SCN and in peripheral oscillators is a
transcriptional-translational feedback loop (TTFL). Study of mutant mouse and drosophila
strains exhibiting longer, shorter or arrhythmic free-running periods helped identify the
core clock genes: period (per), cryptochrome (cry, or timeless in Drosophila), clock
(circadian locomotor output cycles kaput) and Bmal1 (brain and muscle ARNT-like protein
1) (Vitaterna et al., 1994; Allada et al., 1998; Emery et al., 1998; Vitaterna et al., 1999;
Reppert & Weaver, 2002; Ko & Takahashi, 2006). These genes encode for a group of
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proteins that together form the TTFL, and their proper expression and function drives
circadian rhythm generation (Antoch et al., 1997; Dunlap, 1999; Yamazaki et al., 2000).
At the cellular level, the TTFL proteins CLOCK and BMAL1 first form a heterodimer
in the cytoplasm. After entering the nucleus, the heterodimer binds to DNA sequences
(called E-Boxes) upstream of a variety of genes, including per and cry, and acts as a
transcriptional activator (Gekakis et al., 1998). Increased transcription and subsequent
translation lead to PER and CRY accumulation in the cytoplasm. PER and CRY proteins
also form heterodimers and are transported back into the nucleus where they repress
CLOCK/BMAL1 activity (Curtin et al., 1995; Shafer et al., 2002), which inhibits their own
transcription. Over time, the remaining PER and CRY are ubiquinated and degraded. The
decrease in PER and CRY levels reduces CLOCK/BMAL1 inhibition and the entire TTFL
starts again (Price et al., 1995; Darlington et al., 1998; Sangoram et al., 1998).
CLOCK/BMAL1 binding to DNA also drives expression of the nuclear receptors REVERBα and RORα, which form a secondary negative feedback loop to cyclically suppress
expression of Bmal1 (Preitner et al., 2002; Cho et al., 2012). Transcriptomic studies
estimate that endogenous oscillation of the TTFL loop in SCN and somatic tissues (i.e.,
liver, lung, kidney, etc.) results in cyclic expression of 10%-20% of the genome (Akhtar et
al., 2002; Panda et al., 2002; Reddy et al., 2006; Pizarro et al., 2013). The largest
proportion of these genes encode for transcription factors, cell-cycle and proliferationpromoting proteins (Kondratov & Antoch, 2007). Evidence in rats indicates that light
pulses administered at night phase-shift TTFL gene expression in the SCN more rapidly
than locomotor or peripheral rhythms (Field et al., 2000; Yamazaki et al., 2000; Maywood
et al., 2013), demonstrating that the TTFL in the master clock responds to environmental
stimuli first and then drives synchronization of peripheral clocks (Takahashi et al., 2008).
As mentioned above, the SCN communicates time of day signals to the rest of the
brain electrically. Neurons in the SCN exhibit endogenous, spontaneous action potentials
that peaks in rate during the middle of the day as opposed to during the night. This rhythm
can be detected using both in vivo and in vitro electrophysiological techniques (Inouye &
Kawamura, 1979; Green & Gillette, 1982; Groos & Hendriks, 1982; Gillette & Prosser,
1988; Prosser & Gillette, 1989; Gillette, 1991; Yamazaki et al., 1998; Schaap & Meijer,
2001; Lundkvist et al., 2002; van Oosterhout et al., 2012). When the SCN is removed
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from wild-type mammals and maintained in vitro, its neurons continue to exhibit
persistent, robust rhythms in molecular and neuronal activity (Gillette & Prosser, 1988;
Jiang et al., 1997). In fact, Yamazaki and Takahashi found that cultured organotypic slices
expressing Per2:luc (a genetic knock-in of the luciferase protein fused to the C-terminus
of the Per2 gene) can produce luminescence rhythms for up to 478 days (Yamazaki &
Takahashi, 2005).

Combined in vivo and in vitro studies demonstrate that proper

expression of TTFL elements is necessary to generate and maintain SCN circadian
neuronal activity rhythms (Inouye & Kawamura, 1979; Rusak & Zucker, 1979; Watanabe
et al., 1995; Lundkvist et al., 2002; Kudo et al., 2015). For example, the clock gene
mutation lengthens the period of behavioral wheel running in mice and desynchronizes
SCN neuronal electrical rhythms (Herzog et al., 1998).
Physiologically, the TTFL drives rhythmic expression of ion channels, which help
maintain SCN neuronal activity oscillations (Ko et al., 2009; Allen et al., 2017). For
example, evidence in rat SCN shows that the neuronal Na +/K+-ATPase ion-pump, which
regulates the resting membrane potential, exhibits a daytime peak in protein expression
and activity as compared to the night (Wang & Huang, 2004). The gene Kcnma1, which
encodes for a Ca2+ activated K+ channel (also called large conductance potassium
channels) subunit, is highly transcribed during the night (Panda et al., 2002). Genes
encoding for L-Type and T-type Ca2+ channels are also expressed rhythmically (Panda et
al., 2002; Nahm et al., 2005). As a result, electrophysiologic properties like membrane
potential, input resistance and holding current are under the influence of clock genes and
ultimately lead to an SCN that is more depolarized during the day than during the night
(Jiang et al., 1997; de Jeu et al., 1998; Colwell, 2011). From this, we can infer that
alterations in the electrophysiologic rhythms in SCN tissue slices and cultures may signal
that the underlying TTFL is disrupted.
Signaling molecules and peptides in the SCN
The heterogeneous population of SCN neurons contains a variety of
neurotransmitters (Pennartz et al., 1998) and produces both inhibitory and excitatory
signals (Jiang et al., 1997). The majority of SCN neurons express the neurotransmitter γaminobutyric acid (GABA) (Moore & Speh, 1993), which peaks in abundance during the
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night. Animals in constant darkness continue to exhibit a rhythm in GABA expression,
which indicates GABA expression in the SCN is controlled by the circadian clock (AguilarRoblero et al., 1993; van den Pol, 1993). Interestingly, the effect of GABA can be either
inhibitory or excitatory. In rat and mouse SCN tissue, GABA application predominantly
leads to neuronal inhibition at night and excitation during the day (Wagner et al., 1997;
Liu & Reppert, 2000). An experiment by Lundkvist et. al (2000) investigated GABA
signaling using whole-cell patch clamp recordings in rat SCN slices in vitro and found that
spontaneous inhibitory postsynaptic activity was not rhythmic, but appeared to be
regulated

by

glutamate-mediated

activation

of

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid receptors (AMPARs) (Lundkvist et al., 2002). Studies focusing on
downstream GABA-ergic molecular signaling mechanisms are currently ongoing
(Moldavan et al., 2017; Walton et al., 2017; McNeill et al., 2018; van der Vinne et al.,
2018; Ono et al., 2019) and excellent reviews (Albers et al., 2017; Ono et al., 2018)
highlight the recent work in understanding GABA’s role in the SCN.
Two additional major neurotransmitters expressed by the SCN are arginine
vasopressin (AVP) and vasoactive intestinal peptide (VIP). Expression of these two
peptides helps define subdivisions within the SCN: neurons in the ventral “core” region
express VIP, while neurons in the dorsal “shell” region express AVP. Functionally, the
core receives retinal input from the RHT and intergeniculate leaflet and sends efferent
projections to the shell. The shell receives inputs from the limbic system, hypothalamus
and brainstem and sends projections to brain areas like the forebrain, thalamus and
hypothalamus (Moore, 1995; Moga & Moore, 1996; 1997; Abrahamson & Moore, 2001).
While mice and rats deficient in AVP display decreased amplitudes in activity or sleep
rhythms, genetic knockout mice lacking VIP or it’s complimentary receptor are completely
arrhythmic, implicating VIP as more responsible than AVP in maintaining circadian
rhythms (Brown & Nunez, 1989; Harmar et al., 2002; Colwell et al., 2003; Aton & Herzog,
2005; Maywood et al., 2006; Brown et al., 2007; Dragich et al., 2010; Mieda, 2019).
Consistent with this, optogenetic studies recently demonstrated that specific stimulation
of VIP expressing neurons entrains behavioral activity rhythms in mice (Mazuski et al.,
2018). Readers interested in a more extensive discussion of the intertwined role of AVP
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and VIP molecular signaling in the SCN are directed to the following reviews: (Welsh et
al., 2010; Colwell, 2011; Hastings et al., 2014).
The heterogeneity of SCN signaling molecules is even more complex, as a variety
of amino acids, neurotransmitters, and small peptides exhibit rhythmic expression as well.
For example, a microdialysis experiment measuring hamster SCN neuron exudate across
the day saw that the amino acids glutamate, glutamine, and aspartate display peak
abundance during the night (Rea et al., 1993b). GABA and serotonin also exhibit peak
expression during the night in SCN tissue (Aguilar-Roblero et al., 1993; Rea et al., 1993b).
Recently,

a

study

that

combined

microdissection

of

the

SCN

and

liquid

chromatography/tandem mass spectrometry detected 18 amino acids and identified ten
(including proline, histidine and lysine) that exhibit peak expression during the day (Fustin
et al., 2017). Utilization of mass spectrometry also led to identification of known and novel
small peptides (i.e., gastrin releasing peptide, little SAAS, and VIP) that are diurnally
expressed in SCN tissue (Hatcher et al., 2008; Lee et al., 2010; Southey et al., 2014;
Atkins et al., 2018). Characterizing the circadian profile and localization pattern of SCN
signaling molecules helps us understand which signals may be important for the
maintenance of endogenous and peripheral circadian rhythms. This information is also
necessary to understand which signals drive synchronization of the SCN to the
environment.
Light-induced glutamate release synchronizes the clock
Daily entrainment cues to the circadian clock are called Zeitgebers (which is
German for “time giver”, first coined by Jürgen Aschoff). Non-photic signals to the central
clock, like restricted locomotor activity or feeding time, are sufficient to entrain an
organism to a particular time schedule (Mistlberger, 1994; Mrosovsky, 1996), but daily
photic cues are by far the most powerful entrainment signal to the circadian clock (Rea,
1998; Meijer & Schwartz, 2003; Novak et al., 2008; Colwell, 2011; Fonken & Nelson,
2014). Mechanistically, light stimulates melanopsin-expressing retinal ganglion cells in
the eye, which send axonal projections through the RHT that terminate in the SCN (Moore
& Lenn, 1972; Pickard, 1985; Johnson et al., 1988; Morin et al., 1992; Morin et al., 1994;
Moore, 1995; Morin et al., 2003; Hattar et al., 2006). Electrical or light stimulation of the
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RHT results in pre-synaptic release of both glutamate and pituitary adenylate cyclaseactivating polypeptide (PACAP) into the ventrolateral core of the SCN (van den Pol, 1991;
Castel et al., 1993; de Vries et al., 1993; Shirakawa & Moore, 1994; Berson et al., 2002;
Hannibal, 2002; Warren et al., 2003; Tu et al., 2005). This increases the spontaneous
action potential rates of neurons up to 20 Hz (Meijer et al., 1998; Aggelopoulos & Meissl,
2000; Drouyer et al., 2007; Golombek & Rosenstein, 2010) and ultimately synchronizes
spontaneous neuronal activity rhythms to the light cycle.
In vitro, early- or late-night glutamate application to SCN tissue slices produces an
approximate 3 hour phase-delay or -advance, respectively (Ding et al., 1994; Shirakawa
& Moore, 1994; Gillette & Mitchell, 2002). Similarly, PACAP application to hamster SCN
slices or direct injection to the SCN results in photic-like phase shifts (Harrington et al.,
1999). Moreover, PACAP application during the day phase-advances the SCN clock, a
time when glutamate and light have no effect (Hannibal et al., 1998; Chen et al., 1999;
Gillette & Mitchell, 2002; Beaule et al., 2009). This suggests that the circadian clock’s
response to light is both time of day dependent and reliant on crosstalk between
glutamate and PACAP signaling pathways. Work continues to investigate downstream
PACAP signaling mechanisms (Dragich et al., 2010; Webb et al., 2013; Hannibal et al.,
2017), but we are more interested in further understanding glutamatergic signaling
mechanisms in the SCN.
The SCN expresses a variety of glutamate receptors, including AMPARs,
metabotropic glutamate receptors (mGluRs) and N-methyl-D-aspartate receptors
(NMDARs). Although AMPARs and mGluRs are involved in the balance of inhibitory and
excitatory intracellular communication in the SCN, NMDAR signaling is most responsible
for regulating light- and glutamate-induced phase shifts. Application of NMDA induces
glutamate-like phase shifts (Hamada et al., 1998; Mintz et al., 1999). Additionally, both in
vivo light pulses at night (Colwell et al., 1991; Vindlacheruvu et al., 1992; Mintz & Albers,
1997) and in vitro glutamate application to SCN slices induce phase shifts that are blocked
by NMDAR antagonist co-application (Colwell & Menaker, 1992; Ding et al., 1994;
Shibata et al., 1994). This suggests that the phase shifting effects of light at night rely on
NMDAR activation. Together, these studies highlight the importance of studying
downstream mechanisms occurring after NMDAR activation in the SCN.
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NMDARs are ionotropic, hetero-tetrameric transmembrane receptors that are
permeable to Na+, K+, and Ca2+. NMDAR-dependent intracellular signaling pathways in
the SCN are thought to relay time-of-day information to the TTFL via transient influx of
extracellular Ca2+ (van den Pol et al., 1992; Brancaccio et al., 2013). Molecularly,
increases in intracellular Ca2+ activate a protein kinase cascade that converges to initiate
gene transcription. Briefly, Ca2+ binds to and activates calmodulin, which in turn activates
calcium/calmodulin-dependent kinase CAMKII via phosphorylation of the Thr286 residue
(Agostino et al., 2004). CAMKII then activates the mitogen-activated protein kinase
(MAPK) cascade (Akashi & Nishida, 2000) and leads to activation of cAMP response
element binding protein (CREB) via phosphorylation of Ser133 and Ser 142 (Ginty et al.,
1993; Ding et al., 1997; von Gall et al., 1998; Yokota et al., 2001; Gau et al., 2002). CREB
is a transcriptional regulator that binds to DNA sequences (called CRE-elements) to
stimulate immediate-early gene (Hastings et al., 1995) and clock gene transcription
(Yokota et al., 2001; Tischkau et al., 2003). Thus, application of NMDA to SCN cells
results in MAPK and CAMKII activation, phosphorylation of CREB, and induction of the
immediate early gene c-fos (Vindlacheruvu et al., 1992), which ultimately phase-shifts
SCN circadian clock gene expression (Tamaru et al., 2000).
Rhythmic properties of SCN astrocytes
Contributing to the complexity of cellular communication in the SCN, astrocytic
signaling is as vital to the SCN circadian clock as neuronal signaling. Extracellular
electrophysiology recordings of SCN slices treated with a glial metabolism inhibitor
(fluorocitrate) produced ultradian rhythms in neuronal activity the day after drug treatment,
demonstrating a role for astrocytes in generating circadian rhythms in the SCN (Prosser
et al., 1994). In the SCN, astrocytes display multiple rhythms that persist in slice culture
and are required for circadian rhythm synchronization. For example, expression of the
astrocyte-specific transporter excitatory amino acid transporter-1 (EAAT1) is rhythmic
and peaks the early morning. The EAAT1 expression rhythm is lost in Per2 mutant mice,
which suggests that astrocytic uptake of extracellular glutamate is under circadian control
(Spanagel et al., 2005). Other astrocyte-specific rhythms include cycles in metabolism,
cytoplasmic Ca2+ concentration, glutamate release and adenosine triphosphate (ATP)
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release (van den Pol et al., 1992; Womac et al., 2009; Burkeen et al., 2011; Marpegan et
al., 2011; Brancaccio et al., 2013).
Recent work shows that both astrocytic intracellular Ca2+ concentration and
glutamate release oscillate with ~ 24-hour periods that peak during the night and are out
of phase with neuronal activity rhythms (Brancaccio et al., 2013; Brancaccio et al., 2017).
Later studies found that SCN astrocyte-specific Bmal1 deletion or removal of CK1ε tau (a
genetic mutation that shortens the period of behavioral locomotor rhythms) lengthens the
period of wheel running behavior in mice (Barca-Mayo et al., 2017). Further, Brancaccio
et. al (2019) found that transfection of SCN slices obtained from CRY1/2-null mice with
an adeno-associated virus (AAV) that initiates astrocyte-specific expression of CRY1
restores rhythms in astrocytic glutamate release and behavioral activity. Thus,
endogenous rhythms generated by astrocytes are necessary to maintain SCN and
organismal circadian rhythms.
An important characteristic of astrocytes is that the extent and efficiency of their
communication depends on their proximity to each other and to neuronal synapses.
Therefore, changes in astrocytic morphology (for example, in response to increased
neuronal activation, injury, or as a result of neurological disease) can disrupt intercellular
communication (Theodosis et al., 2004; Theodosis et al., 2008; Cheng et al., 2019; Zhou
et al., 2019). In the hamster SCN, cells containing glial fibrillary acidic protein (GFAP), an
astrocyte-specific cytoskeletal protein, are more ramified (a more complex morphological
phenotype as compared to cells with an amoeboid shape) during the night than during
the day (Lavialle & Serviere, 1993). Subsequent ultrastructural analysis of astrocytes in
the SCN determined that astrocytic filopodial insertion into the synaptic space is rhythmic
(Becquet et al., 2008). This rhythmic synaptic insertion is cell-type specific, as dendrites
of VIP neurons interface with glial appositions more at night [Zeitgeber time (ZT) 18],
while the highest coverage of AVP dendrites occurs during the day (ZT 2) (Girardet et al.,
2010). Diurnal variation in glial coverage of VIP neurons is eliminated when mice are
treated with a tyrosine receptor kinase-B (TrkB) inhibitor, 1NaPP1, suggesting the
involvement of brain derived neurotrophic factor [(BDNF); a synaptic plasticity protein that
is the ligand for TrkB)], in regulating astrocyte morphology in the SCN (Girardet et al.,
2013). Astrocyte-specific Bmal1 deletion increases gene transcription of markers
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associated with “activated” astrocytes (including Gfap, Aquaporin 4, and Serpina3n), a
phenotype that normally describes astrocytic responses after neuronal stimulation or
injury (Zamanian et al., 2012; Lananna et al., 2018). Additionally, the complexity of
astrocytic filopodial extensions increases, suggesting that cyclic changes in astrocytic
morphology are regulated by the TTFL (Lananna et al., 2018).

The extracellular environment’s role in circadian rhythm regulation
The mechanisms that underlie phase-shifting in the SCN circadian clock not only
depend on the intracellular processes described above, but also on a variety of
extracellular processes that regulate the composition of the extracellular space (ECS).
Summarized in a recent review, many ECS components and related proteins [i.e.,
membrane receptors, cellular adhesion molecules, extracellular proteases, extracellular
matrix (ECM) molecules] are implicated in circadian rhythm regulation (Cooper et al.,
2018). Here, we will introduce a few that are relevant to the research presented in the
upcoming chapters.
BDNF is involved in myriad neuronal processes (Kowiański et al., 2018), including
the promotion of long-term potentiation (LTP) (Li et al., 1998; Ying et al., 2002) and
suppression of NMDAR-mediated glutamatergic excitotoxicity (Mattson et al., 1995;
Almeida et al., 2005; Lau et al., 2015). In other brain regions, increased neuronal activity
increases bndf transcription and translation of pro-BDNF. In order for pro-BDNF to be
fully active, it must have its pro-domain removed by proteases, either intra- or
extracellulary (Tongiorgi et al., 1997; Hetman et al., 1999; Balkowiec & Katz, 2002; Pang
& Lu, 2004; Ethell & Ethell, 2007).
Extracellular proteolysis of pro-BDNF to its mature form (mBDNF) is part of a web
of interconnected extracellular catabolic pathways. Of importance to our research in the
SCN, and to synaptic plasticity across the brain, is mBDNF activation by the serine
protease plasmin (Pang et al., 2004). To become proteolytically active, the precursor of
plasmin, plasminogen, must have a pro-domain catalytically removed by either tissuetype plasminogen activator (tPA) or its homolog urokinase-type plasminogen activator
(uPA) (Tomimatsu et al., 2002; Pang et al., 2004; Hoirisch-Clapauch & Nardi, 2013; Wiera
& Mozrzymas, 2015). Once activated by plasmin, mBDNF can bind to and initiate TrkB
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kinase activity, which leads to phosphorylation and activation of NMDARs (Black, 1999;
Lu, 2003; Yamada & Nabeshima, 2004).
In the hamster SCN, bdnf transcription peaks during the day, which precedes the
nighttime protein expression peak (Liang et al., 1998). Heterozygous bdnf (BDNF+/-)
knockout mice display dampened amplitudes in behavioral rhythms and take longer to
phase shift to light pulses (Liang et al., 2000). It is suggested that TrkB modulates SCN
circadian rhythms because TrkB inhibition (using K-252A) blocks both light- and
glutamate-induced phase shifts in vivo and in vitro, respectively (Liang et al., 2000; Allen
et al., 2005; Michel et al., 2006). Further, either tPA or uPA activity is required for
glutamate-induced phase shifts in vitro (Mou et al., 2009; Cooper et al., 2017). Coapplication of glutamate with an upstream regulator of tPA/uPA, plasminogen activator
inhibitor-1 (PAI-1)(Rockway et al., 2002; Aso, 2007), blocks glutamate-induced phase
shifts (Mou et al., 2009; Cooper et al., 2017). Additionally, Cooper et al. (2017) found that
uPA mediates glutamate-induced phase shifting in tPA knockout mice, and that uPA
support of glutamate-induced phase shifts involves mBDNF-independent mechanisms.
Together, these studies highlight the importance of extracellular activation of extracellular
proteases and mBDNF in regulating circadian rhythms. However, the precise downstream
mechanisms through which these proteolytic cascades affect NMDAR signaling in the
SCN are still unknown.
Changes in extracellular matrix affect cellular communication
The ECS contains a complex network of interacting molecules that help regulate
cellular communication. ECS components include the extracellular domains of membrane
receptors, cell adhesion molecules, neurotransmitters, extracellular proteases, and
extracellular matrix (ECM) molecules. Once thought to play a passive role, research
within the last 10-15 years collectively agrees that the specific composition of the ECS
actively determines the efficacy of a variety of signaling processes (Ruoslahti, 1996;
Frischknecht et al., 2009; Frischknecht et al., 2014; Tsilibary et al., 2014). Therefore,
correct development and maintenance of the ECS is a requirement for maintaining
intercellular signaling events in the brain.
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One signaling process affected by changes in the ECM and associated molecules
is neurotransmitter diffusion. For example, high densities of intersecting molecules in the
synaptic space can impede neurotransmitter diffusion through the ECS (Dityatev &
Schachner, 2003; Syková, 2004; Dityatev et al., 2006; Syková & Vargová, 2008). Thus,
the composition of the ECS determines the diffusion rate of molecules within the space
and thereby affects synaptic signaling efficiency (Rusakov & Kullmann, 1998; Binder et
al., 2004; Syková & Vargová, 2008; Vargová & Syková, 2008). When ECM associated
molecules are deformed or are deteriorated improperly, it can lead to disrupted
neurotransmitter diffusion and can contribute to the development of conditions like
schizophrenia, bipolar disease, autism spectrum disorders, and other memory and
learning disorders (Bajor & Kaczmarek, 2013; Frischknecht et al., 2014; Tsilibary et al.,
2014; Song & Dityatev, 2018).
Extracellular adhesion molecules and their links to the clock
There is wide interest in cell-attached proteins and receptors that interact with the
ECM or act trans-synaptically as mediators of intercellular communication in the brain
(Dityatev & Schachner, 2003; Cauwe et al., 2007; Frischknecht & Gundelfinger, 2012;
Frischknecht et al., 2014; Lassek et al., 2015; Marcoli et al., 2015; O'Callaghan et al.,
2017; Ferrer-Ferrer & Dityatev, 2018; Hillen et al., 2018; Song & Dityatev, 2018; Fawcett
et al., 2019). These molecules include pre- and post-synaptic cellular adhesion molecules
(CAMs), neural cellular adhesion molecules (NCAMs), synaptic CAMs, neuroligins,
neurexins, dystroglycans, Ephrins and their receptors, and integrins. These molecules
bind to ECM molecules such as collagen, laminin, elastin, fibronectin, and chondroitin
sulfate proteoglycans, as well as to their trans-synaptic adhesion molecule partners and
ligands. These interactions stabilize the ECM and cellular morphology, thereby affecting
synaptic communication (De Luca & Papa, 2017; Song & Dityatev, 2018). Many of these
molecules participate in strengthening and/or weakening of neuronal synaptic
communication (synaptic plasticity) that occurs during neurodevelopment, fear learning,
memory formation, addiction, etc. (Bajor & Kaczmarek, 2013). Because the SCN exhibits
multiple forms of iterative plasticity in regards to intercellular communication (Iyer et al.,

13

2014), full understanding of clock regulation requires the study of ECM-associated
mechanisms.
Certain CAMs that facilitate the connection between pre- and post-synaptic
neurons are emerging as extracellular circadian clock regulators. For example,
neuroligins, neurexins, and polysialyated neural cell adhesion molecule (PSA-NCAM)
have all been linked to the mammalian master clock (Glass et al., 1994; Shen et al., 1997;
Shen et al., 1999; Glass et al., 2000; Shen et al., 2001; Fedorkova et al., 2002; Glass et
al., 2003; Prosser et al., 2003; Kiessling et al., 2017). Neuroligin-1 (NLG-1), a CAM known
to interact with NMDARs (Barrow et al., 2009), exhibits diurnal differences mRNA
transcription and protein expression that are lowest in the mouse forebrain during the
night and that are eliminated in Clock mutant mice (Hannou et al., 2018a). Neurexins, the
trans-synaptic binding partners of neuroligins, exhibit cyclic mRNA and protein expression
in the mouse SCN (Shapiro-Reznik et al., 2012). PSA-NCAM is highly expressed,
particularly on neuronal somas, in the central region of the Syrian hamster SCN during
the early morning (Glass et al., 1994; Shen et al., 1999; Glass et al., 2003). The rhythm
in PSA-NCAM is also expressed in rat SCN slices, and exogenous application of
endoneuraminidase-N (which cleaves PSA from NCAM) in vitro eliminates glutamateinduced phase shifts in neuronal activity rhythms (Prosser et al., 2003). As intercellular
communication relies on the interactions of CAMs with themselves and other extracellular
molecules, their cleavage by extracellular proteases can be disruptive. Two of these
proteases, matrix metalloproteinase 2 and 9 (MMP-2 and -9), are associated with CAM
degradation and are implicated in circadian rhythm regulation.

Matrix Metalloproteinases
The MMP’s are a large family of extracellular proteases that contain at least 25
different members. MMP’s are translated and secreted into the ECS as zymogens,
inactive proteins containing a short pro-domain that blocks their active site. Collectively,
activated MMP’s degrade a large proportion of ECM proteins and can be subdivided into
groups based on their structural homology. For example, “membrane-type” MMP’s (MT1MMP, MT2-MMP, MT3-MMP, and MT5-MMP) contain a unique transmembrane domain
followed by a cytoplasmic tail. Some MMP’s are glycosylphosphatidylinisotol-linked, like
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MT4-MMP and MT6-MMP. Other subgroups, like the collagenases (MMP-1, MMP-8,
MMP-13, and MMP-14) and the gelatinases (MMP-2 and MMP-9), are categorized by
their preferred substrate (Ethell & Ethell, 2007; Cieplak & Strongin, 2017). A
comprehensive discussion of each member of the MMP family reaches beyond the scope
of this introduction, but are the focus of excellent reviews (Visse & Nagase, 2003; Nagase
et al., 2006; Ethell & Ethell, 2007; Rodriguez et al., 2010; Cieplak & Strongin, 2017). For
our investigation, we chose to focus on two prominent MMP’s in the brain that are
expressed in the SCN, MMP-2 and MMP-9 (Agostino et al., 2002).
MMP-2 and MMP-9 are the sole members the gelatinase MMP sub-family. Both
MMP-2 and MMP-9 are Zn2+-dependent endopeptidases that contain a short N-terminal
pro-domain, a conserved Zn2+ binding (HExxHxxGxxH) catalytic domain, three cytosinerich fibronectin-type II inserts, a short hinge domain and a C-terminal hemopexin domain.
Activation of MMP-2/9 occurs after secretion into ECS, where a short pro-domain is
removed by extracellular proteases. For MMP-2, this is accomplished by either
stromelysin (also called MMP-3) or by plasmin. MMP-2 and plasmin both can activate
MMP-9. In the ECS, tissue inhibitors of metalloproteinase-1 and -2 (TIMP-1 and TIMP-2)
can bind and inhibit MMP-9 and MMP-2, respectively. Mechanistically, the TIMP-1/MMP9 heterodimer binds to MT1-MMP and forms a large cell membrane complex that is
internalized and marked for proteolytic degradation. After seizure induction in the
prefrontal cortex, TIMP-1 is initially secreted into the ECS by astrocytes and then by
neurons (Rivera et al., 1997), suggesting MMP-9 inhibition could be time-dependent and
cell-type specific.
MMP’s are pivotal regulators of structural brain plasticity
Most MMPs can degrade ECM scaffolding molecules like collagen, laminin and
fibronectin (Mott & Werb, 2004), but MMP-2 and MMP-9 are best known for their ability
to cleave cellular adhesion molecules (i.e. β- dystroglycan, neuroligins, and NCAMs)
(Michaluk et al., 2007; Shichi et al., 2011; Peixoto et al., 2012), cell surface receptors
(EphB2 and β1-integrin) (Ogier et al., 2006; Atapattu et al., 2014) and extracellular growth
factors [pro-BDNF, transforming growth factor-β (TGFβ), and vascular endothelial growth
factor (VEGF)] (Bruno & Cuello, 2006; Mizoguchi et al., 2011). Due to their wide range
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of substrates and their ubiquitous expression throughout the brain, it is not surprising that
MMP-2/9 participate in many neuronal plasticity processes (Van den Steen et al., 2002;
Rodriguez et al., 2010).
Structural plasticity is a hallmark of many brain functions and dysfunctions. Growth
and development, healthy and cancerous cell migration (Demuth & Berens, 2004;
Björklund & Koivunen, 2005), synaptic plasticity, (Nagy et al., 2006), cell death (Gu et al.,
2002) and neurodegeneration all involve extracellular structural rearrangements and
generally require MMP-2 and/or MMP-9 activity (Malemud, 2006). As MMP-2/9 are
expressed by neurons (Backstrom et al., 1996), astrocytes and microglia (Maeda & Sobel,
1996), and cleave myriad extracellular molecules (Cauwe et al., 2007), they are pivotal
regulators of cellular morphology in development and throughout adulthood. For example,
during developmental granular cell migration in the cerebellum, MMP-2, MMP-9, TIMP-1,
and TIMP-2 expression is upregulated (Rivera et al., 1997; Vaillant et al., 1999; Jaworski,
2000). Further, MMP-2/9 mRNA transcript expression increases during cerebellar cortex
development and levels off around post-natal day 6, but MMP-2/9 proteolytic activity
remains high until post-natal day 21 (Ayoub et al., 2005). This activity is important for
neuronal stem cell migration in mice, because either MMP-2/9 inhibition or genetic
deletion of MMP-9 disrupts this developmental process (Vaillant et al., 2003; Ayoub et al.,
2005).
Throughout the adult brain, the roles of MMP-2/9 are multifaceted (De Luca &
Papa, 2017). MMP-2/9 knock-out mice show deficiencies in learning, memory, addiction
formation and fear acquisition, poor stroke outcome, increased risk of seizures, etc.,
which suggests that the effects of MMP-2 and MMP-9 catalytic activity are stimulus
dependent. In cultured hippocampal neurons, glutamate application increases MMP-9
protein expression in dendrites and increases MMP-9 activation; as measured by
increased cleavage of its substrate, β-dystroglycan (Dziembowska et al., 2012).
Hippocampal LTP, a form of synaptic plasticity necessary for learning and memory
formation that is initiated by increased excitatory post-synaptic current, is eliminated by
chemical inhibition of MMP-9 or by exogenous TIMP-1 application (Nagy et al., 2006;
Bozdagi et al., 2007; Meighan et al., 2007; Okulski et al., 2007). Additionally, acquisition
of fear memories in the amygdala is dependent on MMP-9 activity (Ganguly et al., 2013;
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Knapska et al., 2013). MMP-2 and MMP-9 are also activated by more traumatic stimuli.
Excitotoxic events like kainate-induced seizures or focal cerebral ischemia increase both
MMP-2 and MMP-9 mRNA expression in neuronal dendrites and astrocytic filopodia (Heo
et al., 1999; Konopacki et al., 2007). Together these studies illustrate that increased
MMP-2/9 activity is a common response to a variety of stimuli in the adult brain.
Alterations in cellular morphology are also regulated by MMP-2/9 activity. For
example, dendritic spine formation and retraction that occur during LTP both require
MMP-2/9 enzymatic activity (Wang et al., 2008a; Bilousova et al., 2009; Ould-yahoui et
al., 2009; Michaluk et al., 2011). Studies in the supraoptic nucleus, a brain region known
to undergo morphological plasticity associated with AVP and oxytocin secretion (Oliet et
al., 2004; Theodosis et al., 2004), show that MMP-2/9 activity is necessary for neuronal
structural rearrangements of magnocellular neurons (Maolood et al., 2008). MMP-2 and
-9 have also been shown to modulate astrocyte morphology, which in turn affects
astrocyte function (Abbott, 2002). In primary astrocytic cultures, MMP-2 expression is
pericellular and localizes to astrocytic filopodial-like processes (called endfeet). Further,
MMP-2 activity is required for astrocytic migration through an agarose drop (Ogier et al.,
2006). In a similar study that used interleukin-1β to induce astrocytic migration, both
MMP-2/9 chemical inhibition and siRNA (specifically targeting MMP-9 transcription)
treatment reduced the number of migratory astrocytic cells cultured from the rat cerebrum
(Yang et al., 2015). These studies show proteolytic regulation of the extracellular
environment, by both MMP-2 and MMP-9, is necessary for the structural changes that
facilitate synaptic plasticity and cellular morphology (Romanic et al., 1998).
Although the actions of MMP-2 and -9 are often studied together, there is evidence
for divergent functions of the two proteases. For example, specific inhibition of MMP-9,
but not MMP-2, reduces excitotoxic cell death in rats (Jourquin et al., 2003). Only MMP2 activity, on the other hand, is necessary for increased migration of cultured astrocytes
(Ogier et al., 2006). Along the same line, NMDA treatment only increases MMP-2 activity
in a glioma cell model (U251MG cells) (Ramaswamy et al., 2014). Thus, it is important to
differentiate between the activities of these proteases when possible.
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MMP-2/9 dependent cleavage of β-dystroglycan regulates cellular activity and
morphology
Ultimately, the consequence of MMP-2 and/or MMP-9 activity depends on
substrate availability. One well-characterized substrate of MMP-2/9 implicated in cellular
and synaptic plasticity regulation is the dystroglycan complex (Michaluk et al., 2007; Bozzi
et al., 2009; Sbardella et al., 2012). This protein complex contains two subunits, the
transmembrane β-dystroglycan and extracellular α-dystroglycan. β-dystroglycan binds
intracellularly to dystrophin (Jung et al., 1995), while α-dystroglycan interacts with
extracellular molecules like laminin, neurexin, agrin, aggrecan and perlecan via
carbohydrates on its glycosylated sidechains (Sugita et al., 2001; Michele et al., 2002;
Barresi & Campbell, 2006). Together they act as a bridge to stabilize intracellular actin
cytoskeleton interactions with ECM molecules (Ibraghimov-Beskrovnaya et al., 1992). In
the brain, the interaction of α-dystroglycan with β-dystroglycan is disrupted by MMP-2/9mediated cleavage of β-dystroglycan. Functionally, this event is necessary for
establishment and maintenance of LTP (Michaluk et al., 2007; Huntley, 2012). Addition
of an auto-activating form of MMP-9 (aaMMP-9) to neuronal cell cultures increases βdystroglycan cleavage and decreases dendritic branching complexity (Bijata et al., 2015).
Overexpression of a defective form of β-dystroglycan, which eliminates both αdystroglycan binding and MMP-9 catalysis, restores dendritic branch complexity (Bijata
et al., 2015). Together, these studies provide evidence that dystroglycan subunits
facilitate synaptic plasticity.
The function of α- and β-dystroglycan is also tied to astrocytic morphologic
regulation. Ultrastructural studies examining α-dystroglycan expression revealed that it
localizes to both neuronal post-synaptic membranes and to perivascular astrocytic
endfeet, which indirectly places β-dystroglycan expression near astrocytic extensions
(Zaccaria et al., 2001). In dystroglycan knockout mice, astrocytic endfeet association with
the vasculature decreases and is disorganized, leading to leakage of the blood-brain
barrier (Noell et al., 2011). Further studies show that astrocytic morphological changes
are initiated by acute cerebral ischemia and mediated by MMP-2/9 cleavage of βdystroglycan (Gondo et al., 2014; Yan et al., 2016). To our knowledge, β-dystroglycan
has not been studied in the SCN or within the context of circadian rhythms. Given the
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close mechanistic ties to MMP-2/9-dependent cleavage, synaptic plasticity and astrocytic
morphology regulation, it is worth investigating the role of β-dystroglycan in the
mammalian master clock.
Linking MMP’s to the mammalian circadian clock
Currently, only one study examining MMP-2/9 activity in the SCN exists (Agostino
et al., 2002). Based on the aforementioned evidence that tPA and uPA activity is
necessary for glutamate-induced phase shifts in the SCN (Mou et al., 2009; Cooper et
al., 2017) and that tPA/uPA activity leads to plasmin-mediated MMP activation (Wang
2003), we hypothesized that MMP activity gates glutamate-induced phase shifting in the
SCN. Therefore, we began investigating the role of MMP-2 and MMP-9 enzymatic activity
in the SCN.
Figure 1.1 contains a diagram outlining potential actions through which MMP-2/9
could be acting within the SCN. We hypothesize that proteolytic activation of MMP-2/9 by
plasmin increases mBDNF-mediated TrkB activation and therefore modulates NMDAR
activity. If true, this would suggest that MMP-2/9 activity gates glutamate-induced phaseshifts in SCN neuronal activity rhythms. Secondly, we hypothesize that MMP-2/9
extracellular activity in the SCN regulates the diurnal rhythm in astrocytic morphology via
CAM cleavage. Because MMP-2/9 cleavage of β-dystroglycan alters astrocytic
morphology in other brain regions, we also hypothesize day vs. night differences in
astrocytic morphology are mediated by β-dystroglycan degradation.
In Chapter 2, we focus on experiments characterizing MMP-2/9 expression, activity
and related signaling mechanisms in the SCN. The data suggest a functional role of MMP2/9 in maintaining SCN circadian rhythms phase regulation via NMDAR activation. In
Chapter 3, we use quantitative measurements to characterize SCN astrocytic morphology
across time and examine a potential link between MMP-2/9-mediated β-dystroglycan
degradation as an underlying mechanism regulating diurnal changes in astrocytic
morphology.
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Appendix: Figures for Chapter 1
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Figure 1.1: Potential pathways linking MMP-2/9 activity to circadian processes in
the SCN.
We hypothesize that in the suprachiasmatic nucleus (SCN) plasmin proteolytically
activates matrix metalloproteinase (MMP)-2 and MMP-9. In the extracellular space (ECS),
activation of plasmin occurs through tissue/urokinase-type plasminogen activator
(tPA/uPA)-mediated proteolysis of plasminogen. Activated plasmin cleaves pro-brain
derived neurotrophic factor (pro-BDNF) to its mature form (mBDNF), which then binds to
and activates tyrosine kinase B (TrkB) receptors. TrkB phosphorylates and primes Nmethyl-D-aspartate receptors (NMDARs); which is known to gate glutamate-induced,
Ca2+ dependent phase shifts of the SCN circadian clock. In other areas of the brain,
intracellular Ca2+ also leads increased pro-MMP secretion into the ECS. Because proBDNF is a substrate for MMP-2/9 as well, we predict that MMP-2/9 activity mediates
glutamate-induced phase shifts. However, due to the variety of potential MMP-2/9
substrates, MMP-2/9 may play multiple roles in the SCN. For example, MMP-2/9 could
cleave extracellular matrix (ECM) molecules (i.e., collagen and laminin) and/or pre- and
post- synaptic adhesion molecules. MMP-2/9 dependent cleavage of the dystroglycan
complex could also mediate diurnal changes in astrocytic morphology, a phenomenon
under circadian regulation in the SCN.
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CHAPTER II: TIME OF DAY DETERMINES LEVEL AND OUTCOME OF
MATRIX METALLOPROTEINASE-2 AND -9 ACTIVITY IN THE
MAMMALIAN CIRCADIAN CLOCK.
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A version of this chapter is currently being prepared for submission by Kathryn A. Halter
and Rebecca A. Prosser.
The manuscript written below contains original work designed, executed and
analyzed by Kathryn Halter. Rebecca Prosser contributed to the experimental design,
data analysis, and revisions of the manuscript.

Abstract
Coordinating endogenous physiological and behavioral rhythms with the external
environment is an important function of the mammalian master clock, located in the
suprachiasmatic nucleus (SCN). Proper entrainment depends on a complex network of
intracellular mechanisms. However, the extent to which the extracellular matrix (ECM)
and associated molecules participate in this process is only beginning to be appreciated.
This study aims to elucidate the role of two ECM proteases, matrix metalloproteinase
(MMP) 2 and 9, in the SCN. Our results demonstrate that both MMP-2 and MMP-9
proteins are expressed and active in mouse SCN tissue. Utilizing in situ zymography, we
confirmed MMP-2/9 activity is greater in the SCN than in the surrounding hypothalamus.
Although total expression of neither protein exhibits day-night differences, analysis of their
enzymatic activity using gelatin zymography revealed that MMP-9 activity is highest
during the day. Investigation of MMP-2/9 functional relevance using in vitro extracellular
electrophysiological recordings demonstrates that blocking MMP-2/9 activity using the
selective inhibitor 2-(benzenesulfonylamino)-N-hydroxy-3-phenylpropionamide (BiPS)
shifts SCN circadian clock phase in a time dependent manner. Application of BiPS during
the mid-day and early night induces phase advances and delays, respectively.
Conversely, BiPS application during the late night, when MMP-9 activity is lowest, has no
effect on clock phase. We further determined that all phase shifts induced by BiPS depend
on NMDA receptor activity, but only daytime phase advances require catalytic activity of
plasmin and TrkB receptor activation. Together, these findings suggest clock regulation
of MMP-9 activity and highlight metalloprotease involvement in SCN circadian clock
phase regulation.
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Introduction
The mammalian circadian clock in the suprachiasmatic nucleus (SCN) generates
endogenous daily rhythms and synchronizes mammalian physiology and behavior to the
external environment. Generation and maintenance of these rhythms depends on multiple
levels of neuronal plasticity. Oscillations in gene transcription, protein expression,
metabolism and neuronal activity in the SCN, which are fundamental elements of the
circadian oscillator, adjust their phase in response to entraining signals to maintain proper
phase with the environment (Golombek & Rosenstein, 2010; Muraro et al., 2013).
Desynchronization of circadian rhythms contributes to poor health outcomes. For
example, chronic phase misalignment of circadian rhythms to the environment contributes
to disorders in metabolism, sleep, mood, and endocrine function (Scheer et al., 2009;
Golombek & Rosenstein, 2010; Lall et al., 2012; LeGates et al., 2012; Lucassen et al.,
2016). Therefore, a full understanding of the underlying mechanisms that regulate phaseshifting is warranted.
Many factors can serve as “time of day” signals (or Zeitgebers; German for “timegiver”) but the circadian clock is primarily entrained by light. In animals kept in constant
darkness, light signals during the early or late night can delay or advance, respectively,
the phase of the SCN circadian clock. This effect is mimicked in vitro by glutamate
application to SCN-containing brain slices during the early and late night, where a change
in clock phase is detected as a shift in the peak of neuronal activity rhythms (Prosser et
al., 1993; Ding et al., 1994; Gillette & Mitchell, 2002). It is established that
photic/glutamate entrainment of behavioral and neuronal activity rhythms requires
activation of N-methyl D-aspartate receptors (NMDARs) (Rea et al., 1993a; Mintz et al.,
1999; Bendova et al., 2012). The mechanisms contributing to NMDAR-mediated phase
shifts are complex. Growth factors, protein kinases, intracellular scaffold proteins and a
variety of extracellular molecules are all implicated in modulating NMDAR-dependent
signaling in the SCN (Blanke & VanDongen, 2009; Cooper et al., 2017; Cooper et al.,
2018)
Intracellular mechanisms of NMDAR-mediated regulation of the circadian clock
have been investigated extensively in the SCN, but the exact extracellular proteolytic
mechanisms governing NMDAR-dependent phase shifts are unknown. Previous work in
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our laboratory determined that glutamate-induced phase shifts in SCN brain slices require
activity of the extracellular protease tissue-type plasminogen activator (tPA) (Mou et al.,
2009). Additionally, cleavage of pro-brain derived neurotrophic factor (pro-BDNF) to its
mature form (mBDNF) by tPA mediated activation of the serine protease plasmin is
necessary for glutamate-induced phase shifts. More recently, Cooper et al. (2017) found
that urokinase-type plasminogen activator (uPA) mediates glutamate-induced phase
shifts in tPA knockout mice, although uPA appears to act through mBDNF-independent
mechanisms (Cooper et al., 2017). Thus, extracellular proteolytic activity tightly regulates
entrainment of the SCN circadian clock and we hypothesize that other substrates of
plasmin known to affect NMDAR signaling could likewise be involved in glutamateinduced phase shifts.
Two candidate molecules activated by plasmin are the extracellular matrix (ECM)
proteases matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9) (Ethell & Ethell, 2007;
Rodriguez et al., 2010; Li et al., 2016). These two metalloproteases are initially secreted
into the extracellular space as inactive zymogens and activated after the catalytic site of
the protein is exposed by removal of a small, pro-domain peptide (Visse & Nagase, 2003;
Verslegers et al., 2013). MMP-2 and MMP-9 are often studied together, due to their
structural homology and their shared ability to cleave similar extracellular matrix (ECM)associated substrates (Ethell & Ethell, 2007). These proteases are ubiquitously
expressed in the brain and their activity is necessary for regulating cellular growth,
development, synaptic plasticity and injury response in a variety of brain regions
(Malemud, 2006; Ogier et al., 2006; Bozdagi et al., 2007; Michaluk et al., 2011; Szepesi
et al., 2013; Stawarski et al., 2014; De Stefano & Herrero, 2016; Abdelnaseer et al., 2017).
MMP-2/9 also play a role in neuronal activity regulation, as MMP-2/9 mediated cleavage
of ECM and cellular adhesion molecules (CAMs) increases NMDAR activation and
trafficking to the post-synaptic membrane (Bozdagi et al., 2007; Gorkiewicz et al., 2010;
Kupai et al., 2010; Ning et al., 2015; Niculescu et al., 2018).
MMP expression and/or activity has been linked to circadian clocks in both
vertebrates and invertebrates. Expression of two Drosophila melanogaster homologs of
mammalian MMPs, Dm1-MMP and Dm2-MMP, is required for motorneuron development
and axonal growth (Miller et al., 2008). Moreover, Dm1-MMP exhibits increased
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expression in response to Clock-induced DNA transcription (Kadener et al., 2007). In
Drosophila, it is known that the axonal projections of circadian clock neurons exhibit
greater complexity during the day than the night. Interestingly, this rhythm is eliminated
by genetic overexpression of Dm1-MMP and Dm2-MMP (Depetris-Chauvin et al., 2014).
Further, wildtype Drosophila given an shRNAi to knockdown Dm1-MMP transcription
exhibit arrhythmic locomotor behavior (Depetris-Chauvin et al., 2014). In hamsters, both
MMP-2 and MMP-9 are enzymatically active in SCN tissue homogenates, but only MMP9 shows increased activity during the night (Agostino et al., 2002).
In addition to the MMP-2/9 studies performed in the hamster SCN (Agostino et al.,
2002) and the clock neurons in drosophila (Kadener et al., 2007; Nagoshi et al., 2010),
other researchers have explored circadian regulation of MMP-2/9 in other locations. One
study examined MMP-2/9 activity in the hippocampus and did not observe a diurnal
variation in enzymatic activity of either protease (Nishijima et al., 2015). Using isolated
trabecular meshwork cells of the eye, Li et al. found that 24-hr temperature oscillations
drive rhythmic MMP-2/9 activity (Li et al., 2015). In a cardiac tissue-specific Bmal1
knockout mouse, MMP-9 and its endogenous inhibitor TIMP-1 exhibit increased
expression in the heart relative to wildtype mice (Ingle et al., 2015), suggesting that MMP9 expression could be under circadian clock control.
While intriguing, these studies provide little insight into the functional role of MMP2 and MMP-9 in modulating mammalian circadian rhythms. Given the importance of
NMDAR activity in modulating SCN circadian clock phase and evidence that MMP-2/9
affects NMDAR activity, we sought to determine MMP2/9 expression and activity in the
mouse SCN and test whether they modulate SCN circadian clock phase.

Materials and Methods
Brain slice preparation
All mice handling and dissection followed University of Tennessee, Knoxville
Institutional Animal Care and Use Committee approved protocols. Brains were harvested
during the lights-on period from adult male, C57BL/6 mice (Envigo, Indianapolis, IN)
housed in a 12:12 light:dark cycle, with food available ad libitum. Brain slices containing
the SCN were maintained in a perfusion dish containing Earle’s Balanced Salt Solution
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(EBSS; MP Biomedicals, Solon, OH), supplemented with gentamicin, dextrose, and
sodium bicarbonate, saturated with 95% O2/5% CO2, and kept at 37°C (Prosser & Gillette,
1989; Prosser et al., 1994; Mou et al., 2009; Yamada & Prosser, 2014; Cooper et al.,
2017).
Western blotting
SCN brain slices prepared as described above were maintained in constant
conditions until collection at Zeitgeber time (ZT; where ZT 0 corresponds to lights-on and
ZT 12 corresponds to lights-off in the animal colony) 6, ZT 16 or ZT 23 on the day of brain
slice preparation (Day One in vitro). SCN tissue was rapidly frozen at -80°C at the time of
collection. Protein extraction occurred under reducing conditions and protein
concentration was measured using the Bradford assay. SCN protein samples (10 μg),
recombinant human MMP-2, and recombinant mouse MMP-9 (Calbiochem, San Diego,
CA; 100 ng each), were loaded into 4-12% Bis-Tris BOLT gels (Invitrogen, Carlsbad, CA)
and separated by electrophoresis in 1X MOPS [(3-(N-morpholino)propanesulfonic acid]
buffer (Invitrogen). Proteins were transferred to Immobilon-PVDF membranes using a
Trans-Blot Turbo transfer system (BioRad, Hercules, CA). The IR-Western blot protocol
provided by Li-COR [“Near-Infrared (NIR) Western Blot Detection Protocol”, available
online] was used to fluorescently label pCAMKII (p1005-286, 1:1000; PhosphoSolutions,
Aurora, CO), MMP-2 (MAB13406, 1:1,000 dilution; EMD Millipore, Billerica, MA) or MMP9

(AB19016,

1:1,000

dilution,

EMD

Millipore).

Actin

(sc-1616,

Santa

Cruz

Biotechnologies, Dallas, TX) served as a loading control. Blots were then incubated with
fluorescent secondary antibodies conjugated to LI-COR IR-Dye® and signal intensities
for protein samples were collected with an Odyssey®-CLx system (LI-COR Biosciences,
Lincoln, NE). Band intensity analysis was performed using the Image Studio Lite™ v 5.0
software (LI-COR Biosciences). Fluorescent signal for each protein was measured as
pixel density minus background pixel density and reported as total signal. The total signal
of bands corresponding to each protein was normalized to the total signal of the actin
band.
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Gelatin zymography
SCN-containing brain slices were prepared and maintained as described above.
Tissue was collected at ZT 6, ZT 16 and ZT 23 and frozen at -80°C. Proteins for gelatin
zymography were extracted following an adapted zymography protocol (Toth & Fridman,
2001; Kupai et al., 2010). Briefly, samples were lysed in buffer containing 0.5% Triton-X100 and 50 mM Tris (BioRad). Samples were centrifuged at 13,000 g for 10 min at 4°C.
Protein concentration was measured using a Bradford assay. Protein samples were
diluted with Gelatin Zymography Sample Buffer (BioRAD) and then loaded into a 0.1%
gelatin zymogram (Invitrogen). After separation by electrophoresis, zymograms were
washed in a renaturing solution of 2.5% Triton-X100 and subsequently incubated in a
solution of 50 mM Tris, 0.15 M NaCl, and 10 mM CaCl2 at 37°C for five days. Gels were
stained with Coomassie blue for one hour and destained with 4.0/8.0% methanol/ethanol
solution until clear, gelatinolytic bands were visible. Gels were imaged using the OdysseyClx and inverted images were used for measurement of gelatinolytic bands. Bands were
compared to 100 ng of recombinant human MMP-2 and mouse MMP-9 protein for
identification. Gelatinolytic activity was measured as pixel density minus background pixel
density using Image J Fiji and reported as the mean grey value. For statistical analysis,
the mean grey value of all gelatinolytic bands was set relative to the mean grey value of
the r-MMP-2 gelatinolytic band.
In situ gelatin zymography
SCN brain slices were prepared and maintained as described above. Control slices
were collected 20 minutes before ZT 6, 16 or 23 and slices remaining in the perfusion
dish received bath application of 100 nM MMP-2/9 Inhibitor II [2-(benzenesulfonylamino)N-hydroxy-3-phenylpropionamide, (BiPS; Calbiochem)] (see drug treatment protocol,
below) for the 40 minutes surrounding each time point. At collection time, slices were
placed in a 1X phosphate buffered saline (PBS, pH 7.4) solution containing 30% sucrose
and maintained at 4°C overnight. Slices were then placed in OCT and stored at -80°C
until sectioning. Tissue was cut into 10 μM sections with a Leica cryostat. Serial sections
were collected and divided onto two VWR Vista Vision™ Histobond® adhesive slides.
Slides were stored at -80°C.
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In situ zymography was performed according to established protocols (Oh et al.,
1999; Gawlak et al., 2009; Aguayo et al., 2018). Slides (thawed to room temperature)
were rinsed once with 1X PBS and incubated with a 20 μg/μL stock solution of DQ-Gelatin
from Pig Skin, Fluoroscein Conjugate (catalog # D12054, Thermofisher Scientific,
Waltham, MA) in zymography reaction buffer (100 mM NaCl, 10 mM CaCl2, 100 mM TrisHCl, 0.05% Brij-35, pH=7.5) for 18 hours. Negative control slides were incubated with 4%
paraformaldehyde (PFA) or 100 nM BiPS to inhibit MMP activity during DQ-Gelatin
incubation. Slides were rinsed 3 X 5 minutes in 1X PBS and cover-slipped using
Vectashield Antifade mounting medium containing DAPI (Vector Laboratories,
Cambridgeshire, UK). Brain regions containing the SCN were identified using
neuroanatomical landmarks (the third ventricle and optic chiasm) and the DAPI nuclear
stain. Images of sections containing the SCN were taken using a Leica CTR600
Florescence Microscope at 20X magnification for integrated pixel density measurements
of the SCN region. DQ-Gelatin, a substrate for MMP-2/9, contains a conjugated
fluorophore that becomes unquenched after cleavage by MMP-2/9 and is excited by the
488 nm wavelength. For fluorescent signal analysis, collected images were split into blue
(DAPI stain) and green (DQ-Gelatin) channels and a circular region of interest (ROI) was
drawn around the SCN region in the blue channel using Image J, Fiji (NCBI) (Schindelin
et al., 2012). ROIs were transferred to the green channel and the mean grey value
(average pixel density/area) of DQ-gelatin signal in the SCN was measured. This ROI
was also duplicated and shifted to a nearby portion of the anterior hypothalamus (AH) to
collect the mean grey value. If both bilateral SCN nuclei were present in the tissue sample,
the process was repeated for the contralateral nuclei and the two mean grey values were
averaged.
In vitro extracellular electrophysiology
Extracellular electrophysiology experiments were performed as outlined previously
(Prosser & Gillette, 1989; Prosser et al., 1994; Mou et al., 2009; Yamada & Prosser, 2014;
Cooper et al., 2017). Briefly, brain slices were prepared and maintained in a perfusion
dish as described earlier, and drug treatments were applied as described below. On the
morning of Day 2 or Day 3 in vitro, single unit recordings were collected using a glass
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electrode containing 3 M NaCl. Neuronal activity was recorded and analyzed from 6-8
neurons each hour, for five minutes each, for a total of 8-10 hours. The data were
collected and analyzed using DataWave SciWorks software (DataWave Technologies,
Loveland, CO). The average firing rate from each cell recording was calculated and these
were then grouped into two-hour running averages for the entirety of the recording. As in
prior experiments (Prosser & Gillette, 1989; Prosser et al., 1994; Yamada & Prosser,
2014; Cooper et al., 2017), the mean firing rates ± SEM for each experiment were
calculated and plotted using SigmaPlot v 12.0. The time of peak neuronal activity was
assessed visually to the nearest quarter hour, and the change in the time of peak firing
was expressed in hours deviating from ZT 6 (the time of peak activity in untreated SCN
tissue).
Chemical treatments
Drugs were administered to SCN slices via bath application for 40 minutes
surrounding ZT 6, ZT 16 or ZT 23 (Day One in vitro). Experimental treatments included:
100 nM BiPS (Calbiochem) to block MMP-2/9 activity (Tamura et al., 1998; Lauzier et al.,
2008); 50 μM D-(–)-2-Amino-5-phosphonopentanoic acid, (AP5; Calbiochem), an
NMDAR antagonist; 1.0 μM K252a, Nocardiopsis sp. (EMD Millipore) to inhibit TrkB
receptor activity; and 50 μM α₂-antiplasmin, (α₂-AP; Calbiochem) to inhibit plasmin.
Concentrations of the drugs were chosen based on previous findings by our laboratory
(Mou et al., 2009) or by the IC50 determined by the manufacturer’s specifications.
Statistical analysis
Graphpad Prism software v 8.0.1 was used to generate histogram graphs and run
statistical analyses. For western blotting (n=5-6) and gelatin zymography experiments
(n=5) a significant difference between Zeitgeber times was determined using a One Way
ANOVA. Where significant differences were found, a post-hoc Tukey test was performed
to assess all pairwise comparisons (Holm-Sidak method). In situ zymography results
(n=3-6) were analyzed using a Two Way ANOVA with a post-hoc Tukey’s multiple
comparisons test to assess the effect of time and/or drug treatment between the SCN
and the anterior hypothalamus. For electrophysiology experiments where experimental
groups were compared to a no-treatment control group (n=3), the differences between
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means were determined using a One Way ANOVA analysis with a post-hoc Dunnett’s
test.

Results
MMP-9 enzymatic activity, but not expression, is lowest during the late night
To begin investigating MMP-2/9 in the SCN, we evaluated both the protein
expression level and enzymatic activity of these metalloproteases during the day (ZT 6),
early night (ZT 16) and late night (ZT 23). The expression of both MMP-2 and MMP-9
proteins in the SCN was confirmed at each of the time points using western blotting (Fig
2.1 A and B). To assess differences in protein expression across circadian time,
fluorescent signal intensity for bands corresponding to MMP-2 and MMP-9 were divided
by actin signal (as a loading control). One-way ANOVA of MMP-2 and MMP-9 expression
[relative to actin (Fig 2.1 C and D)] revealed no significant time-dependent differences
between groups (p=0.372, n=6; p=0.064, n=5, respectively).
Next, we investigated the enzymatic activity of MMP-2 and MMP-9 using gelatin
zymography (Fig 2.2 A). Similar to western blotting, protein extracts were separated via
gel electrophoresis, but gels used for gelatin zymography contain gelatin, a substrate for
both MMP-2 and MMP-9. The incubation buffer used contains a mild detergent that
exposes the active sites of the proteins, which means that both pro- and active forms of
MMP-2 and MMP-9 enzymes can be detected. It also removes any endogenous
inhibitors. After staining with Coomassie blue, clear bands corresponding to the molecular
weights of the proteins are reported as “gelatinolytic activity” bands. Thus, gelatin
zymography does not measure endogenous activity; rather, it is a measure of potential
enzymatic activity away from the normal environment and any endogenous regulators
(Toth & Fridman, 2001; Vandooren et al., 2013a; Ren et al., 2017). Traditionally, the
incubation period of a gelatin zymography gel is 72 hours. However, after 72 h we were
unable to visualize any gelatinolytic activity (data not shown). Extension of the incubation
period increases the sensitivity of the assay (Kleiner & Stetler-Stevenson, 1994; Ren et
al., 2017); therefore, we incubated the gels for five days and detected gelatinolytic activity
of our recombinant proteins and in our SCN tissue extracts (Fig 3A). In our SCN extract
lanes, we detected MMP-9 at ~98 kD. We also saw a much fainter band at ~72 kD, the
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molecular weight of active MMP-2, which can be seen more clearly when the image
exposure is increased (Fig 2.2 B). The slight size differences between the recombinant
proteins (r-MMP-2 and r-MMP-9) and those in the SCN protein extracts may be due to in
vivo post translational modifications of MMP-2 and -9 and/or species differences between
the human derived r-MMP-2 and our murine samples (Vandooren et al., 2013b).
For comparative analysis, the total signal of gelatinolytic activity of both MMP-2
and MMP-9 on each gel was set relative to the amount of signal produced by the r-MMP2 band on the same gel (Figure 2.2 C). This was done to control for potential inter-gel
variability due to differences occurring during the staining and de-staining procedures.
SCN tissue extracts collected at ZT 6, ZT 16 and ZT 23 showed robust differences
between MMP-9 gelatinolytic activity than MMP-2 at ZT 6 (p=0.0023), ZT 16 (p=0.009),
and ZT 23 (p=0.008). Comparing activity across time, MMP-2 gelatinolytic activity was
not different between ZT 6 and ZT 16 (Two Way ANOVA followed by post-hoc Tukey test
n=5; p=0.993) nor ZT 6 and ZT 23 (p=0.995). However, the relative level of MMP-9
gelatinolytic activity showed a statistically significant difference. Post-hoc analysis
indicated that MMP-9 gelatinolytic activity was significantly higher at ZT 6 than at ZT 23
(p=0.008) but not different at ZT 16 (p=0.337).
To assess if changing the amount of protein loaded in the zymogram would
improve detection of MMP-2 protein in our extracts, we performed an additional
experiment in which we loaded increasing amounts of SCN extract into a zymography gel
along with SCN samples that had been incubated with BiPS (Fig 2.3). Increasing the total
amount of SCN extract did not substantially change the amount of detected MMP-2 or
MMP-9 gelatinolytic activity. Further, incubation with BiPS before separation on a gelatin
zymogram did not alter the activity of the MMP-9 in the zymogram. We believe that this
is due to treating the zymogram with the detergent Triton-X100 after electrophoretic
separation. Just as this incubation step removes the pro- domain of the protein from the
active site and removes endogenous inhibitors from the MMPs, the detergent likely
removed BiPS from the active site of the protein, allowing proteolytic activity.
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In situ zymography confirms enhanced MMP activity of in SCN tissue
Next, we assessed MMP-2/9 activity in SCN tissue slices using in situ zymography.
In situ zymography aids in visualizing and localizing MMP-2/9 gelatinolytic activity in brain
and other tissues (Gross & Lapiere, 1962; Oh et al., 1999; Yan & Blomme, 2003; Gawlak
et al., 2009; Vandooren et al., 2013a; Chhabra & Rani, 2017; Aguayo et al., 2018).
Hypothalamic slices containing the SCN were prepared and maintained in a perfusion
dish as described above. Control and BiPS-treated slices were collected and prepared as
described in the Methods section. Slides containing SCN tissue sections were incubated
overnight in zymography buffer containing gelatin molecules fused to quenched
fluorescent FITC molecules (DQ-gelatin). The overnight incubation allows active MMP2/9 to cleave the gelatin and unquench the fluorescent molecules (Mook et al., 2003; Guo
et al., 2007). Thus, fluorescence indicates areas containing MMP-2/9 activity. Unlike with
gelatin zymography, the activity of MMP-2 vs. MMP-9 cannot be distinguished with in situ
zymography. After sectioning and staining with DQ-gelatin and DAPI (to confirm the
location of SCN nuclei), 20X magnification images of the brain regions containing the
SCN and the AH were taken with a fluorescent microscope.
In both our no-treatment and BiPS-treated SCN tissue slices, we observed DQgelatin fluorescent signal that overlapped the SCN region (Fig 2.4 A & B). To confirm that
the fluorescence was an effect of MMP-2/9 activity, we co-incubated negative control
sections with either 4% PFA or 100 nM BiPS in the DQ-Gelatin solution to inhibit MMP2/9 catalysis. In both cases we observed markedly dampened fluorescent signal (Fig 2.4
C and D). We then quantified the mean grey value corresponding to the fluorescent signal
for both the SCN and adjacent AH in the control and BiPS treated slices. This analysis
revealed that pre-treatment with 100 nM BiPS in vitro did not reduce gelatinolytic activity
at any time point, as compared to untreated tissue (Fig 2.4 E, n=3-6, Two-way ANOVA
comparison of means ± SEM; α=0.05, p=0.8670). However, there were regional
differences within both control and BiPS treated slices. In ZT 6 control and BiPS slices,
the SCN displayed higher gelatinolytic activity than the AH (p=0.0246 and p=0.0225,
respectively). The SCN also displayed higher activity than the AH at ZT 23 (p=0.0125),
but only in the BiPS treated slices. At ZT 16 no significant differences between
gelatinolytic activity between the SCN and AH were observed, although the data in both
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cases trended towards significance (control slices, p= 0.0821 and BiPS slices, p=0.0670).
To examine this further, we combined the mean grey values of control and BiPS treated
SCN tissue samples of all SCN or AH regions at each ZT. One-way ANOVA analysis
indicates that the gelatinolytic activity of MMP-2/9 is significantly higher in the SCN at
each time point examined (ZT6, p=0.0008; ZT 16, p=0.0004; ZT 23, p=0.0074) as
compared to the surrounding AH.
Blocking MMP-2/9 activity alters SCN neuronal activity rhythms
Based on our data showing MMP-2/9 expression and activity in the SCN, next we
tested the hypothesis that MMP-2/9 are involved in circadian clock phase regulation. For
this we bath-applied the MMP-2/9 inhibitor, BiPS (100 nM) to SCN-containing brain slices
and assessed circadian phase of the neuronal activity rhythm the following day.
Compared to control slices, which exhibit a peak of activity on the second day in vitro at
ZT 6 (Fig 2.5 A), we found that BiPS applied at ZT 6 resulted in a significant phase
advance of 3.0 ± 0.58 h (n=3; One-way ANOVA, post-hoc Dunnett’s Test result p=0.015;
Fig 2.5 B, D). Next, we found that bath application of 100 nM BiPS at ZT 16 resulted in a
phase delay (-2.7 ± 0.34 h, n=3, Fig 2.5 C, D). In a third set of experiments, we evaluated
the effect of BiPS applied at ZT 23. Neuronal activity during the second day in vitro,
immediately following the ZT 23 treatment, did not exhibit a clear peak in neuronal activity
(Fig 2.6 A & B), likely because of acute effects of BiPS on neuronal firing rates. Therefore,
we conducted additional experiments where we assessed the phase of the neuronal
activity rhythm during the second day after drug treatment at ZT 23 (Day 3 in vitro) (Fig
2.6 C, D). Previous studies demonstrate that the phase of the neuronal activity rhythm is
consistent across the first 3 days in vitro (Gillette & Prosser, 1988), which we confirmed
(Fig 2.6 C). Further, BiPS treatment did not significantly shift peak neuronal activity on
Day 3 in vitro [mean phase shift= 1.0 ± 0.33 h, n=3, Student’s t-test with a Mann-Whitney
ranked sum test, p=0.333; Fig 2.6 D).
BiPS-induced phase shifts require NMDAR activity
Because BiPS treatment at ZT 16 induced glutamate-like phase delays (Ding et
al., 1994), we investigated whether NMDAR activity was required for BiPS-induced phase
shifts. The selective NMDAR selective antagonist, AP5, was previously shown to not
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affect clock phase when applied alone, but can block glutamate-induced phase shifts and
NMDAR dependent excitatory post synaptic potentials in the SCN (Biello et al., 1997;
Mintz et al., 1999; Yamada & Prosser, 2014). We followed up these previous studies by
assessing the effect of AP5 on SCN neuronal activity rhythms when applied alone at ZT
16 and found no effect on SCN circadian phase (data not shown). Co-application of BiPS
with AP5 at ZT 16 induced a mean phase shift of -0.333 ± 0.333 h (n=3) (Fig 2.5 D). Oneway ANOVA with a post-hoc Dunnett’s test revealed this treatment was significantly
different from BiPS application alone, indicating that the ZT 16 phase delay was blocked
(p=0.00197). Interestingly, even though glutamate does not induce phase advances when
applied alone to the SCN at ZT 6 (Ding et al., 1994; Biello et al., 1997; Mou et al., 2009),
co-application of AP5 with BiPS at ZT 6 significantly inhibited the BiPS-induced phase
advance (mean phase shift = -0.330 ± 0.333 h, p= <0.001, n=3; Fig 2.5 D).
Daytime but not early night phase shifts induced by BiPS require plasmin and TrkB
activation
In other brain regions MMP-2 and MMP-9 are activated by plasmin, and in turn can
facilitate activation of pro-BDNF to mBDNF (Ethell & Ethell, 2007; Cao et al., 2014). Given
that previous work supports SCN circadian clock phase regulation by mBDNF/TrkB (Liang
et al., 1998; Prosser et al., 2008; Mou et al., 2009; Girardet et al., 2013; Yamada &
Prosser, 2014), we assessed plasmin and TrkB involvement in BiPS-induced phase
shifts. Mou et al., (2009) showed that inhibition of a) TrkB activation using K252a and b)
plasmin activity using α2-antiplasmin by themselves have no effect on in vitro SCN
circadian neuronal activity rhythms. When we applied α 2-antiplasmin with BiPS at ZT 16
this treatment resulted in a phase delay of -3.3 ± 0.33 h, (Fig 2.5 D), which was not
significantly different from that of BiPS treatment alone (p=0.382, n=3; one-way ANOVA
with a post-hoc Dunnett’s test). Likewise, when we co-applied K252a with BiPS at ZT 16
this resulted in a phase delay of -2.0 ± 0.30 h (Fig 2.5 D, which again was not statistically
different from the effect of BiPS-only treatment (p=0.382, n=3; Fig 2.5 D). Interestingly,
when we co-applied α2-antiplasmin with BiPS at ZT 6, the results showed a significantly
decreased phase shift vs. BiPS alone (mean phase shift= 1.3 ± 0.33 h, p=0.0448, n=3;
Fig 2.5 D). Similarly, K252A co-application with BiPS at ZT 6 resulted in a significant
36

inhibition of the phase shift induced by BiPS alone (mean phase shift= 0.50 ± 0.30,
p=0.00556, n=3; Fig 2.5 D). Together, these data suggest that early night phase delays
induced by disrupting MMP-2/9 activity require activity of NMDARs but appear to be
independent of both plasmin activity and TrkB signaling. Conversely, we observed that
application of BiPS during the mid-day induced phase advances that depend on the
activity of plasmin, NMDARs, and mBDNF activation of TrkB receptors.
BiPS treatment does not affect CAMKII phosphorylation
To better understand the mechanisms involved in BiPS-induced phase shifts, we
investigated whether BiPS treatment activates calcium/calmodulin-dependent protein
kinase II (CAMKII) in the SCN. Phosphorylation of CAMKII by calmodulin increases after
Ca2+ influx through active NMDAR or AMPA channels. In addition to serving as a marker
of increased neuronal activity, CAMKII phosphorylation is also necessary for long-term
potentiation in multiple brain regions (Miller & Kennedy, 1986; Giese et al., 1998; Wang
& Peng, 2016). There are four isoforms of CAMKII, of which the α- and β-isoforms are
expressed specifically in brain tissue. Phosphorylation of α- and/or β-CAMKII on the Thr286 residue occurs 1-2 minutes after LTP induction in hippocampal slices and serves as
a marker for increased intracellular Ca2+ levels and synaptic plasticity (Cho et al., 2007;
Senga et al., 2015; Chang et al., 2017). In the hamster SCN, CAMKII phosphorylation,
and subsequent kinase activity, peak during the day and are required for light-induced
phase shifts, clock gene induction, and circadian rhythms of locomotor activity (Yokota et
al., 2001; Nomura et al., 2003; Agostino et al., 2004; Kon et al., 2014). We hypothesized
that if BiPS-induced phase shifts at ZT 6 and ZT 16 require NMDAR activation, then these
phase shifts would be accompanied by increased phosphorylation of either or both
isoforms of CAMKII. Thus, we measured CAMKII phosphorylation of the Thr-286 residue
in control SCN tissue and after BiPS treatment using western blotting.
As seen in Figure 2.7, two-way ANOVA revealed no statistically significant
differences in either CAMKII isoform across time (p=0.8667) or in response to BiPS
treatment (p=0.3436). We further analyzed our data by examining the ratio of
phosphorylated α-CAMKII to β-CAMKII (α:β-CAMKII). Previous research shows that
higher α:β-CAMKII ratios lead to increased translocation of heteromeric CAMKII to the
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post-synaptic density, where its kinase activity is important for elongation of dendritic
spines (Shen et al., 1998). Specifically, increased β-CAMKII can “dock” α-CAMKII to the
actin cytoskeleton and promote synaptic plasticity. Comparison of the α:β ratio of CAMKII
using a two-way ANOVA also revealed no significant differences across ZT (p=0.3898)
or between BiPS treatment groups (p=0.2202). This indicates that although NMDAR
receptor activity is required for BiPS-induced phase shifts at ZT 6 and ZT 16, the level of
CAMKII phosphorylation on Thr-286 remains unaffected.

Discussion
The results of these experiments reveal that the extracellular proteases MMP-2
and MMP-9 are expressed and active in the SCN, and that one or both play a role in
phase regulation of the SCN circadian clock. Specifically, we show that MMP-2/9 are
highly expressed in the SCN compared to surrounding areas, and that MMP-9 exhibits a
circadian rhythm in gelatinolytic activity. We further demonstrate that inhibition of MMP2/9 activity with BiPS at ZT 6 and ZT 16, but not ZT 23, phase-shifts the SCN circadian
clock. These are the first data that implicate a functional role for MMP-2/9 in the SCN.
Our data confirm previous work showing that MMP-2/9 are expressed in the SCN
and that MMP-9, but not MMP-2, exhibits a circadian rhythm in gelatinolytic activity. While
our observation indicates higher MMP-9 activity at ZT 6 vs. ZT 23, Agostino et al. (2002)
found that MMP-9 gelatinolytic activity is higher at night (ZT 16) than it is during the day
(ZT 4). A few differences exist between these two studies, including the light schedule of
housed animals (14:10 LD vs 12:12 LD) and the times of enzymatic assessment. The
Agostino et. al daytime samples were collected 4 h after lights-on and 10 h before lightsoff, while our mid-day collection time was 6 h after lights-on. Additionally, their nighttime
collection time was 2 h after lights off, while ours was 4 h. Differences may also be due
to our SCN slices being maintained in vitro prior to tissue collection rather than the tissue
being collected immediately after brain extraction. Importantly, our experimental design
allowed us to assess MMP-2/9 expression/activity at the same circadian time points when
we assessed their ability to modulate clock phase. Still, we must interpret the results of
both studies cautiously because the zymography assay assesses proteolytic activity after
removing MMP-2/9 from the endogenous extracellular milieu and electrophoretically
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separating them from their endogenous inhibitors, TIMP-1 and TIMP-2. Combined, the
results indicate that further research on diurnal and/or circadian differences in MMP-2/9
activation is necessary.
Using in situ zymography to assess MMP-2/9 gelatinolytic activity in intact brain
slices, we confirmed that MMP-2/9 enzymatic activity is higher in the SCN than in the
surrounding AH. However, we did not observe a significant diurnal variation in MMP-2/9
gelatinolytic activity using this assay. Because both MMP-2 and MMP-9 cleave the DQGelatin molecule, it is possible that non-rhythmic endogenous MMP-2 activity obscures a
diurnal variation in MMP-9 gelatinolytic activity in situ. Further, bound endogenous
inhibitors of either MMP, such as TIMP-1 and TIMP-2, could block the detectable level of
MMP gelatinolytic activity and account for the differences observed between the level of
MMP-9 activity in our assays. Together, our results suggest that BiPS-induced phase
shifts coincide with times of higher endogenous MMP-9 enzymatic activity, as indicated
by gelatin zymography. These data add to literature supporting circadian regulation of
MMP-9 activity, and importantly, are the first to evaluate functional effects of
metalloprotease activity in the SCN.
Our MMP-2/9 gelatinolytic activity data also highlight the importance of
concurrently investigating protease expression and proteolytic activity. In other brain
regions, expression of both MMP-2 and MMP-9 is constitutive, and they only become
activated under specific circumstances such as during increased neuronal activity, injury
or inflammation (Bozdagi et al., 2007; Ethell & Ethell, 2007; Michaluk et al., 2007;
Konnecke & Bechmann, 2013; Ramaswamy et al., 2013; Verslegers et al., 2013). Our
results align with this, given that total expression of both MMP-2 and MMP-9 is constant
in the SCN, while the gelatinolytic activity of MMP-9 changes across time, and is higher
in the daytime when neuronal activity peaks in the SCN. However, we attribute this
difference to the higher sensitivity (lower limit protein concentration= 10 pg) of the gelatin
zymography assay, as opposed to western blotting (detection range= 50 pg - 100ng) (Ren
et al., 2017).
Additional investigations are needed to clarify the regulatory mechanisms
controlling the diurnal difference in MMP-9 endogenous activity in the SCN. One
candidate protein for this is stromelysin 1 (also known as MMP-3), which also can cleave
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pro-MMP-9 (Ogata et al., 1992). Inactivation of MMP-9 can involve TIMP-1 or can occur
through MMP-9 binding to membrane bound receptors RECK (reversion-inducingcysteine-rich protein with kazal motifs) or LRP-1 (low-density lipoprotein receptorrelated protein-1), leading to its internalization (Bernardo & Fridman, 2003; Fridman et
al., 2003; Toth et al., 2003; De Stefano & Herrero, 2016). It is thus noteworthy that LRP1 is expressed in the SCN, and that LRP-1 inhibition also phase-shifts the SCN circadian
clock in vitro (Cooper & Prosser, 2014).
Previous research suggests that MMP-9 in particular can act as a positive or
negative regulator of NMDAR activity. MMP-2 and -9 can cleave a variety of substrates,
including cellular adhesion molecules (CAMs) like neuroligin 1 (NLG1), EphB, and β1integrin, which in turn can regulate NMDAR activity (Dalva et al., 2000; Tian et al., 2007;
Michaluk et al., 2009; Peixoto et al., 2012; Sloniowski & Ethell, 2012). These proteins
function in part to maintain the structural integrity of pre- to post-synaptic adhesion, which
is thought to affect the strength of synaptic signaling.
Mechanistically, cleavage of CAMs by MMP-2/9 can increase the trafficking and/or
lateral mobility of membrane-bound NMDARs on the post-synaptic membrane. For
example, MMP-2 and -9 cleavage of NLG1 can increase the recruitment of NMDARs to
the post-synaptic membrane (Barrow et al., 2009; Peixoto et al., 2012). Integrins, another
MMP-2/9 substrate, recruit NMDARs to the post-synaptic membrane via interaction with
PSD-95 (Barrow et al., 2009) and their cleavage increases lateral movement (surface
diffusion) of NMDAR in the post-synaptic membrane (Michaluk et al., 2009). More
evidence implicating MMP-9 in NMDAR activity regulation includes a study by Tian et al.
showing that MMP-9 cleavage of intercellular adhesion molecule-5 enhances activation
of NMDARs (Tian et al., 2007). Another study showed that adult MMP-9 knockout mice
exhibit increased excitability, indicated by increased mEPSC frequency in CA1 pyramidal
neurons and enhanced severity and duration of kainate induced seizures (Murase et al.,
2016). Also, application of auto-activating MMP-9 to hippocampal slices accelerates the
deactivation kinetics of NMDARs (Gorkiewicz et al., 2010). Taken together, these studies
suggest that MMP-2/9 cleavage of CAMs can negatively affect NMDAR activity either
through downstream signaling pathways, altering channel kinetics, or by modulating
NMDAR localization within the synaptic membrane.
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Our data showing that daytime phase advances induced by BiPS application at ZT
6 are blocked by the NMDAR antagonist AP5 were unexpected. It has been shown
previously that glutamate or glutamate agonist application to SCN slices in vitro at ZT 6
does not phase-shift the SCN circadian clock (Ding et al., 1994; Prosser, 2001; Yamada
& Prosser, 2014). On the other hand, co-application of mBDNF with glutamate to SCN
brain slices at ZT 6 induces phase advances much like those seen here (Mou et al., 2009).
Similarly, we found that K252a is able to block these phase advances, illustrating that
NMDAR-dependent phase advances during the day require co-activation of TrkB.
Previous studies have shown that mBDNF levels are low in the SCN during the daytime
(Liang et al., 1998). Thus, one possible scenario is that MMP-2/9 inhibition increases the
probability of NMDAR activation by extracellular glutamate via mBDNF binding to TrkB.
Because BiPS-induced phase shifts at both ZT 6 and ZT 16 are blocked by the
NMDAR antagonist AP5, we were surprised to see that phosphorylation of α- or β-CAMKII
did not change in response to BiPS treatment. In the SCN, activation of NMDAR leads to
increased intracellular Ca2+ and subsequent CAMKII phosphorylation. This pathway is
commonly observed as a downstream signaling mechanism that phase-shifts the clock
(Vindlacheruvu et al., 1992; Colwell et al., 1994). However, in cultures of cortical neurons,
CAMKIV, but not CAMKII, activity regulates activity-dependent BDNF long-term
potentiation mechanisms (Shieh et al., 1998). Thus, the presence of different isoforms of
CAMK and their overlapping calcium-dependent mechanisms may contribute to why we
did not see increased phosphorylation of either α- or β-CAMKII.
There is evidence that the master clock regulates cyclic expression of CAMs, and
MMP-2/9 cleavage of CAMs could provide feedback to the clock. Candidate MMP-2/9
substrates include the neuroligins, neurexins, and polysialyated neural cell adhesion
molecule (PSA-NCAM), (Glass et al., 1994; Shen et al., 1997; Shen et al., 1999; Glass et
al., 2000; Shen et al., 2001; Fedorkova et al., 2002; Glass et al., 2003; Prosser et al.,
2003; Kiessling et al., 2017). For example, NLG-1 exhibits a diurnal oscillation in mRNA
transcription and protein expression in the mouse forebrain that decreases during the
night and is absent in Clock mutant mice (Hannou et al., 2018a). The transynaptic binding
partners of neuroligins, neurexins, are also linked to the circadian clock, as they exhibit
cyclic mRNA expression in the mouse SCN that peaks at approximately mid-day, followed
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by peak protein expression shortly after lights off (Shapiro-Reznik et al., 2012). PSANCAM is another MMP-2/9 substrate that is highly expressed in the Syrian hamster SCN
during the early morning with lower expression at night (Glass et al., 1994; Shen et al.,
1999; Glass et al., 2003). Application of endoneuramidase (which cleaves PSA from
NCAM, similar to the action of MMP-2/9) to in vitro SCN slices prevents glutamateinduced phase shifts (Prosser et al., 2003). Thus, BiPS application may affect SCN
circadian clock phase by altering the expression of various CAMs, but this possibility has
yet to be studied.
Given that the network of interacting partners of MMP-2/9 is extensive, future work
is necessary to parse out the mechanisms underlying the phase shifts we observed.
Nevertheless, our results add to a growing body of evidence (Cooper et al., 2018) that
the differential expression and enzymatic activities of extracellular proteases in the SCN
across circadian time may help constrain the abilities of particular stimuli to phase-shift
the clock to specific circadian times. The field of neuroscience is showing a robust
appreciation of the ECM and its interacting proteins as active participants in neuronal
communication. Our research on the role of MMP-2/9 in the SCN is consistent with this
viewpoint. The results suggest that endogenous MMP-2/9 activity participates in SCN
circadian clock phase regulation. Moreover, they demonstrate that MMP-9, but not MMP2, activity could be under circadian regulation by the master clock. Although further
studies are necessary to untangle the web of upstream and downstream mechanisms,
we propose that extracellular regulators of MMP-2/9 activity and the cleavage of MMP2/9 substrates may also be under circadian clock regulation.
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Appendix: Figures for Chapter 2
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Figure 2.1: Protein expression of MMP-2 and MMP-9 in SCN tissue does not
change between ZT 6, ZT 16 and ZT 23.
A) Western blot results comparing SCN tissue extract collected at ZT 6, ZT 16 and ZT
23. Each lane contains SCN tissue homogenate collected from one mouse. A ladder of
known protein standards and recombinant MMP-2 protein (r-MMP-2) and r-MMP-9
confirmed identification of the MMP’s. Actin (lower panel) served as a loading control.
The two images were produced using the same blot and fluorescence was detected with
the LiCOR Odyssey-ClX.

B) Separate western blot showing detection of MMP-9

[compared to known, recombinant MMP-9 protein (r-MMP-9)] and actin. (C & D)
Quantification of bands of fluorescence corresponding to MMP-2 (C) and MMP-9 (D).
Fluorescent intensity (reported as total signal) for the protein of interest was set relative
to total actin signal. One-way ANOVA showed that neither MMP-2 nor MMP-9 fluorescent
intensity levels exhibit significant differences between ZT 6, ZT 16 and ZT 23 (MMP-9:
n=5, p=>0.05 between groups and MMP-2: n=6, p=>0.05).
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Figure 2.2: MMP-9 activity is higher than MMP-2 and varies across the circadian
cycle.
A) Gelatin zymography of known recombinant protein (r-MMP-2 and r-MMP-9; 100 ng)
and homogenates of SCN tissue collected at ZT 6, ZT 16 and ZT 23 (10 ug samples
loaded for each time point). B) The same image as (A) displayed with increased contrast
to visualize the fainter gelatinolytic bands chosen to analyze for MMP-2. (C) Histogram
plotting gelatinolytic activity (reported as mean grey value) relative to r-MMP-2 band. Two
way ANOVA examining interaction effects (Tukey’s Multiple Comparisons Method) show
that only gelatinolytic activity of MMP-9 is significantly different than MMP-2 activity at
each time point (*p< 0.01). Additionally, activity of MMP-9 at ZT 6 is significantly higher
than MMP-9 activity at ZT 6 (*p=<0.01) but not ZT 16. Note: It was previously determined
that the latent and active forms of r-MMP-2 generally run at ~66.3 kD and ~55.4 kD,
respectively (Toth & Fridman, 2001). These weights coincide with where our r-MMP-2
band shows up, however our gels were incubated for a longer timeframe, which may
account for our inability to distinguish the two forms of r-MMP-2. The higher band in the
r-MMP-2 lane (between 110 and 130 kD), we believe is a dimer of r-MMP-2, as reported
previously (Frankowski et al., 2012). The doublet that we see with r-MMP-9 likely reflects
the pro- and active forms of this protein (~98 kD and 84 kD, respectively), which were
easier to distinguish on our gel. Below the doublet, we also see a fainter band in our
purified r-MMP-9 sample. As reported previously (Toth and Fridman, 2001), this ~73 kD
form may an auto-activated or mutated species of MMP-9. For more details on identifying
gelatinolytic bands, see (O'Connell et al., 1994; Toth & Fridman, 2001; Frankowski et al.,
2012).
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Figure 2.2 continued
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Figure 2.3: Increasing protein content does not increase detection of MMP-2 in
SCN tissue extract.
Gelatin zymography of SCN tissue samples collected at ZT 6. The results illustrate that
increasing protein concentration of SCN tissue extract did not improve visualization of
MMP-2 gelatinolytic activity. Arrows point to known MMP-9 zymographic bands and the
expected molecular weight where MMP-2 should be present. Also, incubating SCN tissue
extract (40 μg) with the MMP-2/9 inhibitor (100 nM BiPS) before loading does not affect
activity of MMPs in the gelatin zymogram (n=1).
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Figure 2.4: In situ zymography confirms activity of MMP-2/9 in the SCN.
A) In situ zymography images of control and BiPS treated (B) hypothalamic tissue slices
collected at ZT 6, ZT 16 and ZT 23. For each image, the location of the SCN was
confirmed with the nuclear stain, DAPI (blue in merged panel). DQ-Gelatin fluorescence
(green in merged panel) shows strong signal in hypothalamic slices. Negative control
sections (C and D) incubated with either 4% PFA or 100 nM BiPS in the DQ-Gelatin
solution to inhibit MMP-2/9 activity confirm green fluorescence is due to MMP-2/9 activity.
Analyzed images were all taken under 20X magnification using the same laser exposure
settings. Scale bars= 200 μM. To compare DQ-Gelatin fluorescent signal between brain
regions, two circular regions of the same dimensions were selected within each image,
one within the SCN and one within the adjacent anterior hypothalamus (Ant Hypo). E)
The mean grey value of the pixel density corresponding to DQ-Gelatin channel and was
measured in each experimental group (n=3-6). Two-way ANOVA with a post-hoc Tukey’s
test for multiple comparison analysis shows that gelatinolytic activity is lower in the
anterior hypothalamus than in the SCN at ZT 6 and ZT 23, but not at ZT 16, in BiPS
treated slices. However, there were no differences in gelatinolytic activity in either brain
region across time or in response to BiPS treatment of the brain slices prior to harvesting
for zymography. (Asterisks indicate significance level at p<0.05). F) Combined data (n=811) of mean grey values corresponding to MMP-2/9 gelatinolytic activity between control
and BiPS-treated SCN slices. At each time point (**= p<0.01, ***=p<0.001) the
gelatinolytic activity in the SCN is higher than the surrounding anterior hypothalamus
(AH).

48

Figure 2.4 continued
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Figure 2.4 continued

50

Figure 2.5: Inhibiting MMP-2/9 activity during the day and early night phase-shifts
the clock.
Representative single-unit recordings from SCN tissue slices ± BiPS (100 nM) drug
treatment; each graph represents a recording of SCN tissue from one animal. Two hour
running averages of firing rate (Hz) are plotted against zeitgeber time (ZT) in hours. Black
horizontal bars indicate subjective night in the animal colony (ZT 12 - ZT 24). Vertical
dashed line at ZT 6 represents the time of peak of activity in control slices, as seen in (A).
Vertical white bar indicates time of drug treatment (100 nM BiPS) at ZT 6 (B), and ZT 16
(C). BiPS treatment at ZT 6 and ZT 16 induces phase advances and delays, respectively.
(D) Compiled phase shift (h) responses of the SCN circadian clock when treated with
different combinations of drugs targeting MMP-2/9 activity (BiPS), NMDAR receptor
(AP5), Trk-B (K252A), and plasmin [α2-antiplasmin (α2-AP)]. One-way ANOVA comparing
the combined drug treatments to BiPS treatment alone revealed that AP5 blocks BiPSinduced phase shifts at ZT 6 (*** p= < 0.001) and ZT 16 (**p= < 0.01). SCN tissue cotreated with BiPS and α2-AP or K252A (* p=<0.05) at ZT 6 blocks BiPS-induced phase
advances. BiPS treatment at ZT 23 did not produce a significant phase shift, therefore we
did not perform further drug treatments at the time point. N=3 for each treatment, exact
p-values are listed in our results section. Statistical analysis was performed using a Oneway ANOVA, post-hoc Dunnett’s test, where each experimental group was compared to
BiPS treatment alone.
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Figure 2.5 continued
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Figure 2.5 continued
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Figure 2.6: Inhibition of MMP-2/9 at ZT 23 acutely affects firing rates but does not
phase-shift the SCN circadian clock.
A & B) Extracellular electrophysiology recordings in SCN tissue slices maintained in vitro
show that 100 nM BiPS application at ZT 23 shows a double peak in firing rate on Day 2.
Each graph represents data gathered from a separate experiment. C) Control recording
of extracellular firing rates of SCN tissue collected on Day 3 in vitro show a peak at ZT 6.
D) SCN slices treated with 100 nM BiPS at ZT 23 on Day 1 in vitro show a peak at ZT 5
on Day 3, suggesting that acute effects of BiPS treatment on SCN tissue are not
sustained, and the treatment does not induce statistically significant phase shifts
(p=>0.05).

54

Figure 2.6 continued
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Figure 2.7: Inhibition of MMP’s does not affect phosphorylation of α- and βCAMKII.
A) Immunoblot results from control and BiPS-treated SCN tissue homogenates. Green
bands correspond to the primary antibody that detects phosphorylation of the conserved
Thr-286 residue on both α- and β-CAMKIIs (50 and 60 kDa, respectively). Actin (red
bands) served as the housekeeping protein. B) Fluorescent signal for both α- and βCAMKIIs was measured at each time point and set relative to actin signal. Neither the
total signal nor the ratio of α:β isoforms (C) appear to change over time or with BiPS
treatment. Two way-ANOVA with post-hoc Tukey’s test for multiple comparisons results
were non-significant for all pairwise comparisons (p>0.05)
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Figure 2.7 continued
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CHAPTER III: LINKING TIME DEPENDENT STATE CHANGES IN
ASTROCYTIC RAMIFICATION TO THE EXTRACELLULAR
ENVIRONMENT
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This version of this chapter contains completed work of Kathryn A. Halter towards
a second manuscript. Complimentary experiments and data analysis are concurrently
being performed.
Halter, KA and RA Prosser. “Linking time-dependent state changes in astrocytic
ramification to the extracellular environment.” (Manuscript in prep) 2019.
The manuscript written below contains original work designed, executed and
analyzed by Kathryn Halter. Rebecca Prosser contributed to the experimental design,
data analysis, and revisions of the manuscript.

Abstract
Located in the suprachiasmatic nucleus (SCN), the mammalian master clock
synchronizes near 24 hour, or circadian, behavioral and physiologic rhythms. The SCN
also exhibits endogenous, intracellular rhythms to coordinate intercellular synchronization
of its heterogeneous cell types. For example, astrocytes and neurons both express
distinct rhythms in gene expression, intracellular Ca2+ influx, and glutamate secretion.
Astrocytes uniquely exhibit a circadian rhythm in morphology accompanied by rhythmic
glial fibrillary acidic protein (GFAP). In other brain regions, reorganization of GFAP is
necessary for astrocytic morphological changes. This process is mediated by matrix
metalloproteinase (MMP)-dependent cleavage of β-dystroglycan, a cellular adhesion
molecule that localizes to astrocytic endfeet. In the SCN, the level of GFAP increases
expression and becomes more diffusely distributed at night relative to the day. As MMPs
are expressed and active in the SCN, we hypothesized that there may be diurnal
differences in β-dystroglycan expression and/or degradation by MMP-2/9. Further, MMP2/9 cleavage of β-dystroglycan could contribute to astrocytic morphological changes in
the SCN. We determined that β-dystroglycan is highly expressed in the SCN and appears
to colocalize with astrocytes, although its expression is constitutive and its degradation is
unaffected by inhibition of MMP-2/9 activity. Quantitative analysis of SCN GFAP-positive
cells revealed astrocyte morphology is more complex during the late night relative to the
day, without altering a change in total cellular volume. Together, our results suggest that
diurnal SCN astrocytic filopodia extension depends on rearrangement of their intracellular
scaffolding and that these changes may rely on their interactions with ECM molecules.
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Introduction
The mammalian master clock, located in the suprachiasmatic nucleus (SCN),
generates endogenous ~24-hour (circadian) rhythms and synchronizes daily rhythms in
behavior and physiology with the external environment (Schulz & Steimer, 2009;
Golombek & Rosenstein, 2010; Yan et al., 2018). In order to generate the appropriate
output signals needed to regulate circadian physiology of the entire organism, this master
clock must coordinate the self-sustaining oscillators contained within its own
heterogeneous cell types (Aton & Herzog, 2005). Of these cells, astrocytes are major
participants in coordinating the circadian network within the SCN (Prolo et al., 2005), a
role consistent with their robust intracellular rhythms in clock gene expression (Prolo et
al., 2005), Ca2+ rhythms (Brancaccio et al., 2017) and glutamate secretion (Brancaccio et
al., 2017). In SCN primary neuronal cultures devoid of astrocytes or in in vitro SCN slices
treated with drugs disabling glial cell metabolism, spontaneous firing rates of individual
SCN neurons become desynchronized and the master clock is disrupted (Prosser et al.,
1994; Welsh et al., 1995; Shirakawa et al., 2001). Thus, astrocytes are a vital component
in facilitating intercellular synchronization.
Astrocytes exhibit dynamic morphologic responses to increased neuronal activity,
injury, or as a result of neurological disease (Theodosis et al., 2004; Theodosis et al.,
2008; Cheng et al., 2019; Zhou et al., 2019). Examination of mechanisms regulating
astrocytic morphology provide essential information regarding network communication
because the extent and efficiency of inter-neuronal communication depends on the
physical proximity of surrounding cells (Pirttimaki & Parri, 2013). In the SCN of animals
housed in light:dark conditions, the cytoskeletal protein glial fibrillary acidic protein
(GFAP) exhibits increased expression and its distribution pattern becomes more diffuse
at night as compared to the day (Morin et al., 1989; Lavialle & Serviere, 1993; Leone et
al., 2006; Becquet et al., 2008). However, it is unclear if this rhythm is under circadian
regulation because there are conflicting reports concerning GFAP rhythms in animals
housed in constant darkness (Lavialle & Serviere, 1993; Becquet et al., 2008).
Ultrastructural electron microscopic studies of rat SCN observed that the amount that glia
cover neuronal somas (indicated by the percentage of contact between glial appositions
to different neuronal cellular components), does not exhibit diurnal differences, but is
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higher in the SCN compared to the surrounding anterior hypothalamus (Elliott & Nunez,
1994). In contrast, another study found that glial coverage is cell-type and time-of-day
specific. SCN glia exhibit greater dendritic coverage of vasopressin intestinal peptide
(VIP) neurons and less dendritic coverage of arginine vasopressin (AVP) neurons at night
relative to the day (Becquet et al., 2008). Further, brain derived neurotrophic factor
activation of tyrosine receptor kinase B, which is necessary for synaptic plasticity (Lu,
2003), is required for the diurnal changes in astrocytic envelopment of VIP neurons
(Girardet et al., 2013). These studies provide evidence that astrocytic morphological
rhythms are influenced by the SCN circadian clock, but the underlying mechanisms may
depend on extracellular factors.
Proteins interacting with the extracellular matrix (ECM) of the brain form the
physical scaffolding between neurons and astrocytes. These molecules include pre- and
post-synaptic cell adhesion molecules (CAMs), neural cell adhesion molecules (NCAMs),
synaptic CAMs, neuroligins, neurexins, dystroglycans, Ephrins and their receptors, and
integrins. These molecules bind to ECM molecules such as collagen, laminin, elastin,
fibronectin, chondroitin sulfate proteoglycans, as well as to their partner synaptic
adhesion molecules and ligands. Functionally, this interconnected web of proteins
mediates both cellular morphology and intercellular communication (Dityatev &
Schachner, 2003; Cauwe et al., 2007; Frischknecht & Gundelfinger, 2012; Frischknecht
et al., 2014; Lassek et al., 2015; Marcoli et al., 2015; De Luca & Papa, 2017; O'Callaghan
et al., 2017; Ferrer-Ferrer & Dityatev, 2018; Hillen et al., 2018; Song & Dityatev, 2018;
Fawcett et al., 2019). It is well established that ECM-associated molecules play extensive
roles in regulating endogenous circadian rhythms in the SCN (Glass et al., 2000; Shen et
al., 2001; Mou et al., 2009; Girardet et al., 2013; Cooper et al., 2018), but further
characterization of ECM-associated molecules facilitating diurnal changes in astrocyte
morphology is needed.
One candidate extracellular CAM known to regulate astrocytic morphology in other
brain regions is dystroglycan (Michaluk et al., 2007; Bozzi et al., 2009; Sbardella et al.,
2012). Dystroglycan contains two subunits: an extracellular glycoprotein, α-dystroglycan,
and a transmembrane portion, β-dystroglycan (Durbeej & Campbell, 1999; Esapa et al.,
2003). This protein complex stabilizes intracellular cytoskeletal interactions with the ECM
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by bridging actin-bound β-dystrophin molecules (Ibraghimov-Beskrovnaya et al., 1992) to
ECM proteins like laminin, aggrecan and perlecan via carbohydrates on the glycosylated
sidechains of α-dystroglycan (Barresi & Campbell, 2006). Studies examining regional and
subcellular location of dystroglycan subunits in the brain have clarified its function in
structural stabilization. In the developing mouse brain, β-dystroglycan expression in
perivascular glial cells precedes astrocytic filapodial-like protrusions (called astrocytic
endfeet) formation. This implicates β-dystroglycan as an anchor for glial cell attachment
to the basal lamina of vascular epithelial cells (Kalman et al., 2018). Zaccaria et al. found
that neurons in the adult mouse cerebral cortex, olfactory bulb and cerebellum contain αand β-dystroglycan. Supporting work with dystroglycan knockout mice shows that
astrocytes adjacent to pia mater require dystroglycan expression to swell, a
neuroprotective response, after ischemic stroke (Noell et al., 2011). Further assessment
using electron microscopy revealed preferential expression on neuronal post-synaptic
membranes (Zaccaria et al., 2001). Later, the presence of β-dystroglycan on the postsynaptic membrane of hippocampal neurons was confirmed, and long-term potentiation
(LTP)-inducing stimuli were found to increase degradation of β-dystroglycan (Michaluk et
al., 2007). β-dystroglycan localization to astrocytic endfeet that interface with the
vasculature is also seen in the adult mouse cerebral cortex and in the supraoptic nucleus
(Gondo et al., 2014; Souttou et al., 2019). In summary, it is likely that dystroglycan
subunits act as an anchor for neurons and/or astrocytes to bind and stabilize intercellular
connections and communication.
The main extracellular proteases known to degrade dystroglycan are matrix
metalloproteinase (MMP)-2 and MMP-9. MMP-2 and MMP-9 participate in cleavage of
ECM-associated molecules during development, synaptic plasticity and learning and
memory (Ethell & Ethell, 2007). With respect to β-dystroglycan, the catalytic sites of MMP2/9 bind to and cleave the β-dystroglycan subunit (43 kDa), generating a 30 kDa fragment
(Sbardella et al., 2012). This shorter fragment of β-dystroglycan is unable to bind to αdystroglycan and thus this cleavage disrupts dystroglycan interactions with the ECM.
Transfecting an auto-activating MMP-9 (aaMMP-9) protein (Fisher et al., 2002) into a
primary culture of cortical neurons increases expression of the 30 kDa fragment,
confirming β-dystroglycan as a substrate for MMP-9 (Michaluk et al., 2007). Conversely,
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increased β-dystroglycan cleavage after glutamate application is blocked by coapplication of tissue inhibitor of metalloproteases-1 (TIMP-1), the endogenous inhibitor of
MMP-9 (Michaluk et al., 2007).
Cleavage of β-dystroglycan by MMP-9 occurs during a variety of processes that
involve structural reorganization of astrocytes and the surrounding microenvironment. In
mouse brains subjected to an ischemic challenge, cleavage of β-dystroglycan is blocked
by the MMP-2/9 inhibitor captopril (Yan et al., 2016). The same study found that βdystroglycan is expressed near aquaporin-4 (AQP4), a water channel protein specifically
expressed in astrocytic endfeet. In a mouse model of epilepsy, depletion of extracellular
Mg2+ increases β-dystroglycan degradation due to excessive neuronal activity, which
subsequently decreases β-dystroglycan’s association with AQP4 on astrocytic endfeet.
Once again, this degradation-induced reduction is mediated by MMP-2/9 activity (Gondo
et al., 2014). In a model of intracerebral hemorrhage, a non-specific MMP inhibitor,
GM6001, blocks cleavage of β-dystroglycan and increases expression of GFAP (Zhang
et al., 2019). Thus, although β-dystroglycan-modulation of astrocytic morphology is seen
broadly, it is not known whether β-dystroglycan cleavage mediates astrocytic
morphological changes in the SCN.
Past research demonstrates that MMP-2 and -9 are present and active in the
SCN. In hamster SCN tissue homogenates, gelatinolytic activity of both MMPs is
detected, but only MMP-9 gelatinolytic activity peaks during the night as compared to the
day (Agostino et al., 2002). Our laboratory has confirmed the expression of MMP-2/9 in
mouse SCN. Using gelatin zymography, we observed increased gelatinolytic activity
during mid-day, while in situ zymography revealed that MMP-2/9 gelatinolytic activity in
the SCN is greater than in the surrounding anterior hypothalamus (see Chapter 2).
Inhibiting

MMP-2/9

activity

with

2-(benzenesulfonylamino)-N-hydroxy-3-

phenylpropionamide (BiPS) results in time-dependent phase shifts of the clock. BiPS
application at Zeitgeber time (ZT; where ZT 0 corresponds to lights-on and ZT 12
corresponds to lights-off in the animal colony) 6 and ZT 16 produces phase advances
and delays, respectively, while ZT 23 drug application has no effect on clock phase.
Importantly, phase shifts are blocked by the competitive NMDAR antagonist, AP5,
indicating a potential role for glutamate in phase shifts mediated by MMP-2/9 inhibition.
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Because glutamatergic stimulation increases cleavage of β-dystroglycan via MMP-9
activity (Dziembowska et al., 2012), we hypothesized that β-dystroglycan is expressed
and functionally active in the SCN. Using complimentary techniques, we sought to
visualize and quantify β-dystroglycan protein expression in the SCN. We also examined,
using western blotting, if β-dystroglycan is a preferred substrate for MMP-2/9. Further, we
investigated the potential participation of β-dystroglycan as a regulatory component in
astrocytic morphological rhythms.

Materials and Methods
Immunohistochemistry
All animal procedures followed University of Tennessee, Knoxville Institutional
Animal Use and Care Committee approved protocols. Animals used for this study were
adult male, C57BL/6 mice (Envigo, Indianapolis, IN) housed in a 12:12 light:dark cycle,
with food available ad libitum. Blocks of hypothalamic tissue containing the SCN were
harvested at ZT 6, ZT 16 or ZT 23 (n=5-11) and immediately fixed in 4%
paraformaldehyde (PFA) for 30 minutes. Tissue blocks were stored in 1X PBS solution
containing 30% sucrose overnight and placed in optimum cutting temperature (OCT)
compound (Sakura® Finetek, USA INC) the following morning. 25 μm tissue sections
were prepared using a Leica cryostat and mounted to VWR Vista Vision™ Histobond®
adhesive slides (VWR). Slides were selected for staining with one of two β-dystroglycan
antibodies (see Tables 1 and 2 in the appendix for all antibody information), either antimouse β-dystroglycan (1:500; Leica Novocastra) or anti-rabbit β-dystroglycan (1:500;
Abcam), and/or an antibody for GFAP [chicken-anti-GFAP (1:1,000; Abcam)]. Slides were
dried at room temperature, rinsed in 1X PBS and fixed again with 4% PFA for 30 minutes.
After 3 X 5-minute washes in 1X PBS, slides were incubated in a 80°C waterbath for 20
min in antigen retrieval solution (10 mM Tri-sodium citrate, pH 6.0). Three washes in 1X
PBS were repeated and slides were left to block for an hour in blocking solution (5%
Normal Goat Serum, 5% Bovine Serum Albumin, and 0.1% Triton-X 100 in 1X PBS).
Immediately after blocking, primary antibodies were added to a volume of 1:2 dilution of
blocking solution in 1X PBS and allowed to incubate overnight at 4°C. After three washes
with 1X PBS, slides were incubated with complementary secondary antibodies
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conjugated to fluorophores of non-overlapping wavelengths: (1) anti-chicken-568, (2)
anti-mouse-488, and/or (3) anti-rabbit 488 (all from Invitrogen). Slides were mounted
using Vectashield Antifade mounting medium containing DAPI (Vector Laboratories;
Burlingame, CA), cover-slipped, and sealed. Images were taken using a Leica CTR600
Florescence Microscope [20X magnification for integrated pixel density (mean grey value)
measurements of bilateral SCN regions] or an Olympus 1x-83 inverted confocal
microscope (for 40X and 60X magnification of GFAP-labeled cells for qualitative colocalization and Sholl Analysis). Acquisition settings and laser exposures were kept
constant during and between imaging sessions.
Sholl analysis
For Sholl Analysis (Sholl, 1953) a Z-stack of 10 images taken at 1μm steps (60X
magnification) was collected using the Olympus 1x-83 inverted confocal microscope. Only
SCN glial cells that had a clear nucleus and extensions contained within the Z-stack of
images were selected for analysis. Two reviewers who were blind to the treatments were
trained to perform cell tracing. Ten practice astrocytes (from three images of SCN tissue,
one at each time point) were given to reviewers. The percent difference of the average
“ending radii” and average “max intersections” were compared and fell within 90%
agreement for these morphologic measures. Next, experimental images were assigned
random identification and each blind reviewer analyzed an equal number of GFAPpositive cells corresponding to each time-point.
Using Image-J, Fiji (NCBI), the images were converted to 8-bit and pixel
dimensions were converted into μm. Cells were traced using the Simple Neurite Tracer
program according to previously published methods and tutorials (Longair et al., 2011;
Schindelin et al., 2012; Binley et al., 2014; Sampedro-Piquero et al., 2014; Tavares et al.,
2017). Each branch-point belonging to a single astrocyte was traced through the entire
Z-projection of the image and saved. After tracing was completed and individual traces
were saved, fill volumes were measured and Sholl Analysis was performed. To measure
the cell soma volume, each individual cell trace was loaded back onto the original Z-stack
of images. A new branch-point was drawn from the center point of the cell to the outermost
boundary of the cell soma. After selecting only the new cell path, the “Fill Volume” feature
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was selected on the Simple Neurite Tracer program again and the volume data for each
cell was saved. The data collected from the two reviewers was un-blinded and merged
for further statistical analysis. In total, the morphology of 5-6 randomly selected astrocytes
in the SCN from two animals for each experimental group was quantified. Therefore, 1012 astrocytes at each time-point (ZT 6, ZT 16 and ZT 23) were included in our analysis.
Colocalization analysis using Coloc-2 ImageJ Program
After astrocytes (10-12 astrocytes at each time-point) were traced using the Sholl
Analyses protocol above, the SCN images were further analyzed to quantify the signal
overlap between fluorescence corresponding to β-dystroglycan (red channel) and GFAP
(green channel). Z-stacks of both red and green channels of the 60X, Z-stack images
were re-opened and merged. Previously saved astrocyte traces corresponding to the
correct image were opened and the ROI freehand tool was used to outline the edges of
GFAP staining of the loaded cell trace. The ROI was maintained throughout the Z-stack
and adjustments to the ROI were made if necessary. Next, the Coloc-2 plugin program
was opened to run the Pearson’s coefficient test after selecting the “bisection” option
under the “threshold regression” prompt. The Pearson’s coefficient test is a multipurpose
test for measuring the statistical association (R-value) between two variables where -1=
no correlation and +1=perfect correlation. The R-value for each cell was saved and the
mean R-value (+/- SEM) between each time point was analyzed for statistical significance
using One-Way ANOVA analysis.
Brain slice preparation
Brain slices containing the SCN were maintained in a perfusion dish containing
Earle’s Balanced Salt Solution (EBSS; MP Biomedicals, Solon, OH), supplemented with
gentamicin, dextrose, and sodium bicarbonate, saturated with 95% O2/5% CO2, and kept
at 37°C (Prosser & Gillette, 1989; Prosser et al., 1994; Mou et al., 2009; Yamada &
Prosser, 2014; Cooper et al., 2017). Coronal slices (500 μm) containing the SCN were
kept in constant conditions until collection, unless otherwise noted.
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Chemical treatment
The experimental concentration (100 nM) of BiPS (Calbiochem) to block MMP-2/9
activity (Tamura et al., 1998; Lauzier et al., 2008), was chosen based on the IC50
determined by the manufacturer’s specifications and on previous research performed by
our laboratory. BiPS was bath-applied to SCN slices for the 40 minutes surrounding ZT
6, ZT 16 or ZT 23 on the day brain slices were prepared. Slices collected immediately
after drug treatment were immediately frozen on dry ice and stored at -80°C until utilized
for protein extraction.
Western blotting
Brain slices containing the SCN were prepared in the morning on day one in vitro
and maintained as described above. Control and drug treatment slices remained in the
perfusion dish until collection. Control slices were collected immediately before a 40
minute BiPS (100 nM) bath application at ZT 6, ZT 16, or ZT 23 (n=6 for each time point).
BiPS-treated slices were immediately collected after drug treatment. All tissue samples
were rapidly frozen at -80°C.
Protein extraction utilized reducing conditions, and protein concentration (μg/μL)
was measured using the Bradford assay. 30 μg of protein extract from each sample was
loaded into a 4-12% Bis-Tris BOLT gel (Invitrogen, Carlsbad, CA) and separated by
electrophoresis in 1X MOPS [(3-(N-morpholino)propanesulfonic acid] buffer (Invitrogen).
Proteins were transferred from the gel to an Immobilon-PVDF (EMD-Millipore) membrane
using a Trans-Blot Turbo (BioRad, Hercules, CA) transfer system. Proteins of interest
were detected following the Near-Infrared (NIR) Western Blot Detection protocol,
available online. For this experiment, we detected β-dystroglycan (rabbit anti-βdystroglycan, 1:1,000; Abcam) and actin (goat anti-actin, 1:5,000; sc-1616, Santa Cruz
Biotechnologies, Dallas, TX) as a loading control. Incubation and subsequent detection
of the signal intensities of fluorescent secondary antibodies conjugated to LI-COR IRDye® were detected with an Odyssey®-CLx system (LI-COR Biosciences, Lincoln, NE).
Band intensity analysis was performed using the Image Studio Lite™ v 5.0 software (LICOR Biosciences). Fluorescent signal for each protein was measured as pixel density
minus background pixel density and reported as total signal. The total signal
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corresponding to each protein is reported as relative to the total signal of the actin band
present for each sample.
Statistical Analysis
Statistical significance was determined using GraphPad Prism software version
8.0.1. One way-ANOVA was performed to compare means ± SEM across time. Two wayANOVA with a post-hoc Tukey test for multiple comparisons was performed to compare
means ± SEM across time and between experimental treatment groups.

Results
Staining patterns revealed by two β-dystroglycan antibodies
We began our study by determining which of two commercially available antibodies
for β-dystroglycan works best in SCN tissue. First, we tested a commonly used mouse
monoclonal antibody for β-dystroglycan developed by Novocastra. Previous reports using
this antibody reveal that β-dystroglycan expression appears to localize with endothelial
vasculature cells in brain tissue (Zaccaria et al., 2001; Agrawal et al., 2006; WolburgBuchholz et al., 2009; Kalman et al., 2018). Surprisingly, many of the studies using this
antibody also used Mus musculus as their model organism. This can be problematic
because the secondary antibodies can recognize mouse IgGs (Daneshtalab et al., 2010;
Notter et al., 2014) and therefore result in non-specific binding to off-target proteins.
Therefore, we also tested a second β-dystroglycan antibody, developed by Abcam, that
was isolated from a rabbit host organism. Based on a previous study, we elected to postfix unperfused brain tissue in 4% PFA with the goal of preserving the integrity and
structure of ECM proteins (Notter et al., 2014).
Our initial assessments aimed to confirm and compare the binding efficacy of
commercially available of β-dystroglycan antibodies. Mouse brain tissue samples
collected at ZT 6 were incubated with either anti-mouse-488 or anti-rabbit-488 fluorescent
secondary antibodies and the DAPI nuclear stain. Using DAPI, we were able to identify
the cell dense SCN region in the hypothalamus. In SCN tissue incubated with the antimouse secondary antibody we observed diffuse background fluorescence and a staining
pattern that resembled epithelial vasculature cells (Fig 3.1 A). In comparison, neither the
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vasculature epithelial cell-like pattern nor the diffuse background staining was apparent
in tissue samples incubated with the anti-rabbit secondary antibody (Fig 3.1 C). Tissue
incubated with mouse anti-β-dystroglycan primary antibody followed by anti-mouse-488
secondary antibody (Fig 3.1 B) exhibited a stronger signal than that seen in samples
incubated with the anti-mouse-488 secondary antibody alone, but the pattern continued
to exhibit the “epithelial vasculature-like” pattern seen in Fig 3.1 A. Conversely, the
staining observed in tissue incubated with rabbit anti-β-dystroglycan primary and antirabbit-488 secondary antibodies (Fig 3.1 D) was substantially different and appeared to
localize to cell bodies. We observed strong fluorescent signal that overlapped the SCN
region, along with fluorescent signal near the cell-layer surrounding the third ventricle.
Based on the apparent non-specific staining observed when the tissue sections were
incubated with the anti-mouse-488 secondary antibody, we elected to use the rabbit-antiβ-dystroglycan throughout the rest of our study.
β-dystroglycan expression in the SCN is constitutive and colocalizes with
astrocytes across circadian time
Previous work examining the diurnal expression of various extracellular CAMs in
the mammalian SCN has implicated a few in circadian clock regulation (Glass et al., 1994;
Lee et al., 1995; Shen et al., 1997; Shen et al., 1999; Glass et al., 2000; Shen et al., 2001;
Fedorkova et al., 2002; Glass et al., 2003; Prosser et al., 2003; Cooper et al., 2018).
Although the expression of β-dystroglycan has not been studied in the SCN, it has been
found to localize on GFAP-positive astrocytic endfeet in other brain regions (Zaccaria et
al., 2001; Agrawal et al., 2006; Wolburg-Buchholz et al., 2009; Noell et al., 2011; Gondo
et al., 2014). Reports of mRNA and protein expression in the SCN indicate that GFAP is
concentrated in the SCN and expressed in a rhythmic pattern (Morin et al., 1989; Lavialle
& Serviere, 1993; Ikeda et al., 2003; Leone et al., 2006; Becquet et al., 2008; Deng et al.,
2010). Therefore, we hypothesized that β-dystroglycan would colocalize with GFAP
positive cells in the SCN and potentially be expressed at different levels during the midday (ZT 6), early night (ZT 16) and late night (ZT 23).
Figure 3.2 A shows fluorescent images taken from unperfused SCN tissue colabeled with DAPI and antibodies detecting both β-dystroglycan and GFAP. We observed
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the presence of both proteins in the region corresponding to the SCN at each time point.
Next, we measured the mean gray value of the fluorescent signal corresponding to either
β-dystroglycan or GFAP by outlining the region that corresponded to SCN region defined
by DAPI signal. The mean gray area ± SEM for the total signal (minus background
selected from a non-SCN region) was calculated and plotted at each time point for both
proteins. One-way ANOVA with a Tukey’s multiple comparisons test revealed that βdystroglycan expression levels were not statistically different at any selected ZT time
(p=0.9609) (Fig 3.2 B). Previous research has demonstrated that GFAP expression varies
across time (Lavialle & Serviere, 1993) and is lowest during the night (Leone et al., 2006).
However, a One-way ANOVA with a Tukey’s multiple comparisons test found that total
GFAP expression was not significantly different across time (Fig 3.2 C, p=0.5664) nor
between SCN subregions (Fig 3.2 E). However, analysis of the mean grey value of βdystroglycan expression between the ventral and dorsal sub-regions of the SCN and the
AH determined that at each time point β-dystroglycan expression in dorsal SCN was
higher than the AH (Fig 3.2 D; ZT 6 p=0.0339 , ZT 16 p=0.0161 , ZT 23 p=0.0246) and
that the SCN ventral region was significantly different than the AH at ZT 16 (p=0.0392).
To assess potential co-localization of GFAP and β-dystroglycan, we re-imaged the
same immunolabeled tissue samples under higher magnification with a confocal
microscope. From each of the previously identified regions of interest examined under
lower power, we took a series of ten Z-stack images at higher magnifications (40X and
60X) using a step size of 1 μM, displayed in Figure 3.3 A, are representative images (40X)
of flattened Z-stacks (by average pixel density) taken at each time point. To more
precisely assess potential colocalization of β-dystroglycan and GFAP (overlapping red
and green channels produce a yellow signal), for several of these images we separated
the Z-stacks and scanned the image at each Z-step to locate overlapping signal using
60X magnification. Through this process we identified areas of overlapping signal, as
shown in Figure 3.3 B. Careful examination through the entire Z-plane of images showed
that β-dystroglycan staining is in close proximity to GFAP-containing astrocytic somas
and filiopodia in certain planes and not in others. These areas of overlapping fluorescence
further support a potential interaction between β-dystroglycan and GFAP in the SCN.
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β-dystroglycan and GFAP colocalization is highest during the late night
Cell morphology of 10-12 GFAP-positive cells for each ZT (60 X magnification,
n=2 mice per ZT) was analyzed by two reviewers that were blind to experimental
conditions. Cells were visually assessed for GFAP expression throughout the entire Zplane (10 μm), and only cells contained within the Z-plane were selected for tracing and
subsequent analysis. After the center of a cell was located, all branches were traced
outward from the center, starting with the longest branch, using the Simple Neurite
Tracer program. The Z-projection of the image stack was maintained and helped
determine if a branch was contiguous with the cell of origin or if it originated from
surrounding GFAP-positive cells. Subsequent (secondary, tertiary, etc.) branches were
added until all branches were traced. Quantification of β-dystroglycan and GFAP
overlap using the ImageJ Coloc-2 program shows a higher degree of signal overlap (a
Pearson’s R-value of 1 indicates perfect overlap) at ZT 23 as compared to ZT 16 (p=
0.0362). This suggests that although the total expression of GFAP and β-dystroglycan
do not change between time points, the proximity of the two proteins with one another
increases during the late-night as compared to the early night.
Sholl analysis of GFAP positive cells in the SCN suggests astrocytes at ZT 23 are
more ramified
Previous light and electron microscope studies in SCN tissue report that GFAP
protein expression levels change over time and GFAP-labeled cells exhibit daily
morphological rhythms (Lavialle & Serviere, 1993; Leone et al., 2006; Becquet et al.,
2008; Girardet et al., 2010). However, our immunohistochemistry data showed that
overall GFAP expression in the SCN is constant across time. Because our confocal
images of GFAP-positive cells were of sufficient resolution to view individual glial cells
and their branches, we continued our study by performing a quantitative assessment of
their morphological characteristics across the day using a Sholl Analysis (Sholl, 1953).
Representative images of GFAP-positive cells and an illustration of the Sholl Analysis
process are shown in Figure 3.4 A.
First, the volume of each cell was measured using the fill feature and then Sholl
analysis was performed. Briefly, Sholl analysis uses concentric circles drawn around the
71

center point of the cell at set intervals (1 μM radius step size) and counts the number of
times the circles are crossed (Sum intersections). A mathematical model then
extrapolates various features of cellular morphology, introduced below, and generates a
quantified value for each feature. Figure 3.4 B contains histograms of the data that
summarize our findings. Interpretations of the data were aided by previous studies
utilizing this technique (Ristanovic et al., 2006; Binley et al., 2014; Ferreira et al., 2014;
Tavares et al., 2017).
We found that both the total cell volume [Volume (μm3)] and Soma Volume (μm3)
of GFAP-positive SCN astrocytes was not significantly different between the sampled
cells across time (p=0.4184 and p=0.4876). Additionally, neither the total number of circle
intersections for each cell (Sum intersections) nor the maximum number of circle
intersections along a single arbor (Maximum intersections) was significantly different
between ZT 6, ZT 16 and ZT 23 (p=0.0799 and p=0.9031, respectively). We interpret
these findings to mean that astrocytes in the SCN maintain their total cellular volume and
total number of branches across the time points observed.
In contrast to the features mentioned above, data corresponding to cell extension
and ramification (a term that describes the complexity of the branching network of the
cell) identified statistically significant differences over time. We found that the total radial
extension (Ending Radius; the radial length of the last concentric circle intersected) of
astrocytes at ZT 23 (mean ± SEM: 44.22± 9.561 μm) was significantly greater than at ZT
6 (33.30 ± 3.002 μm; p=0.0370) and ZT 16 (30.82 ± 2.964 μm; p=0.0074). The
Ramification index (sampled) is calculated by dividing the Maximum intersections
(defined above) by the number of primary branches. Higher Ramification index values
indicate a larger number of secondary, tertiary, etc. branches. Our data indicate that
astrocytes at ZT 23 (mean ± SEM: 7.472 ± 1.254) had a significantly higher Ramification
index than at ZT 6 (3.182 ± 0.3958; p=0.0019) and ZT 16 (3.546 ± 0.1813; p=0.0044). A
second measure of ramification is the Maximum intersection radius. This value represents
the distance from the cell body (μM) at which the highest number of branch intersections,
or branch density, occurs. Again, this measurement was significantly higher at ZT 23
(mean ± SEM: 22.22 ± 2.330 μM) when compared to ZT 6 (10.08 ± 1.717 μM; p=0.0009)
and ZT 16 (12.84 ± 2.273 μM; p=0.0106). Thus, cells at ZT 23 have their highest
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concentration of branches further away from their cell body than at ZT 6 and ZT 16. The
Mean Value, representing the average number of circle intersections per astrocyte, was
significantly lower at ZT 23 (mean ± SEM: 2.752 ± 0.1527) than at ZT 6 (4.297 ± 0.3136;
p=0.0002) and ZT 16 (3.956 ± 0.2265; p=0.0002). Together, these data show that
although cells at ZT 23 do no change their total volume or total branch number, their
branching structure that is more complex, and increases ramification as the distance from
the cell body increases. Across all these parameters, it is noteworthy that the differences
were consistently greater between ZT 6 and ZT 23 than between ZT 16 and ZT 23. This
suggests that astrocytes at ZT 23 were slightly more ramified than they are at a ZT 16
and dramatically more ramified than at ZT 6.
Two additional Sholl analyses are useful in understanding the differences in
astrocyte morphology derived from our data (see Sholl Plot panel of Fig 3.4 A for
illustration). The first measurement, kurtosis, describes the distribution of concentric
circle-branch intersections across the entire circumference of the cell. Cells with kurtosis
values close to zero exhibit a Gaussian distribution of intersections centered around the
concentric circle corresponding to the mean number of intersections. Numbers greater
than 1.0 indicate that the distribution of circle intersections exhibits a sharper peak in
distribution around the circle corresponding to the largest number of intersections, while
negative values are consistent with a flattened distribution of intersections. Our data show
that cells at ZT 23 had a significantly greater kurtosis value (mean ± SEM: 1.457 ± 0.1527)
than cells at ZT 6 (0.05582 ± 0.4350; p=0.0457) but were not significantly different from
cells in the ZT 16 (0.3771 ± 0.3326; p=0.1478) experimental group. Lastly, the Sholl
skewness measurement describes the directional distribution of intersections around the
concentric circle where the mean number of intersections is located. A skewness number
close of zero indicates that the number of intersections is distributed symmetrically around
the mean number of intersections. Positive values indicate an asymmetrical distribution
where a higher population of intersections exists further away from the cell, while negative
values indicate the distribution of intersections is closer toward the cell body. We found
that the largest measure of skewness occurred at ZT 23 (mean ± SEM: 1.154 ± 0.1135)
and was significantly different from ZT 16 (0.2140 ± 0.2140; p=0.0013) and ZT 6 (-0.2887
± 0.1773; p<0.0001). These data suggest that the amount of branching displayed by SCN
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astrocytes at ZT 23 is highly concentrated at the distal end of the cell, with a distribution
skewed distally from the cell body compared to the day and the early night.
Beta-dystroglycan protein expression in SCN tissue slices is not rhythmic and is
not affected by inhibiting MMP-2/9 activity
In other brain regions, such as the hippocampus, the extracellular proteases MMP2/9 are known to cleave the β-dystroglycan subunit into a 30 kDa fragment (Michaluk et
al., 2007). Additionally, β-dystroglycan cleavage increases when MMP-2/9 activity
increases (Li et al., 2016). As MMP-2/9 are expressed and active in the SCN (Agostino
et al., 2002)(Chapter 2) we investigated whether MMP-2/9 enzymatic activity modulates
β-dystroglycan degradation over the course of the day.
The benefits of utilizing SCN tissue slices maintained in vitro are that the
rhythmicity of the circadian pacemaker remains unaffected (Gillette & Prosser, 1988;
Prosser & Gillette, 1989) and this preparation easily allows for tissue collection and
subsequent protein extraction after an acute drug treatment (Mou et al., 2009; Lindsay et
al., 2014; Cooper et al., 2017; Yamada & Prosser, 2018). Using western blotting, we
measured β-dystroglycan protein expression in SCN tissue slices incubated with or
without the BiPS inhibitor (see Methods) using the rabbit anti-β-dystroglycan antibody,
which detects the full and truncated forms of β-dystroglycan. Therefore, we analyzed full
length (43 kDa) vs. cleaved (30 kDa) β-dystroglycan levels with and without MMP-2/9
inhibition at ZT 6, ZT 16 and ZT 23.
Figure 3.5 shows that both the full length (43 kDa) and truncated (30 kDa) forms
of β-dystroglycan are expressed in SCN tissue slice homogenates. Two-way ANOVA
determined that there were no statistically significant differences in expression of the fulllength (p=9.879) or truncated fragments (p=9.870) of β-dystroglycan (relative to actin)
across time or in response to BiPS treatment. Further analysis showed that the total
amount of β-dystroglycan ([full-length signal + truncated signal])/actin signal) also did not
exhibit statistically significant changes across time (p=0.9196). Lastly, we examined the
ratio of truncated to full-length β-dystroglycan across the three time-points. Again, there
was no statistically significant difference in this ratio across time (p=0.5998).
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Discussion
In this study, we investigated a possible link between MMP-2/9 function and
circadian rhythms in astrocyte morphology by examining the expression and proteolytic
cleavage of β-dystroglycan in the SCN. We found that β-dystroglycan is highly enriched
in the SCN and that it appears to be partially co-localized with GFAP. The co-localization
pattern suggests that β-dystroglycan is in close proximity to astrocytes and thus could
serve as a structural bridge to facilitate binding to the ECM. Additionally, we demonstrated
with quantitative morphological analysis that SCN astrocytic morphology exhibits
changes in select parameters across the circadian cycle while the total intracellular
volume of GFAP remains constant. However, MMP-2/9 cleavage of β-dystroglycan may
not directly regulate the diurnal astrocytic state changes, as the total level and level of
cleaved β-dystroglycan does not change dependent on either time or MMP-2/9 inhibition.
Before selecting an antibody, it is necessary to choose a secondary antibody that
is raised in a species outside of the host animal you wish to use for protein detection
(Harlow, 1999; Daneshtalab et al., 2010). A proper secondary antibody-only negative
control should be performed to confirm antibody specificity. We used these basic
principles of immunohistochemistry to characterize the localization pattern of βdystroglycan in SCN tissue. The staining pattern observed in SCN tissue incubated with
only the anti-mouse-488 secondary antibody was almost identical to the stain visualized
after the combination mouse anti-β-dystroglycan + anti-mouse-488 antibodies. This
pattern produced using the anti-β-dystroglycan closely resembles the microvasculature
of the brain and is consistent with past studies, (Zaccaria et al., 2001; Agrawal et al.,
2006; Wolburg-Buchholz et al., 2009; Kalman et al., 2018); however, we did not detect
this pattern in either the secondary-only or primary-secondary combination of the rabbit
anti-β-dystroglycan and anti-rabbit-488 antibodies. Therefore, we concluded that the
staining observed using the rabbit antibodies was specific to β-dystroglycan expression.
We also believe that the localization data from the previous studies should be considered
with caution, given our comparison of the two antibodies.
Changing levels of either β-dystroglycan or GFAP can accompany changes in
astrocytic structure (Noell et al., 2011; Gondo et al., 2014). Our observations of βdystroglycan and GFAP protein expression in the SCN, however, found no significant
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changes between ZT 6, ZT 16 and ZT 23 using both immunohistochemistry and western
blotting (Figs 3.2 and 3.5). Although our GFAP protein expression data are not consistent
with a previous observation of increased GFAP expression at ZT 6 compared to ZT 18
(Leone et al., 2006), they are consistent with a different study that observed constant
GFAP levels in the SCN of hamsters housed in light:dark conditions (Moriya et al., 2000).
These inconsistencies may be due to different antibodies used, the model system (mice
vs. hamster vs. SCN glial cell culture), using in vivo vs. in vitro tissue samples, or the
manner in which our samples were collected (perfused vs. non-perfused tissue). In the
future, it may be necessary to measure GFAP protein expression across more time
points, under different lighting schedules, and utilizing a variety of analyses to better
understand the factors regulating GFAP expression in the SCN.
Highlighting the benefits of using more nuanced analyses, quantitative
examination of GFAP positive cells in the SCN using Sholl analysis revealed multiple
aspects of astrocytic morphology that vary over time. Our analysis shows that astrocyte
morphology is different between the early night (ZT 16) and late night (ZT 23), while even
larger differences exist between mid-day (ZT 6) and late night (ZT 23). First, Sholl analysis
shows astrocytes in our samples do not exhibit a change in total cellular or somal volume,
the total number of radii intersections or the maximum number of branches per individual
arbor. We interpret these findings as indicating that the total volume of each astrocyte (as
well as total GFAP expression within each astrocyte) does not change significantly across
these three time points.
The complexity of the branch pattern, however, increases as the circadian clock
progresses from midday (ZT 6) to late night (ZT 23), as does the length of the cell. Thus,
without changing the total number of branches, the filopodia intersect with the concentric
circles drawn around the cell body more frequently, suggesting that the path through
which the branches extend becomes more irregular. Next, an increased Ramification
index at ZT 23 vs. ZT 6 and 16 indicates that at ZT 23 astrocytes have more higher-order
branches. In contrast, the branching pattern shows that there are more primary branches
at ZT 6 and ZT 16 than at ZT 23. This suggests that in the late evening, when astrocytes
are extending their filopodia, they reorganize their cytoskeleton to reduce the number of
primary braches while increasing the number of higher-order branches. The results of the
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skewness and kurtosis measurements align with this interpretation, as they indicate that
the branching pattern of astrocytes is more asymmetrical and that the distribution of
GFAP within each cell shifts further away from the cell body at ZT 23. Together, we
interpret these results to mean that astrocyte morphology transitions from a non-complex
and more condensed form towards an extended shape with increased ramifications distal
from the cell body as circadian time progresses from the day into the late night. However,
these changes do not require a change in overall GFAP expression. Consistent with this,
other studies have found that changes in astrocyte morphology do not necessarily require
a change in GFAP expression (Safavi-Abbasi et al., 2001), but rather are thought to
involve a redistribution of the protein within each cell. Because we observed that
colocalization of GFAP with β-dystroglycan is highest at ZT 23, we hypothesize that the
coincident increase in ramification of astrocytes requires increased interactions with
ECM-associated molecules. Further, the proteolytic mechanisms governing the
anchoring of astrocytic extensions to the extracellular environment may require the
activity of MMP-2/9.
In a previous study, we used gelatin zymography to indirectly measure MMP-2/9
activity in the SCN and found that MMP-2/9 gelatinolytic activity is highest during the midday (ZT 6) and lowest during the late night (ZT 23). It is possible that the increased MMP2/9 proteolytic activity at ZT 6 creates an extracellular environment that permits
morphologic change that reaches a maximum at ZT 23. Therefore, we suggest that the
day to night transition in astrocytic morphologic change is mediated by MMP-2/9
dependent degradation of ECM-associated molecules, providing unobstructed space for
astrocytic filopodia to extend in length and increase the complexity of their branches.
In other brain regions, β-dystroglycan cleavage by MMP-2/9 is necessary for
astrocytic morphological changes. Because β-dystroglycan expression is higher in the
SCN than the AH (Fig 3.2 D) and exhibits greater colocalization with GFAP at ZT 23 than
at ZT 16 (Fig 3.3 C), regulation of β-dystroglycan expression and subsequent differences
in astrocytic morphology may be regulated by circadian variations in extracellular
protease activity. Based on our data and the literature, we proceeded to assess βdystroglycan proteolysis by MMP-2/9 as a potential mechanism contributing to the
astrocytic structural changes in the SCN. However, we found that β-dystroglycan
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cleavage is unaffected by MMP-2/9 activity at any of the timepoints we investigated.
Further, β-dystroglycan total, full length and cleaved peptide expression is constant over
time. It is possible that the time we collected tissue samples before and after BiPS
treatment was not optimal for assessing the effect of MMP-2/9 activity on β-dystroglycan
cleavage. For example, researchers investigating the effects of epileptic activity in cortical
brain slices waited one hour after stimulation before tissue collection and observed a
marked degradation of β-dystroglycan (Gondo et al., 2014). In primary cortical neuron
cultures, β-dystroglycan-mediated reduction of neurite outgrowth (by 30%) requires a
minimum incubation period of 24-hours with TIMP-1, an endogenous inhibitor of MMP-9,
to induce a change (Ould-yahoui et al., 2009). In another study, a 50 μM dose of
glutamate applied for 10 minutes increased cleavage of β-dystroglycan for up to 20
minutes after treatment; however, the highest level of degradation was seen just 10
minutes after the treatment (Michaluk et al., 2007). As our BiPS treatment lasted for 40
minutes, it would be interesting to collect SCN samples at more frequent and extended
times after treatment and compare the amount of truncated β-dystroglycan at each
interval to fully elucidate the effect of BiPS on β-dystroglycan cleavage.
Our examination of β-dystroglycan and GFAP staining did unveil potential
differences in localization patterns within the SCN and surrounding hypothalamus. First,
the expression of β-dystroglycan is higher in the dorsal subregion of the SCN relative to
the anterior hypothalamus at all three times, while the ventral SCN exhibited higher
expression only at ZT 16 Future studies examining a possible difference in dorsal vs.
ventral SCN expression of β-dystroglycan should utilize antibodies for neuropeptides,
such as AVP or VIP, that are differentially expressed in these sub-regions, to more
confidently characterize β-dystroglycan localization patterns, expression patterns and
identify regulatory mechanisms that are tied to the circadian clock.
A secondary observation based on our immunohistochemistry results is that both
β-dystroglycan and GFAP are highly expressed near cells surrounding the third ventricle.
Many laboratories have investigated the contribution of astrocytes to regulation of the
blood brain barrier (BBB). Higher neuronal activity increases nutrient demand, which
activates astrocytes, increases capillary fenestration size and increases blood flow to
regions that are nutrient deficient (Iadecola, 2004). Research has shown that extracellular
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CAMs, including β-dystroglycan, mediate the changes in fenestrations between the
endothelial capillary walls and astrocytic endfeet (Abbott, 2002; del Zoppo & Milner,
2006). Given that BBB permeability is regulated by the circadian clock (Nakazato et al.,
2017; Cuddapah et al., 2019), it would be interesting to investigate if astrocytic
morphological changes, mediated by β-dystroglycan cleavage, are involved in circadian
BBB regulation.
As mentioned earlier, cleavage of β-dystroglycan by MMP-2/9 generally occurs
after injury or response to significant increases in neuronal activity (Michaluk et al., 2007;
Frischknecht et al., 2014; Yan et al., 2016). In our study, BiPS application did not affect
β-dystroglycan protein levels, suggesting MMP-2/9 catalyzes a different substrate in SCN
tissue. A variety of ECM-associated molecules that are expressed in the SCN and/or
implicated in the regulation of circadian rhythms (Cooper et al., 2018) are also recognized
as MMP-2/9 substrates (Ethell & Ethell, 2007). For example, quantitative PCR and in situ
hybridization experiments in mice determined that the SCN and other retinorecipient
regions are enriched in collagen25a1, a main substrate for MMP-2/9 (Monavarfeshani et
al., 2017). Interestingly, the composition and mechanical stiffness of the extracellular
microenvironment, of which collagen is a pivotal component, can determine the amplitude
of clock gene rhythms in breast tissue (Yang et al., 2017; Broadberry et al., 2018). In
fibroblasts isolated from mice, qPCR analysis found that genes encoding for collagen-I
precursors and binding immunoglobulin protein (BiP), a protein that aids in collagen
secretion and folding, exhibit rhythmic mRNA expression (Pickard et al., 2019). Because
collagen expression in other tissues appears to be controlled by endogenous circadian
clocks, it would be worth investigating if MMP-2/9 modulation of clock phase involves
collagen cleavage in the SCN.
Another cellular adhesion molecule that may serve as a substrate for MMP-2/9 in
the SCN is PSA-NCAM (polysialylated-neural cell adhesion molecule). PSA-NCAM is
known to play an important role in brain plasticity (Theodosis et al., 1994; Bonfanti, 2006)
and injury. In a mouse model of cerebral artery occlusion, inhibition or gene knockout of
MMP-9 ameliorates ischemia-induced neuronal damage and decreases the amount of
NCAM cleavage (Shichi et al., 2011). Although the majority of PSA-NCAM expressed in
the brain is located on neuronal membranes, it is also expressed on the cell surface of
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astrocytes in cortical primary cultures (Minana et al., 1998). In the substantia nigra,
chemical lesion increases PSA-NCAM expression in isolated reactive astrocytes and
colocalizes with GFAP (Nomura et al., 2000). It is also known that PSA-NCAM expression
is enriched and rhythmic in the adult mouse SCN (Glass et al., 1994; Glass et al., 2003)
and upon genetic deletion, can disrupt locomotor activity rhythms in mice (Shen et al.,
1997). Also, in vitro removal of PSA from NCAM using endoneuraminidase-N prevents
glutamatergic phase shifts in SCN rat brain slices (Prosser et al., 2003). Thus, PSANCAM is a key ECM-associated molecule that may be a target for MMP-2/9 in regulating
SCN circadian rhythms.
Other potential extracellular targets for MMP-2/9 that are implicated in circadian
rhythm regulation (i.e., neuroligins, neurexins, Eph receptors)(Hannou et al., 2018a), are
beginning to be studied in the context of astrocytic morphology regulation in a variety of
brain phenomena as well (Carmona et al., 2009; Puschmann & Turnley, 2010; Murai &
Pasquale, 2011; Ruscher et al., 2011; Zhao et al., 2011; Stogsdill et al., 2017).
Nevertheless, the exact targets of MMP-2/9 activity in the SCN are still to be determined.
Until each of these molecules is characterized in regard to their expression pattern,
location and proteolytic cleavage by MMP-2/9 in the SCN, we will not understand the full
relationship between circadian variation in MMP-2/9 activity, ECM-associated molecules
and diurnal astrocytic morphology in the SCN.
In conclusion, these studies reveal that astrocytic interactions with β-dystroglycan
may facilitate diurnal changes in astrocytic morphology in the SCN. However, this
hypothesis needs to be tested in the SCN with future experiments that disrupt astrocytic
adherence to β-dystroglycan. Because β-dystroglycan cleavage in SCN does not appear
to be mediated by MMP-2/9 nor does it change over time, it is also unclear if βdystroglycan participates in the maintenance of SCN circadian rhythms. Finally, our
findings suggest that the astrocytic day to night transition toward a ramified state, requires
a rearrangement of GFAP intracellular distribution. In the future, more research on this
topic will help us understand how ECM-linked mediated structural changes facilitate the
generation and regulation of the SCN circadian clock and the maintenance of intercellular
synchronization in the SCN.
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Appendix: Figures for Chapter 3
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Figure 3.1: β-dystroglycan is expressed in the SCN.
Images of hypothalamic sections (25 μm) immunostained for β-dystroglycan, using either
an anti-mouse (1:500, Novocastra) or anti-rabbit (1:500, Abcam) antibody, and cell nuclei
using DAPI (blue) (n=1). Our negative controls that contain secondary antibodies to detect
mouse or rabbit IgG’s show that the anti-mouse secondary antibody alone (A) produces
non-specific fluorescent signal, while the anti-rabbit antibody (C) does not. As such, we
suspect the endothelial pattern visualized in panel B is most likely due to non-specific
binding and not presence of β-dystroglycan. Thus, anti-rabbit antibody used in panel D is
superior for detection of β-dystroglycan in situ and highlights its expression within the
SCN.
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Figure 3.2: Expression of β-dystroglycan and GFAP does not change over time.
A) Brain tissue collected at ZT 6, ZT 16 and ZT 23 was sliced into 25 μM sections and
stained to detect β-dystroglycan (1:500), GFAP (1:1000). Tissue was also stained with
DAPI to confirm the region of the SCN. Fluorescent images, 8-bit, were taken at 20X
magnification and highlight marked expression of both proteins in the SCN. Using Image
J-Fiji, the images were separated into their corresponding channels. The region of the
SCN was circled first in the DAPI channel and then transferred to both the red and green
channels to measure the mean gray value of pixels present within the SCN region. The
background was selected from adjacent hypothalamic tissue outside of the SCN and
subtracted from the total mean gray value. Panels B) and C) plot the mean gray value
measured from biological replicates collected at each time point (β-dystroglycan: n=7-11;
GFAP: n=5-7). A One-way ANOVA analysis was performed on the data and revealed
neither β-dystroglycan expression (p=0.9609) nor GFAP expression (p=0.5664) is
different between the time points selected. The final panel (D) illustrates regions of
interest selected [ventral SCN (V), dorsal SCN (D), and anterior hypothalamus (AH)] for
hypothalamic subregion analysis of β-dystroglycan and GFAP expression. While GFAP
expression (mean grey value) remained constant across time, the mean grey value for βdystroglycan expression in the dorsal SCN at ZT 6 and ZT 23, and both SCN subregions
at ZT 16 were significantly higher than the AH (*=p< 0.05).
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Figure 3.2 continued
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Figure 3.2 continued

85

Figure 3.3: β-dystroglycan and GFAP fluorescence overlaps at multiple timepoints and is highest at ZT 23.
A) Confocal images (40X magnification) of SCN tissue collected at ZT 6, ZT 16 and ZT
23 reveal punctate co-localization of β-dystroglycan (green channel) and GFAP (red
channel) signal. B) Un-stacked, sequential image slices (60X magnification) collected
from SCN tissue suggest co-localization of β-dystroglycan and GFAP occurs on both
filopodial extensions and cell bodies of astrocytes. The white arrows/arrowheads point to
areas where overlapping signals change intensity through the Z- plane (different shapes
point to different astrocytic features containing β-dystroglycan signal). Images collected
are a step size of 1 μm, and 10 sequential images were collected. C) Quantification of βdystroglycan and GFAP overlap using the ImageJ Coloc-2 program shows a higher
degree of signal overlap (a Pearson’s R-value of 1 indicates perfect overlap) at ZT 23 as
compared to ZT 16 (*p< 0.05).
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Figure 3.3 continued
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Figure 3.3 continued
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Figure 3.4: Examination of astrocyte morphology over time using Sholl analysis.
A) Average intensity merged Z-stacks (40X magnification, 10 μm total depth, 1 μm step
size, scale bar= 20 μm) of representative GFAP positive cells (n=10-12) located in the
SCN at each time point (left panels). Using the Simple Neurite Tracer program available
on Image-J (Fiji), individual astrocytes were traced, total and somal fill volumes collected,
and Sholl analysis was performed. The middle panels show representative tracings of
individual astrocytes (pink, artificially enlarged from 40X image for illustration). Included
in the rightmost panel are Sholl plots (Distance from soma (μm) vs. number of intersecting
radii) for each traced cell and illustrate the distribution of radial intersections along the
length of the cell (radius=μm). The dotted line represents half the distance of the furthest
radius away from the center of the cell. B) Summary of astrocytic characteristics
measured by tracing GFAP positive cells in SCN tissue at ZT 6, ZT 16 and ZT 23.
Individual data points are plotted around the mean value for each characteristic ±
standard deviation. Sholl results indicate that cell volume (Volume (μm)), total
intersections (Sum inters.), hiighest number of branch points on a cell (Max intersections),
and Soma Volume are not statistically different. The total length of the cell (Ending radius)
and the ramification indices (Ramification index (sampled) and max intersecting radius)
are highest at ZT 23. The total number of branches (ZT 6), however, is lowest at ZT 23.
Further, the cell shape changes across time. Cells at ZT 23 are less symmetrical (positive
Skewness value compared to ZT 6) and their distribution of branch points across the
circumference of the cell do not fit a normal, Gaussian distribution (positive Kurtosis).
Asterisks denote statistical significance as determined by Ordinary One-Way ANOVA
analysis (α=0.05); *p<0.05, **p<0.01, ***p<0.005 and ****p<0.0001.
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Figure 3.4 continued
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Figure 3.4 continued
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Figure 3.5: β-dystroglycan expression in SCN tissue homogenate does not
change over time and is unaffected by MMP-2/9 inhibition.
Fluorescent western blot results of control and drug treated (MMP-2/9 inhibitor, BiPS)
SCN tissue slices collected at ZT 6, ZT 16 and ZT 23 (n=6). Blots were incubated with
primary antibodies to detect β-dystroglycan and actin (as a house keeping protein, 42
kDa) expression. Both the full length (43 kDa) and truncated (30 kDa) forms of βdystroglycan can be observed (Note: the red band (~33 kDa) in the β-dystroglycan is of
unknown origin but may be residual dye contained in the sample loading dye, as the actin
antibody was applied to blots after β-dystroglycan antibody incubation and detection).
Quantification of fluorescent signal intensity reveals that neither the full length (B) or
truncated (C) forms change expression over time or after BiPS treatment. Additional
analysis showed the neither the total amount of β-dystroglycan expression (D) or the ratio
(E) of truncated:full length β-dystroglycan (30 kDa: 43 kDa) changes between time points
and is unaffected by BiPS treatment.
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Figure 3.5 continued
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CHAPTER IV: CONCLUSIONS AND FUTURE DIRECTIONS
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Summary
The extracellular space (ECS) is dynamic in both structure and function (Dityatev
et al., 2006). The microenvironment existing in this space is a complex network of
structural proteins that form the extracellular matrix (ECM), together with interacting
signaling molecules, cellular adhesion molecules (CAMs) and transmembrane receptors.
ECM composition changes over the course of organism development, and its
dysregulation can lead to a variety of disease pathologies. Research investigating the
ECM and its associated proteins in the context of circadian rhythms demonstrates cyclic
expression of ECM molecules in multiple brain regions. Further, many are implicated in
regulating the mammalian master circadian clock, located in the suprachiasmatic nucleus
(SCN) (Cooper et al., 2018). However, little is known about the proteolytic mechanisms
mediating circadian and/or diurnal changes in ECS composition.
The goal of this research was to expand upon past findings in our laboratory that
identified a pivotal role of extracellular proteases, namely those in the plasminogen
activation cascade, in gating glutamate-induced phase shifts of the SCN circadian clock.
Matrix metalloprotease-2 and -9 (MMP-2 and MMP-9) activation is a direct result of
plasmin proteolysis and can modulate N-methyl-D-aspartate receptor (NMDAR)dependent signaling across the brain (Bozdagi et al., 2007; Ethell & Ethell, 2007; Michaluk
et al., 2009; Gorkiewicz et al., 2010; Wiera et al., 2017). A previous study of MMP-2/9 in
the hamster SCN reported that MMP-9, but not MMP-2, exhibits a diurnal rhythm in
activity (Agostino et al., 2002). However, neither the mechanisms of MMP-2/9 activation
nor the physiologic consequences of MMP-2/9 inhibition in the SCN were examined.
Thus, we first aimed to further characterize MMP-2/9 expression and activity and explore
MMP-2/9 mediated mechanisms in the SCN.
The experiments in Chapter 2 tested the hypothesis that MMP-2/9 activity is
necessary to gate glutamate-induced phase shifts in the SCN circadian clock. We
confirmed, using western blotting and gelatin zymography, that MMP-2/9 are expressed
and active in SCN tissue extracts. We found that MMP-9 activity is highest at ZT 6 and
lowest at ZT 23. We further showed that MMP-2 activity is constitutive across the
circadian cycle. Using in situ zymography, we confirmed that the MMP-2/9 inhibitor 2(benzenesulfonylamino)-N-hydroxy-3-phenylpropionamide (BiPS) co-incubated with DQ95

Gelatin solution in SCN tissue eliminates MMP-2/9 activity in situ. However, neither in
vitro bath application of BiPS nor time affected the observed level of gelatinolytic activity
of MMP-2/9 compared to control tissue. It is possible that we did not observe the same
day vs. night difference in MMP-9 activity that we did with gelatin zymography because
this assay does not distinguish between the activity of MMP-2 and 9. However, in situ
zymography was able to reveal enhanced MMP-2/9 activity in the SCN as compared to
the anterior hypothalamus. After confirming MMP-2/9 activity in the SCN, we continued
our efforts to examine if these proteases serve a functional role in gating glutamateinduced phase shifts of the master clock.
Our data showed that MMP-2/9 inhibition during the day and early night phase
shifts the SCN clock. This is the first indication that MMP-2 and/or MMP-9 participate in
maintaining correct circadian clock phase. We then found that BiPS-induced phase
delays and advances are blocked by the NMDAR antagonist D-(–)-2-amino-5phosphonopentanoic acid (AP5). This demonstrates that phase shifts resulting from
MMP-2/9 inhibition require NMDAR activity. When we examined additional mechanisms
regulating BiPS phase shifts, we found that only phase advances in response to BiPS
treatment at Zeitgeber Time (ZT) 6, not the phase delays induced at ZT 16, require both
plasmin activity and brain derived neurotrophic factor (BDNF) activation of tyrosine
receptor kinase B (TrkB).
Lastly, we investigated a potential intracellular, NMDAR-dependent downstream
mechanism of BiPS-induced phase shifts. We hypothesized that BiPS treatment leads to
increased NMDAR activation and channel opening, increases in intracellular Ca2+
concentration ([Ca2+]i), and subsequent increases in phosphorylation of CAMKII. Using
western blotting, we found that BiPS does not alter the phosphorylation of either isoform
of CAMKII (α-CAMKII or β-CAMKII) in SCN tissue. Together, the experiments in Chapter
2 reveal that MMP-2/9 activity is required for circadian clock phase regulation but the
mechanisms through which they regulate clock phase still need clarification.
In the experiments presented in Chapter 3, we examined a potential link between
MMP-2/9 activity and the diurnal structural rearrangements exhibited by SCN astrocytes.
We chose to investigate β-dystroglycan because it is a common substrate of MMP-2/9
(Michaluk et al., 2007; Sbardella et al., 2012; Yan et al., 2016) and is tightly linked to
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regulating changes in astrocytic morphology in many brain regions (Peng et al., 2008;
Noell et al., 2011; Gondo et al., 2014), but it has not been investigated in the SCN.
Therefore, we sought to examine if extracellular proteolysis of β-dystroglycan is mediated
by MMP-2/9 activity and if this activity is linked to astrocytic morphological changes in the
SCN.
We determined that glial fibrillary acidic protein (GFAP) and β-dystroglycan are
both expressed in the SCN, are higher in the ventral SCN than the AH, and that their total
expression is consistent across ZT 6, ZT 16 and ZT 23. Our observations also suggest
the two molecules exhibit significantly higher colocalization in the SCN at ZT 23 than ZT
6. Although GFAP levels were constitutive across time and between sub-regions of the
SCN and AH, our data detected a significant difference in day vs. night astrocyte
morphology, which is in agreement with past observations of diurnal rhythms in astrocytic
morphology (Lavialle & Serviere, 1993; Elliott & Nunez, 1994; Becquet et al., 2008;
Girardet et al., 2010; Girardet et al., 2013). Quantitative Sholl analysis of SCN astrocytes
revealed that astrocytic morphology is most complex and distributed during the late night.
Specifically, astrocytes exhibit a significant increase in distal branches, branch extension,
ramification, kurtosis, and skewness at ZT 23 vs. ZT 6. Interestingly, these changes occur
without significant changes in either total cell volume or GFAP expression, suggesting
that astrocytic morphological changes rely on the re-distribution of existing GFAP. We
also determined that β-dystroglycan expression is higher in the SCN than the AH at all
three timepoints, suggesting a role for β-dystroglycan in the SCN. Because βdystroglycan colocalization with GFAP is highest at ZT 23, it is possible that astrocytes
within the SCN utilize β-dystroglycan as an interaction partner to facilitate their
morphological changes. However, given that BiPS treatment does not affect the amount
of total or degraded β-dystroglycan, this suggests that changes in astrocyte morphology
are not regulated by MMP-2/9-dependent cleavage of β-dystroglycan in the SCN, but this
does not rule out β-dystroglycan participating in the astrocytic transition to a highly
ramified state. However, this hypothesis still needs to be tested.
Collectively, the work presented in this dissertation expands our understanding of
how proteins interacting in the extracellular space modulate the SCN circadian clock.
However, there remain many questions regarding the roles of MMP-2/9 in the SCN.
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Below, we discuss proteolytic and signaling mechanisms that we postulate may be
involved in these processes. We also suggest how the use of different or emerging
technologies could clarify the functional role of MMP-2/9 activity in the SCN’s dynamic
extracellular environment.
Regulating MMP-9 diurnal activity
The first major finding in this study is that MMP-9, but not MMP-2, exhibits diurnal
activity in the SCN. Specifically, gelatin zymography showed MMP-9 activity is greater at
ZT 6 than at ZT 23. As discussed in Chapter 2, our data do not fully agree with those of
Agostino et al., 2002, who found that MMP-9 activity is highest during the night (ZT 18).
The differences between our two studies could be due to the use of different animal
models (mouse vs. hamster), light schedules (14:10 LD vs. 12:12 LD) or the analysis of
in vivo vs. in vitro tissue samples. However, both of our studies agree that a diurnal
difference in MMP-9, and not MMP-2, activity exists in the SCN.
Several studies support circadian clock regulation of MMP-9. For example, Ingle
et al., (2015) found that cardiomyocyte-specific Bmal1 knockout (CBK) mice have
decreased lifespans and display increased necropsy and hypertrophy in heart tissue. The
authors further demonstrated that 20 week old CBK mice display increased transcription
and translation of MMP-9, Tissue inhibitor of metalloproteinase- 1 (Timp-1, MMP-9’s
endogenous inhibitor), and several collagen type I-V genes. These results suggest that
Bmal1 deletion (and therefore circadian rhythm disruption) leads to a deleterious
upregulation of an MMP-9 expression feedback loop. However, the authors provide no
explanation for this phenomenon, nor did they investigate whether there are changes in
MMP-9 proteolytic activity after Bmal1 deletion. Thus, while normal Bmal1 appears to
suppress expression of MMP-9 and Timp-1 the exact regulatory mechanism has not been
investigated, nor has day vs. night MMP-9 gene expression, to our knowledge, been
assessed in the SCN.
Proper transcription of CRY2 is necessary for a functioning transcriptionaltranslational feedback loop (TTFL), and deletion of CRY2 can lead to increased risk of
certain cancers. Thus, Yu et al., (2018) examined the role of CRY2 in osteosarcoma cell
proliferation. They found that decreasing CRY2 transcription using a short-hairpin RNA
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(shRNA) sequence leads to overexpression of MMP-2 in osteosarcoma protein extracts,
and increased cell proliferation and migration. If increased MMP-2 protein expression
translates into increased proteolytic activity, this could ultimately lead to increased MMP9 activation, but the study above did not investigate this possibility.
We hypothesize that circadian clock regulation of MMP-9 activity could arise from
rhythmic expression of upstream extracellular proteases, for example, the plasminogen
activation cascade. Circadian variations in the onset of heart attacks and strokes have
spurred research examining potential extracellular proteolytic activity rhythms in the
cardiovascular system. One study found that clock genes regulate the expression of
fibrinolytic proteases [plasmin and tissue/urokinase-type plasminogen activator
(tPA/uPA)] and their inhibitor, plasminogen activator inhibitor-1 (PAI-1) (Maemura et al.,
2007). In humans, both tPA protein levels and PAI-1 activity in plasma are greater in the
morning than they are night (Angleton et al., 1989). In 2000, Maemura et al. saw that the
CLOCK/BMAL2 heterodimer binds to an upstream E-box promoter and initiates
transcription of PAI-1 in vitro. Conversely, the PER2/CRY1 heterodimer inhibits
transcription of PAI-1 (Maemura et al., 2000). These regulatory processes may generate
circadian oscillations in PAI-1 mRNA and protein levels in blood plasma, as they are
eliminated in clock knockout mice (Ohkura et al., 2006). Further, day/night rhythms in
PAI-1 transcription and translation are eliminated in Cry1/2 knockout mice (Ohkura et al.,
2006). Our lab has shown that in the SCN, tPA protein expression peaks during the night,
and inhibiting its activity by applying PAI-1 to SCN slices eliminates glutamate-induced
phase shifts (Mou et al., 2009; Cooper et al., 2017). It is possible that increased tPA levels
during the night drives catalysis of pro-MMP-9 and precedes the day-time increase in
MMP-9 activity. To test this, one could examine if tPA knockout mice, which take longer
to entrain to inverted or shifted light cycles (Cooper et al., 2017; Krizo et al., 2018), exhibit
disrupted MMP-9 activity rhythms. Ultimately, we will not know if MMP-2/9 activity in the
SCN is under the influence of the TTFL until their proteolytic activities are investigated
using clock gene mutant mice (i.e. clock or Cry1/2 double knockouts) or other methods
(i.e. si-RNA, DREADDS, CRISPR) that disrupt the molecular clock. In summary, we
hypothesize that the diurnal rhythm in MMP-9 activity could be the result of clock gene-
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dependent transcriptional regulation of MMP-9 mRNA directly or through clock regulation
of its regulatory proteins.
Reciprocal relationship between MMP-2/9 and NMDAR activity
Many studies investigating effects of MMP-2/9 enzymatic activity in the brain have
focused on their roles after neuronal excitation, such as those associated with long term
potentiation (LTP) or epileptic seizures (Dzwonek et al., 2004; Nagy et al., 2006; Meighan
et al., 2007; Wojtowicz & Mozrzymas, 2010; Trivedi et al., 2019). For example, when latephase LTP, which requires protein synthesis, is induced in a hippocampal (area CA1)
slice culture using tetanic stimulation, gelatin zymography shows that MMP-9, but not
MMP-2, proteolytic activity is up-regulated. Further, application of either a broad-spectrum
MMP inhibitor (FN-439) or BiPS eliminates late-phase LTP (Nagy et al., 2006; Meighan
et al., 2007). Studies examining seizure pathogenesis have found that excessive
NMDAR/AMPAR activity resulting from kainic acid treatment (Berg et al., 1993) increases
MMP-2/9 activity (Jourquin et al., 2003; Konopacki et al., 2007), blood brain barrier break
down and neuronal atrophy (Kaur et al., 2004).
Previous studies show that NMDAR activation positively effects MMP-2/9 activity.
In mouse cortical neurons and cerebrovascular endothelial cells, NMDA application
increases both expression and activity of MMP-2/9 (Conant et al., 2010; Chen et al.,
2016). Dopamine stimulation in striatal medium spiny neurons increases NMDARdependent [Ca2+]i influx and increases MMP-9 activity (Li et al., 2016). NMDARdependent LTP in the mouse hippocampus also increases MMP-2/9 activity (Wiera et al.,
2017). These studies show that NMDAR activity positively affects MMP-2/9 activity, but
it is less clear if MMP-2/9 activity feeds back to affect NMDAR activity.
A few studies have investigated how altering MMP-2/9 activity affects NMDAR
activity (Gorkiewicz et al., 2010; Li et al., 2016). For example, application of auto-active,
recombinant MMP-9 increases the deactivation kinetics of the NMDAR, suggesting,
conversely, that MMP-9 inhibition may allow NMDAR Ca2+ channels to remain open
longer (Gorkiewicz et al., 2010). However, the mechanisms through which altered MMP2/9 activity modulates NMDAR activity is unclear. In murine cortical slice cultures, it was
shown that NR1-NMDAR subunit cleavage increases when recombinant MMP-7 is
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applied, but not MMP-2 or MMP-9 (Szklarczyk et al., 2008). Given the lack of evidence
that MMP-2 or MMP-9 directly binds to or cleaves NMDARs, it seems likely that the
actions of MMP-2/9 on NMDAR are indirect. For example, MMP-2/9 catalytic cleavage of
CAMs can influence NMDAR channel activity. Application of an auto-activating form of
MMP-9 increases the surface diffusion of NMDAR’s in hippocampal neurons. This is not
observed when an MMP-9 “protease-dead” mutant is applied (Michaluk et al., 2009),
suggesting that MMP cleavage of CAMs such as β-dystroglycan that stabilize NMDAR
membrane expression, could ultimately affect NMDAR activity. We observed that βdystroglycan is expressed in the SCN, but both the full length and truncated peptide
expression were constant across time and appear to be unaffected by MMP-2/9 inhibition.
Therefore, we suggest that other extracellular substrates of MMP-2/9 may be responsible
for the NMDAR-dependent phase shifts induced by BiPS in the SCN.
As mentioned in Chapter 2, polysialylated neuronal cell adhesion molecule (PSANCAM) is one possible substrate of MMP-2/9 in the SCN. PSA-NCAM participates in
many structural and functional brain plasticity events and is sometimes a target of MMP2/9 (Theodosis et al., 1994; Bonfanti, 2006; Kochlamazashvili et al., 2012; Varbanov &
Dityatev, 2017). For example, in a mouse model of middle cerebral artery occlusion,
MMP-9 inhibition reduces cleavage of the full length NCAM (180 kDa) (Shichi et al., 2011).
Additionally, a proteomic study comparing fibroblasts from MMP-2 knockout vs wildtype
mice identified PSA-NCAM as a substrate for MMP-2 (Dean & Overall, 2007).
NCAMs and NMDARs are expressed together, and studies suggest they are
functionally connected as well. An early ultrastructural study found that NCAM
accumulates at the post-synaptic density near NMDARs and increases after induction of
LTP (Fux et al., 2003). PSA-NCAM knockout mice exhibit deficiencies in LTP that are
rescued by application of d-cycloserine, an NMDAR agonist (Kochlamazashvili et al.,
2012). A study in cultured mouse hippocampal neurons identified a more direct
relationship between PSA-NCAM and NMDA, as they found that exogenous application
of soluble PSA-NCAM inhibits glutamate-induced, NMDA-mediated currents (Hammond
et al., 2006). Importantly, PSA-NCAM expression is enriched and rhythmic in the adult
mouse SCN (Glass et al., 1994; Glass et al., 2003) and its genetic deletion disrupts
locomotor activity rhythms in mice (Shen et al., 1997). Also, in vitro removal of PSA from
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NCAM using endoneuraminidase-N prevents glutamatergic phase shifts in SCN rat brain
slices (Prosser et al., 2003). Given that NMDAR activity is necessary for glutamateinduced phase shifts, it is possible that MMP-2/9 activity modulates PSA-NCAM in the
SCN, and that inhibition of this modulation leads to increased NMDAR signaling.
However, this hypothesis has yet to be tested.
Other candidate molecules worth investigating are the postsynaptic neuroligins
(NLGN1, 2, 3, 4) and their presynaptic partners, neurexins (NRXN) 1, 2, and 3. Transsynaptic binding and interaction of these dyads is important for NMDAR-dependent
synaptic plasticity. Genetic deletion or mutations of amino acids that interfere with NRXNNLGN interactions disrupt NMDAR-dependent LTP (Jiang et al., 2017; Dai et al., 2019;
Rudenko, 2019; Wu et al., 2019). Also, NLGN1 binds intracellularly to post synaptic
density molecule-95 (PSD-95) (Barrow et al., 2009), the main scaffolding molecule
responsible for trafficking NMDAR to the postsynaptic membrane (Cousins &
Stephenson, 2012). Importantly, MMP-2/9 mediated cleavage of NLGN1 eliminates
NMDAR/NLGN1-containing clusters on the postsynaptic membrane (Barrow et al., 2009)
and results in increased lateral diffusion of NMDAR on the post-synaptic membrane
(Szepesi et al., 2014), which impairs NMDAR function. Another study found that MMP2/9 cleavage of NLGN1 is induced by NMDAR-dependent LTP stimulation. This cleavage
disrupts NLGN1 binding to pre-synaptic NRXNs and decreases pre-synaptic
neurotransmitter release (Peixoto et al., 2012). It is noteworthy that mRNA transcription
of Nlgn1/2 and Nrxn1/2 (in the mouse forebrain and SCN, respectively) is cyclic and
regulated by circadian clock genes (Shapiro-Reznik et al., 2012; Hannou et al., 2018a;
Hannou et al., 2018b). However, it is unknown if the oscillations in transcription lead to
rhythmic expression of functional proteins and if NLGN/NRXN are MMP-2/9 enzymatic
targets in the SCN.
Integrin-1β is another CAM that can affect NMDAR activation (Lin et al., 2003) and
trafficking (Michaluk et al., 2009). Integrin-1β generally binds to ECM proteins (i.e.,
collagen, laminin, fibronectin, etc.) that contain Arg-Gly-Asp (RGD) peptide sequences.
Further, when MMP-2/9 cleaves these ECM molecules, the RGD peptides can become
diffusible ligands for integrin-1β (Mogford et al., 1997; Wu et al., 1998; Petitclerc et al.,
1999; Sternlicht & Werb, 2001; Wildering et al., 2002). Binding of integrin-1β to RGD
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ligands triggers activation of intracellular kinases such as protein kinase C and Src family
kinases and subsequent NMDAR phosphorylation and activation (Chen & Leonard, 1996;
Giancotti & Ruoslahti, 1999; Hisatsune et al., 1999; Ali & Salter, 2001; Grosshans &
Browning, 2001; Miranti & Brugge, 2002).

In mouse hippocampal slice cultures,

incubation with an RGD ligand increases both the amplitude and duration of NMDARmediated inward currents (Lin et al., 2003). Another study in mice striatopallidal neurons
found that dopamine application increases NMDAR excitation, as indicated by increased
expression of GCaMP3. Further, inhibition of integrins or MMPs eliminates NMDARinduced Ca2+ influx (Li et al., 2016). When integrin-1β binding to the ECM is inhibited,
MMP-9-dependent LTP in hippocampal neurons is abolished (Wang et al., 2008b).
Interestingly, one study found that higher concentrations (10 μM) of a cyclic RGD peptide
inhibited integrin binding to ECM components vitronectin, fibronectin and fibrinogen, but
lower concentrations (100 pM) were “super activating” and increased ECM binding
compared to control (Legler et al., 2001). These studies suggest that the level of MMP2/9 activity affects the degree of integrin-1β binding to the ECM and the level of binding
determines the effect on NMDAR activity. Thus, inhibiting MMP-2/9 activity in the SCN
may lead to “super activation” of integrin-1β and facilitate increases in NMDAR
phosphorylation. Currently, we are unaware of research investigating the role of integrin1β in the SCN, but we believe examining whether integrin-1β protein levels are expressed
diurnally and whether RGD-peptide application phase-shifts the circadian clock would be
informative.
How does BiPS affect NMDARs?
Although we found that BiPS-induced phase shifts require NMDAR activity, we
also observed that BiPS application does not affect phosphorylation of either CAMKII
isoform. As this event typically occurs after NMDAR mediated influx of Ca2+, it is possible
that BiPS treatment does not lead to increased [Ca2+]i. This is surprising because previous
studies show that day/night variation in CAMKII activity contributes to behavioral activity
rhythm maintenance. Additionally, CAMKII phosphorylation is necessary for light-induced
phase shifts in vivo (Yokota et al., 2001; Nomura et al., 2003; Agostino et al., 2004; Kon
et al., 2014). Possible explanations for our findings include: 1) BiPS induces NMDAR
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ionotropic activity but the resulting Ca2+ influx activates CAMKII-independent intracellular
signaling pathways; and 2) BiPS-induced phase shifts involve NMDAR Ca2+ fluxindependent (metabotropic) protein signaling cascades. Therefore, characterizing the
direct effects of BiPs on NMDAR is necessary to determine how MMP-2/9 endogenous
activity participates in SCN circadian rhythm regulation.
In Chapter 2, we saw that BiPS treatment at ZT 23 resulted in high firing rates ~2
hours after treatment that subsequently decreased. However, it is unclear if this is due to
increased NMDAR activity. We suggest that studying NMDAR channel activity directly
would be ideal to assess whether acute (40 minutes) BiPS treatment alters neuronal
activity. Preliminary experiments using extracellular electrophysiological recordings were
conducted to assess acute BiPS-induced changes in SCN neuronal firing rate, focusing
on the times when BiPS phase-shifts the clock, ZT 6 and ZT 16. However, sampling the
spontaneous firing rates of individual neurons dispersed across the SCN generated data
that was extremely variable and did not identify a significant, BiPS-induced change in
firing rate (Fig 4.1). Thus, we believe that using alternative methods might be more fruitful.
For example, extracellular recordings using a multi-electrode configuration could allow
the activity of the same group of neurons to be characterized before, during and after
BiPS treatments. Alternatively, intracellular recordings could be used for these
experiments. Whole-cell patch clamp electrophysiology has been used previously to
characterize NMDAR receptor behavior after acute drug treatments in SCN slices (Kim &
Dudek, 1991; Pennartz et al., 1998; Lundkvist et al., 2002). This technique also helped
determine how MMP activity acutely affects NMDAR ionotropic activity in hippocampal
slices (Gorkiewicz et al., 2010; Wiera et al., 2017).
Rather than acutely modulating Ca2+ channel activity, MMP-2/9 could affect
NMDARs by regulating the composition of NMDAR subunits in the SCN. NMDARs are
heterogeneous, tetrameric protein channels consisting of two NR1 and a combination of
two NR2 (NR2A-2D isoforms) or NR3 (NR3A-3B isoforms) subunits (Hollmann, 1999).
Different combinations of subunits affect NMDAR function by altering the voltagedependent Mg2+ ion block, glutamate and/or glycine binding affinity, and the Ca2+ ion flux
volume (Cull-Candy & Leszkiewicz, 2004; Paoletti, 2011; Suzuki et al., 2013). During
development, NMDAR composition transitions from mostly NR1/NR2B-containing to
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NR1/NR2A-containing NMDARs. Increased incorporation of NR2B subunits increases
the time of channel deactivation, resulting in the NMDAR channel staying open longer.
This was first characterized by Vicini et al. (1998) when they observed that glutamate
stimulates NR2B-containing receptors to remain open for 250 msec, compared to NR2Acontaining receptors that stay open for 100 msec (Vicini et al., 1998). This and other
studies support NR2B-containing NMDARs being more active and more permissive to
synaptic/behavioral plasticity processes, like LTP and fear conditioning, than NR2Acontaining NMDARs (Crair, 1999; Szinyei et al., 2003; Cull-Candy & Leszkiewicz, 2004).
In the SCN, both transcription of NR2B mRNA and phosphorylation of the subunit
increases at night, which could increase SCN clock sensitivity to glutamate-induced
phase shifts during the night. Functionally, increased expression and activity of NR2B
subunits is necessary for NMDA-induced Ca2+ currents and light-induced phase shifts
(Williams, 2001; Wang et al., 2008a; Bendova et al., 2012). NR2B inhibition also alters
clock gene expression, as the NR2B inhibitor ifenprodil blocks glutamate-induced
phosphorylation of CREB and ERK1/2, proteins that increase transcription of per1 and
per2 in rat SCN tissue (Bendova et al., 2012).
Research indicates that MMP-2/9 activity may preferentially affect the expression
and activity of NR2B-containing NMDARs. In the hippocampus, TIMP-1 application blocks
MMP-9-mediated degradation of Reelin (Tinnes et al., 2013), a large ECM glycoprotein
implicated in NR2B subunit surface mobility and trafficking on neuronal membranes (Groc
et al., 2007). Thus, quantifying the effects of BiPS treatments on the NR2A:NR2B
expression ratio using western blotting or immunohistochemistry in the SCN could provide
evidence for a mechanism underlying BiPS-induced phase shifts. Further, experiments
that combine BiPS and ifenprodil treatments could assess whether phase shifts resulting
from MMP-2/9 inhibition require NR2B-expressing NMDARs.
However, the SCN also contains other NMDAR subunits that affect clock activity.
A study showing NMDAR currents in the SCN after applying ifenprodil in a Zn2+-deficient
solution, which inhibits both NR2A and NR2B subunits, suggests that the SCN also
expresses NR2C- and NR2D-containing NMDARs (Clark & Kofuji, 2010). Moreover,
Brancaccio et al. found that during the night, application of the NR2C specific antagonists,
DPQ-1105 and QNZ-46, but not NR2A or NR2B-selective inhibition, reduces the
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amplitude and lengthens the period of PER2::LUC rhythms in SCN tissue in vitro. Further,
DPQ-1105 application eliminates neuronal intracellular Ca2+ circadian rhythms
(Brancaccio et al., 2017). Thus, further examination of which NMDAR subunits are
affected by MMP-2/9 inhibition may clarify mechanisms associated with BiPS-induced
phase shifts.
Ca2+ imaging experiments could also help identify MMP-2/9 actions in the SCN.
Previously, the effect the dopamine antagonist, SKF81297, in striatal medium spiny
neurons was examined using the fluorescent Ca2+ indicator GCaMP3. SKF81297
potentiates NMDAR-dependent Ca2+ influx while also increasing MMP-2/9 activity (Li et
al., 2016). Changes in Ca2+ flux in the rodent SCN have been measured previously
(Colwell, 2001; Brancaccio et al., 2013) and the adrenal adenoviral vectors that induce
expression of GCaMP3 molecules can be genetically driven by either astrocytic or
neuronal promoters (Brancaccio et al., 2017). Utilizing this tool in conjunction with
NMDAR subunit specific inhibitors in SCN slices could determine whether BiPS
treatments affect astrocytic and/or neuronal Ca2+ levels.
Recently our lab started a collaborative study with Dr. Chris Baker to develop and
test a microfluidics device for perfused brain slices. The set-up allows for simultaneous
Ca2+ imaging of the tissue, application of experimental treatments, and collection of
perfusate for off-line analysis. While still in development, this device could aid in
examining multiple physiologic responses of SCN tissue after BiPS treatments. For
example, we could investigate the response of NMDARs during BiPS application by
measuring changes in [Ca2+]i. Further, we could compare the peptide/molecular content
of the perfusate after BiPS treatment using mass spectrometry (methods discussed
below), and potentially identify which molecules are affected by BiPS.
Because BiPS does not increase the phosphorylation of CAMKII in our SCN
samples, it is possible that the signaling cascade downstream of BiPS-induced NMDAR
activation is Ca2+-independent. Although uncommon, evidence exists for a non-canonical,
ion flux-independent NMDAR signaling (f-iNMDARs) pathway (Chung, 2013; Dore et al.,
2016; Gray et al., 2016; Dore et al., 2017; Montes de Oca Balderas, 2018). The first
evidence of f-iNMDARs came from studies in hippocampal neurons investigating the
different mechanisms underlying LTP and long-term depression (LTD); two NMDAR106

dependent processes that result in increased and decreased synaptic communication,
respectively. Two separate research groups showed that showed MK-801 (an antagonist
that blocks ion flux through NMDAR channels) blocks LTP but not LTD in hippocampal
neurons (Mayford et al., 1995; Scanziani et al., 1996), suggesting that LTD involves fiNMDARs.
Recently, FRET-FLIM (Forster resonance energy transfer measured by
fluorescence lifetime imaging of the FRET donor) was used to investigate if extracellular
ligand binding to NMDAR could result in intracellular conformational changes, a
phenomenon associated with metabotropic receptor activity (Aow et al., 2015). First, Dore
et al. genetically modified the intracellular cytoplasmic domains of NMDAR-NR1 subunits
to concurrently express either green fluorescent protein or mCherry molecules in primary
hippocampal neuronal cultures. These modifications produced a measurable FRET
signal (indicating an interaction between the two fluorescent tags), suggesting physical
interaction between NR1 subunits. When the neurons were treated with glutamate in the
presence of MK-801 or 7CK (another NMDAR ion channel antagonist), the FRET signal
decreased and LTD was blocked, indicating that LTD requires ligand binding to NMDARs
and that this binding induces an intracellular conformational change (Aow et al., 2015). A
follow-up study by the same group used FRET to examine how conformational changes
in the NMDAR cytoplasmic domain affect intracellular signaling pathways (Aow et al.,
2015). It is known that NMDAR Ca2+ influx increases CAMKII phosphorylation on the Thr286 residue, which increases CAMKII kinase activity and promotes CAMKII binding to
NMDARs (Giese et al., 1998; Bayer et al., 2001; Chang et al., 2017). Aow et al. observed
that bath application of NMDA ligands in the presence of 7CK reduces the FRET signal
between NMDAR-NR1-GFP and CAMKII-mCherry (Aow et al., 2015). This implies that
NMDAR activation initiates a conformational change in the intracellular portion of the NR1
subunit that favors CAMKII binding in the absence of Ca2+ influx. Thus, it would be worth
investigating if BiPS treatment induces a conformational change in NR1 subunits that
facilitates

NMDAR

activation

by

increased

interaction

with,

not

necessarily

phosphorylation of, CAMKII.

107

MMP-2/9 and β-dystroglycan involvement in astrocytic morphological changes
One drawback of immunohistochemistry is that it cannot be used to determine
protein-protein interactions (Seidal et al., 2001; de Matos et al., 2010). Therefore,
although we detected puncta of overlapping signals for β-dystroglycan and GFAP using
immunohistochemistry, we cannot definitively assert whether 1) the astrocytes express
β-dystroglycan or 2) the proteins are interacting in the SCN. Proper examination of
functional interactions between β-dystroglycan and astrocytes could be performed using
the FRET-FLIM technique introduced in the previous section.
However, it is well accepted that MMP-2/9-dependent cleavage of β-dystroglycan
is necessary for changes in glial cell morphology in other brain regions. Here we
observed, for the first time, that β-dystroglycan is expressed in the SCN and colocalizes
with GFAP expression. We determined, by quantifying fluorescent signal in our
immunohistochemistry and through western blotting experiments, that β-dystroglycan
expression is constitutive and unaffected by blocking MMP-2/9 activity with BiPS. We also
discovered that, although the total amount of GFAP does not change with time, astrocytes
exhibit a day to night transition in ramification state. Thus, diurnal astrocytic morphology
rhythms are likely accompanied by redistribution of intracellular molecules, and potentially
involve a reorganization of their interactions with extracellular molecules. Therefore, it
would be informative to examine astrocytic morphology and GFAP colocalization with βdystroglycan in the SCN after BiPS treatment. We hypothesize that BiPS will have its
largest effects on astrocyte morphology when applied at times that correspond with high
MMP-9 activity, specifically ZT 6 and ZT 16. If differences in one or more morphologic
parameter are observed, this would support MMP-2/9 modulation of astrocytic
morphological changes in the SCN. Moreover, it would suggest that astrocyte morphology
changes could be involved in BiPS-induced phase shifts.
Because β-dystroglycan expression in the SCN appears to be enriched compared
to the surrounding hypothalamus, its role in circadian rhythm regulation should be
explored in more detail. Experiments investigating β-dystroglycan function in the SCN
could utilize an antibody targeting α-dystroglycan (IIH6). Previous reports show that
application of IIH6 disrupts dystroglycan’s ability to bind to the ECM and disrupts
astrocytic adhesion to laminin after ischemic brain injury (Hawkins et al., 2013). This
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essentially mimics the effect of MMP-2/9 activity, as degradation of β-dystroglycan can
be blocked with both broad and specific MMP2/9 inhibitors, which results in decreased
attachment of glia cells to laminin (Milner et al., 2008). Preliminary results testing the
effects of IIH6 on SCN circadian rhythms are so far inconclusive. IIH6 (diluted in EBSS
1:5) was applied at ZT 16 for 40 minutes, and extracellular electrophysiology recordings
were performed on the following day. Neither concentration of IIH6 induced a shift in SCN
circadian rhythms (Fig 4.2). However, the previous studies using this antibody were
performed in astrocyte cell cultures using a 24 h incubation period. Therefore, future
experiments involving SCN tissue slices may require higher antibody concentrations or
an extended incubation time.
Circadian matrisome and proteomic profiling of the SCN
Recent mass spectrometry experiments in the brain and other tissues have
focused on identifying molecular components of the ECS isolated from other cellular
fractions. By combining mass spectrometry (MS) with extraction techniques that use
surfactants to separate ECM-associated molecules from intracellular components,
researchers have successfully isolated ECM fractions from bone, cartilage, kidney, lung,
liver and brain tissue (Byron et al., 2013; Naba et al., 2017). Further, cluster analysis of
data collected from MS can help identify groups of peptides containing conserved
residues or post-translational modifications. MMP-2/9 cleavage of extracellular substrates
generates small peptides containing a conserved RGD-motif in their peptide sequence
(Kridel et al., 2001; Wenk et al., 2013). Thus, identification of peptides in SCN extracellular
protein extracts containing this motif using MS would be useful for identifying potential
MMP-2/9 substrates.
The proteomic profile of tissue collected from the pineal gland, retina, SCN, and
other peripheral body organs were previously characterized using MS and revealed that
a number of proteins exhibit diurnal expression rhythms (Moller et al., 2010). Multiple
groups have utilized MS to identify peptides in SCN tissue that are regulated by light
stimuli or the circadian clock, and a few of these peptides are ECM-associated (Reddy et
al., 2006; Hatcher et al., 2008; Deery et al., 2009; Tian et al., 2011; Chiang et al., 2014;
Ling et al., 2014). In the rat pineal gland, Moller et al., found that expression of a
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transmembrane type I glycoprotein, leucine-rich repeat-containing protein 15 precursor,
is upregulated during the day (Moller et al., 2007). Another study utilizing SCN slices
identified which peptides were released into the ECS before and after optic nerve
stimulation using matrix-assisted laser desorption/ionization- tandem mass spectrometry
(MS/MS). This method mostly identified cyclic expression of peptides that act as
neurotransmitters and/or neurohormones, for example somatostatin, little SAAS, big LEN
and PEN (Hatcher et al., 2008). Using “Stable Isotope Labeling with Amino Acids in Cell
Culture”-based quantitative mass spectrometry, Chiang et al. found that 20% of proteins
identified in homogenized murine SCN tissue of mice kept in constant darkness exhibited
sinusoidal expression rhythms over a ~24 hr period (Chiang et al., 2014). The authors of
this study, however, only found one ECM-associated protease exhibited peak expression
at night, prolyl 4-hydroxylase (an enzyme pivotal in collagen synthesis). Therefore, it is
possible to detect ECM-associated proteins using mass spectrometry, but only a few have
been identified in the SCN. Additionally, the effects of extracellular protease inhibition on
expression of ECM proteins in the SCN have not been examined using MS techniques.
A preliminary experiment in collaboration with Dr. Shawn Campagna and Dr. Dan
Jacobsen was conducted to test an ECM extraction technique on SCN tissue slices. Two
biological replicate experiments were performed using a protocol based on recently
published ECM extraction methods (Naba et al., 2017; Sethi & Zaia, 2017). The cellular
and ECM fractions from the SCN were collected, digested with trypsin, and run on a QExactive Plus Orbitrap Mass Spectrometer (Thermo Scientific), and the Ultimate 3000
RSLnano system. The separation was carried out using a 2D online chromatography
approach. The digested sample was loaded onto a C18 PEPMap100 precolumn for
sample clean up, then using an organic gradient the sample was separated on a reverse
phase EASY-Spray Nano source. The Orbitrap was operated in TOP 10-mode utilizing
dynamic exclusion to maximize sample characterization. The data were analyzed using
the Crux open source proteomic platform (McIlwain et al., 2014). The raw data were
aligned with known peptide sequences from a previously published ECM proteome
(called the matrisome) and the Mus musculus reference proteome available on
Uniprot.org (Church et al., 2009; Naba et al., 2017).
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Preliminary western blots comparing the content of our intra- and extracellular
protein fractions collected after ECM isolation revealed that actin was absent from the
extracellular fractions, which suggests our ECM isolation method may be effective.
However, initial assessment of our mass spectrometry examining the identity of protein
fragments present in both our intra- and extracellular protein fragments showed that ECMassociated proteins were detected in our intracellular fraction. Additionally, the Q-values
(a confidence interval measurement for proper identification) that aligned with each ECMidentified protein in either fraction were low, indicating a low probability of certainty in our
protein identifications. Trouble-shooting this experiment would include successful
identification of positive control peptides added to control samples and utilization of
western blotting to confirm the presence or absence of known intra- and extracellular
proteins in SCN fractionated extracts. Thus, we believe the best next step for the
experiment would be to increase the number of technical replicates and/or increase the
amount of SCN tissue per sample to increase our certainty in extracellular peptide
identification.
Another MS method that could be used to identify potential ECM-associated
substrates that are affected by BiPS treatment is called iTRAQTM labeling. Previously, a
study used MS/MS combined with amine-targeted iTRAQTM tags (Applied Biosystems,
Foster City, CA) to identify the “degradome” of MMP-2. Dean et al. (2007) incubated cell
cultures with the iTRAQTM tag to exclusively label extracellular proteins in full and partial
MMP-2 knock-out fibroblasts. The authors then compared the peptide sequences
identified by tandem mass spectrometry in both cell cultures. They found that the iTRAQ
ratio (iTRAQ labeled protein in control: iTRAQ protein in active MMP-2 cultures) is
significantly reduced for certain peptides, suggesting the proteins might be substrates of
MMP-2. Specifically, they identified previously known MMP-2 ECM substrates (such as
osteopontin, galectin-1 and HSP-90) and potential substrates [Procollagen C-proteinase
enhancer (PCPE) and chemokine (C-X3-C motif) ligand 1]. Further, they confirmed MMP2 mediated, proteolytic cleavage of each of the above substrates using a previously
described in vitro biochemical assay (Dean & Overall, 2007). Thus, if the extracellular
extraction technique described above does not work in SCN slices, MS experiments
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aimed at characterizing the ECM content, and the effect of extracellular protease activity,
in the SCN using the iTRAQ labeling method could be successful.
Linking the ECM to the intracellular circadian clock
Given that MMP-2/9 activity can disrupt ECM integrity via protein degradation, it is
noteworthy that changes in mechanical forces induced by altering ECM composition in
somatic tissues affects circadian clock regulation. For example, one study found that the
extracellular mechano-environment of cancerous human breast tissues contains more
collagen and was measurably stiffer than normal breast tissue (Williams et al., 2018). This
observation correlated with a reduction in Bmal1 mRNA expression; however, the link
between ECM stiffness and clock gene expression was not directly investigated (Williams
et al., 2018). Another study grew mammary epithelial cells (MECs) isolated from
PER2::LUC mice in culture flasks coated with either a two- or three-dimensional ECM
substrate (conferring high or low mechanical stiffness, respectively). They found that
MECs grown on a three-dimensional ECM exhibit stronger PER2::LUC rhythms,
indicating that a less rigid environment favors robust oscillation of clock gene expression
(Yang et al., 2017). Further, they found that disrupting the Rho-Rock pathway, which
leads to degradation of intracellular actin and disrupts the shape of the nuclear envelope,
increases the robustness of PER2::LUC rhythms. These and other works reviewed by
Streuli & Meng (2019), suggest that disease-related disruptions in the mechanoenvironment of the brain are facilitated by alterations in ECM composition and leads to
dampened clock gene expression. Conversely, decreased ECM and intracellular stiffness
increases the amplitude of clock gene expression rhythms. Because decreased strength
of circadian rhythms is associated with many age-related diseases, like dementia and
Alzheimer’s (Witting et al., 1990), it would be interesting to examine if changes in SCN
ECM content or composition affects disease progression.
Our studies align with previous work highlighting ECM-associated molecules as
active participants in regulating both physiological (e.g., LTP) and pathological (e.g.,
ischemia, seizure) activity in the brain. In some cases, these processes also involve
changes in astrocyte function/morphology. MMP-2/9 are essential molecules in regulating
ECM-mediated changes in brain plasticity and our findings support their involvement in
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yet another plastic process, the regulation of circadian rhythms in the SCN. Below we
present several mechanistic models of endogenous MMP-2/9 expression and activity in
the SCN, how they may participate in circadian clock regulation, and how MMP-2/9
inhibition leads to phase-shifts in the SCN clock.
Similar to other areas of the brain, the effects of MMP-2 and MMP-9 activity depend
on the particular substrates they cleave. The substrates we discussed above (βdystroglycan, PSA-NCAM, integrin-1β, neuroligin, and neurexins) all generally have a
positive effect on NMDAR activity when they are intact. Our data do not support MMP-2/9
cleavage of β-dystroglycan in the SCN, so we still do not know the identity of the functional
substrate(s) for MMP-2/9 in the SCN. Nevertheless, we predict that MMP-2/9 affects
NMDAR activity in the SCN through cleavage of a yet to be identified CAM. Figure 4.3
illustrates a possible mechanism regulating MMP-2/9 activity and downstream actions in
the SCN. As shown in the figure, (1) Glutamate activation of post-synaptic NMDARs
increases intracellular Ca2+ concentration ([Ca2+]i). (2) This initiates the secretion of proMMP-2 and pro-MMP-9 into the ECS where they are activated by plasmin. Because
MMP-2 can also activate pro-MMP-9, the amount of active MMP-9 is higher than active
MMP-2. (3) MMP-9-mediated enzymatic cleavage of CAMs disrupts protein-protein
interactions with membrane-bound NMDARs, leading to a conformational change that
decreases the probability of NMDAR activation by extracellular glutamate. (4) MMP-9
activity also can lead to the maturation of BDNF, TrkB phosphorylation and priming of
NMDARs. Therefore, the ultimate effect of MMP-9 activity on NMDAR also depends on
the abundance of extracellular molecules like plasmin, tPA/uPA, and BDNF, which could
tip the scales toward increased or decreased phosphorylation and activity of NMDARs.
(5) Further, MMP-2/9- mediated cleavage of ECM molecules, could alter astrocytic
morphologic rhythms.
In Fig 4.4 we incorporate endogenous MMP-2/9 into a model of the SCN circadian
clock that connects the extracellular milieu and independently operating clocks in neurons
and astrocytes, and in particular suggests a feedback mechanism that involves CAMNMDAR interactions. During the day, SCN spontaneous neuronal activity is high and
astrocytes are in a quiescent state. This time is coincident with the lowest amount of
astrocytic glutamate release and low levels of endogenous NR2B expression. The high
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daytime level of intracellular neuronal [Ca2+] stimulates pro-MMP secretion by neurons
into the ECS and leads to high MMP-9 activity. Increases in MMP-9-mediated CAM
cleavage leads to decreases in NMDAR interactions with CAMs, which results in lower
potential NMDAR activity. Additionally, plasmin and mBDNF levels are low, therefore
NMDAR phosphorylation by TrkB is minimal. Together, these events decrease the
chance that in vivo light stimulation or exogenous application of glutamate can phaseshift the clock.
We further predict that high MMP-9 activity at ZT 6, by cleaving CAMs and ECM
components, facilitates the beginning of the astrocytic transition to the more ramified state
we observed at ZT 16. The higher ramification seen at ZT 16 is coincident with the
previously demonstrated increase in astrocytic glutamate release and may be associated
with higher astrocytic metabolic activity. Further, NR2B expression and phosphorylation
of NMDAR by TrkB (due to increased plasmin/mBDNF expression) are highest at ZT 16,
two conditions that enhance the probability that membrane-bound NMDARs can be
activated by glutamate (due to light or exogenous application), and thereby phase-shift
the circadian clock. The potential for NMDAR activity could be further enhanced through
decreased MMP-9 cleavage of CAMs, allowing more NMDAR-CAM interactions.
Importantly, the high astrocytic glutamate release at ZT 16 is insufficient by itself to trigger
NMDAR activation (and phase-shift the clock) due to the decrease in SCN neuronal
[Ca2+]i and the continued (although decreased) MMP-9 cleavage of CAMs at this time.
At ZT 23, astrocytes are highly ramified and extend their filopodia to their greatest
extent, but also are decreasing their secretion of glutamate, which would decrease
intrinsic NMDAR activation. On the other hand, MMP-9 activity is at its lowest, leading to
minimal CAM cleavage. Therefore, the increased number of intact CAMs on the
postsynaptic membrane is more favorable for interaction with NMDARs, which enhances
potential NMDAR activity. Additionally, plasmin expression is high, so BDNF is still able
to activate TrkB. Thus, NMDARs are in a sufficiently phosphorylated and primed state so
that light/glutamate stimulation can phase-shift the clock, while the low amount of
glutamate being released by astrocytes is not sufficient to initiate a phase shift by itself.
Based on the model just presented, in Figure 4.5 we illustrate how BiPS application
could induce phase shifts at ZT 6 and ZT 16, but not ZT 23 through mechanisms that
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disrupt our proposed CAM-NMDAR interactions. At ZT 6, we hypothesize that BiPS
inhibition of MMP-2/9 prevents MMP-9-mediated cleavage of CAMs. The resulting
conformation and/or amount of membrane-bound CAMs is now favorable for interaction
with NMDARs, which increases NMDAR sensitivity glutamate. Although astrocytic
glutamate release is normally low during the daytime, the CAM-bound NMDARs would
now be sufficiently primed so that the endogenously derived glutamate is able to activate
NMDARs and initiate a phase advance. At this same time BDNF expression and TrkB
activation are low, but we propose that the baseline levels of activity are sufficient to
support NMDAR activation and allow phase-shifts of the clock. This scenario is supported
by our data showing that treatments that inhibit plasmin (α-2-antiplasmin) or TrkB
activation (K-252A) are able to block BiPS-induced phase shifts.
At ZT 16, BiPS application blocks endogenous (albeit decreasing) MMP-9 activity,
again increasing the abundance of intact CAMs. At the same time, NR2B expression
peaks, shifting the overall population of NMDARs to a more excitatory composition. The
increase in full-length CAMs allows more NMDAR-NR2B receptors to be incorporated
into the post-synaptic membrane. As these events are coincident with the peak in
astrocytic glutamate release, NMDAR-dependent [Ca]i influx is enough to phase-delay
the SCN clock. ZT 16 is also concurrent with maximum plasmin and BDNF expression,
therefore TrkB receptors are highly activated and NMDARs are more phosphorylated
compared to ZT 6. Thus, we believe the concentration of α-2-antiplasmin or K-252A able
to block BiPS-induced phase shifts during the day is now ineffective in blocking BiPS
phase shifts.
Lastly, at ZT 23, CAM-NMDARs and BDNF/TrkB signaling are primed and ready
to respond, and astrocytic release of glutamate is still high but is decreasing. These
conditions are such that exogenous light/glutamate can readily phase-shift the clock.
However, BiPS-induced inhibition of MMP-2/9 activity is unable to affect clock phase
because endogenous MMP-2/9 activity is low at this time, so there is no enzymatic activity
for it to inhibit.
In summary, we suggest that the MMP-2/9-mediated NMDAR negative feedback
loop proposed above is a pivotal mechanism in maintaining endogenous SCN circadian
rhythms. Specifically, MMP-9 cleavage of ECM and associated molecules regulates the
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composition and integrity of the ECS and allows for astrocytes to alter their morphology
across the circadian cycle. MMP-9-mediated CAM cleavage in the daytime decreases the
probability that endogenous levels of glutamate will phase-shift the clock, while lower
MMP-9 CAM cleavage at night enhances NMDAR priming to allow appropriate responses
to photic/glutamatergic stimuli. Therefore, we conclude that MMP-9 activity contributes to
the time-of-day sensitivity of the SCN circadian clock to glutamate, and therefore MMP-9
is an essential component in regulating SCN circadian clock phase.

116

Appendix: Figures for Chapter 4
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Figure 4.1: Acute recording of in vitro SCN firing rate surrounding BiPS treatment
at ZT 16.
Acute SCN extracellular neuronal activity recordings from tissue being treated with the
inhibitor BiPS for 40 minutes surrounding ZT 16 (grey box). Plotted are the average
firing rates (+/- SEM) of 5-6 neurons were recorded each hour. Preliminary comparison
of identical BiPS treatments (i.e., BiPS 1, BiPS 2 and BiPS 3 in n=3 animals) to vehicle
control (n=1) does not reveal a clear effect of BiPS treatment on the average firing rate
across time.
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Figure 4.2: Preliminary data showing α-dystroglycan antibody application to SCN
slices does not phase-shift the clock.
Shown are extracellular electrophysiology recording data of SCN slices. A 40-minute
drug treatment (white bars during Day 1 in vitro) with the α-dystroglycan antibody (IIH6)
at either Zeitgeber time (ZT) 6 (A) or ZT 16 (B) does not appear to shift the peak
neuronal firing rate on Day 2 of recording (as compared to the time of normal peak
firing, ZT 6, indicated by the dotted line.
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Figure 4.3: Hypothesized reciprocal feedback between MMP-2/9 and NMDAR
activity in the SCN.
In the suprachiasmatic nucleus (SCN), presynaptic and/or astrocytic glutamate release
activates N-methyl-D-aspartate receptors (NMDARs) and increases intracellular Ca2+
concentrations ([Ca2+]i). This signals the release of pro-matrixmetalloproteinase (proMMP) zymogens into the extracellular space (ECS) and regulates the molecular
transcriptional translational feedback loop (TTFL) oscillator. Further, the plasminogen
activation cascade is also activated [i.e, tissue- and/or urokinase plasminogen activator
(tPA/uPA) cleaves plasminogen into plasmin]. As a result, plasmin can activate both proMMP-2 and pro-MMP-9. Additionally, MMP-2 can catalytically activate pro-MMP-9. We
propose that circadian activity of MMP-9 in the SCN degrades extracellular matrix (ECM)
molecules, cleaves cellular adhesion molecules (CAMs) and cleaves pro-brain derived
neurotrophic factor (pro-BDNF) into its mature form (mBDNF). We predict that 1)
degradation of ECM molecules could influence astrocytic morphological changes, 2)
MMP-9 mediated cleavage of an unknown CAM disrupts NMDAR-CAM interactions and
decreases NMDAR activity, 3) plasmin and MMP-9 activity increases mBDNF
concentration in the ECS, increasing mBDNF binding to tyrosine kinase B (TrkB)
receptors and positively influences NMDAR priming/activation via phosphorylation.
Therefore, the level of MMP-2/9 activity can either positively or negatively affect NMDAR
activity.

120

Figure 4.3 continued
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Figure 4.4: MMP-9 participation in SCN circadian clock regulation.
During the day [Zeitgeber time (ZT) 6], MMP-9 proteolytic activity (illustrated by yellow
stars), but not MMP-2, is highest and cleavage of one or multiple unidentified CAMs keeps
NMDAR activity low. Levels of plasmin, pro-BDNF and mBDNF are all at their lowest and
TrkB phosphorylation of NMDAR is minimal. This time coincides with the lowest
concentration of endogenous, extracellular glutamate ([Glu] e) release by quiescent,
amoeboid astrocytes bound to β-dystroglycan. Further, spontaneous neuronal activity in
the SCN is highest at ZT 6, leading to increased intracellular Ca2+ levels ([Ca2+]i) and
membrane voltage (Vm) in postsynaptic neurons. Across circadian time, the level of βdystroglycan does not change, but we propose that astrocytes continue to utilize this
molecule to facilitate their morphological changes throughout the course of the day. The
high level of MMP-9 activity during the day clears away ECM molecules in the synaptic
space and facilitates the astrocytic transition to a more ramified state during the early
night (ZT 16). At ZT 16, increased astrocytic [Glu]e secretion, NMDAR-NR2B subunit
expression, plasmin-mediated maturation of BDNF (mBDNF), and TrkB phosphorylation
of NMDARs all contribute to increased sensitivity of night-time NMDARs. However, MMP9 CAM cleavage continues, which decreases the probability of NMDAR activation.
Therefore, spontaneous SCN activity reaches its nadir at night and phase delaying the
clock requires aberrant light stimulation or exogenous glutamate application. During the
late night (ZT 23), MMP-9 activity is at its lowest level and intact CAMs are able to stabilize
NMDARs on the post-synaptic membrane. Astrocytes, now in their most ramified state,
begin to increase their colocalization with -dystroglycan molecules and decrease
secretion of [Glu]e. However, NR2B expression and activity of the plasminogen activation
cascade is still high, which increases the level of primed NMDARs that, when activated,
can phase advance the clock.
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Figure 4.4 continued
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Figure 4.5: The effects of MMP-2/9 inhibition on NMDAR are time dependent.
Blocking MMP-2/9 activity, with the inhibitor BiPS (signified by the red X), in SCN tissue
during the day (ZT 6) eliminates MMP-9 mediated cleavage of CAMs. The conformation
and/or amount of membrane bound CAMs is now favorable for interaction with NMDARs,
which increase the sensitivity of existing NMDARs. Although the expression of plasmin
and pro-BDNF are low, activation of TrkB still occurs and phosphorylates NMDARs,
further priming them for activation. Therefore, although astrocytic derived concentrations
of extracellular glutamate are low, NMDARs are sufficiently activated to initiate a phase
advance of the clock. Inhibitors targeting plasmin (α -2-antiplasmin) or TrkB (K-252A) are
effective in blocking BiPS induced phase shifts, because the phosphorylation of NMDARs
(indicated by yellow dots in figure) is blocked as well. At ZT 16, BiPS can induce a phase
shift because although MMP-9 activity begins to wane, enough CAMs remain intact and
TrKB mediated phosphorylation is enough to sufficiently prime a level of NMDARs that
can be activated by astrocytic [Glu]e, which is also at its peak. However, the same
concentration of α-2-antiplasmin or K-252A applied during the day is now ineffective to
block the BiPS phase shift, as the endogenous level of plasmin/TrkB activity is much
greater at ZT 16 than ZT 6. Lastly, MMP-2/9 inhibition at ZT 23 has no effect on the
circadian master clock, because MMP-9 activity at this time is at its lowest and [Glu]e is
declining. Therefore, BiPS does not initiate a great enough response to initiate the
required amount of NMDAR activity to phase shift the clock. However, plasmin/TrkB
activity remains high, so exogenous glutamate application could phase shift the clock.
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Figure 4.5 continued
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Table 1. Primary Antibody Information
Primary Antibody
(Information; Catalog#, Manufacturer)
Actin, I-19:
(Polyclonal;sc-161 Santa Cruz)

Application
(dilution)

Host

WB (1:5000)

Goat

β-dystroglycan:
(B-DG-CE, Lyophilised Concentrated IHC (1:500)
monoclonal; Leica Novocastra)

Mouse

β-dystroglycan
(Polyclonal; ab43125, Abcam)

WB, IHC (1:500)

Rabbit

GFAP
(Polyclonal; ab4674, Abcam)

IHC (1:100)

Chicken

MMP-2
WB (1:1000)
(Polyclonal; MAB13406 EMD Millipore)

Rabbit

MMP-9
(Polyclonal; AB19016, Abcam)

WB (1:1000)

Rabbit

p-CAMKII; Thr 286
(Polyclonal; p1005-286)

WB (1:500)

Rabbit
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Table 2: Secondary Antibody Information
Secondary Antibody
(Information; Catalog#, Manufacturer)
Fluorescent Dyes:

Application
(dilution)

Host

Anti-Rabbit IgY (H+L), Alexa Fluor 488
(A-11041, Invitrogen)

IHC (1:1000)

Goat

Anti-Chicken IgY (H+L), Alexa Fluor 568
(A-21206, Invitrogen)

IHC (1:1000)

Goat

IRDye® Anti-Rabbit-800 CW
(925-32213, LI-COR)

WB (1:5000)

Donkey

IRDye® Anti-Goat-680 RD
(925-68074, LI-COR)

WB (1:5000)

Donkey

Infrared Dyes:
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Supplementary Protocols
Western Blotting for Protein Expression
This protocol was developed to isolate proteins from the suprachiasmatic nucleus
(SCN), separate them, and detect them with immunoblotting. It is written specifically for
use with the Life Technologies “Bolt” electrophoresis system and detection using the
Odyssey Clx laser detector. You will need SCN tissue slices, 500uM thick, from one
mouse (2 slices per mouse). The Odyssey system is very sensitive to low protein
quantities, so this reduces the amount of tissue used. Keep the slices in the -80 °C
freezer until use.
Protein Extraction Protocol:
1. Prepare Lysis buffer:
RIPA buffer

490 uL

Protease inhibitor

5.00 uL

Phosphatase inhibitor

5.00 uL

2.

Add 40 uL of Lysis buffer to each sample tube.

3.

Sonicate each sample x 10 pulses.

4.

Place on rotator in cold room for 25 minutes.

5.

Prepare the Bradford assay and turn on the spectrophotometer.

6.

Fill six centrifuge tubes (standard tubes will be labeled 0-5) plus one centrifuge
tube for each sample you are extracting protein from with 1 mL of Bradford
reagent.

7.

Add BSA (2.0mg/mL) to each standard tube in the following amounts
1. Tube 0 = 0 uL

BSA= 0 g

2. Tube 1= 1.00 uL

BSA= 2 ug

3. Tube 2= 2.50 uL

BSA= 5 ug

4. Tube 3= 5.00 uL

BSA= 10 ug

5. Tube 4= 7.5-0 uL

BSA= 15 ug

6. Tube 5= 10.0 uL

BSA= 20 ug

5.

Centrifuge samples on max speed for 2 min.

6.

Sonicate samples x 5 pulses.
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7.

Centrifuge samples for 10 minutes on max speed (13,000 rpm).

8.

Remove and measure supernatant.

9.

Calculate uL of sample to = 15 ug total protein
15 g ÷ (concentration measured using Bradford )= # uL
sample to add to sample tube.

10.

Create a table in your notebook that contains these headings and record

volumes of solution required for each sample.
Sample Concentration
ZT #

(Bradford)
ug/uL

uL
Sample
X uL
*see
above

Reducing
Buffer
4.0 uL

Sample
Buffer
12.0 uL

H2O

Total

[40-(4-12X)] uL

40
uL

11.

After prepping Loading Samples, boil them at 80 °C for 10 minutes.

12.

Prepare 1 X MOPS buffer – need at least 500 mLs per gel.

13.

Place a 4-12% Bolt Pre-cast Gel into the Bolt electrophoresis box and pour the
MOPS buffer into the box, enough to cover the gel.

14.

Load samples into the gel, along with 5 uL of Kaleidoscope Ladder (BioRAD)
(If the last lane does not contain sample, load 12 uL of loading dye into the last
well for balance).

15.

Run gel @ 150 volts until proteins are completely separated ~1.00 hour

Protein Transfer Protocol:
1.
Prepare 1 X Transfer Buffer if not already made. The recipe will be on the 5X
Transfer buffer bottle.
2.

Remove gel from cassette and equilibrate in 1 X Transfer Buffer for 10 minutes.

3.

Activate the Immobilon membrane with methanol, then equilibrate for 5 minutes
in 1 X transfer buffer.

4.

Cut enough chromatography paper to act as your filter papers for the transfer.
Need six squares.

5.

In the transfer box, begin to make your Protein Transfer Sandwich:
i. Bottom: Filter Paper
ii. Second Layer: Immobilon Membrane
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iii. Third layer: Gel
iv. Top/ Final Layer: Filter paper

6.

Lock the transfer cassette and load into the TransBlot Turbo

7.

Select the correct Transfer program to run. This will depend on how large your
proteins of interest are.

8.

Remove Cassette when finished, trim the membrane, and place into a gel box to
dry.
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Gelatin Zymography Protocol
Adapted from Toth and Fridman, 2001 and Kupai et al., 2011
Solution Preparation:
All solutions can be stored at room temp, ESPECIALLY the sample buffer.
Homogenization Buffer (500 mL)
0.335 g Tris Base
1.00 mL Triton X 100
-Dissolve ~500 mL ddH2O, adjust pH to 7.4.
Renaturing Buffer (250 mL)
6.25 mLs Triton X 100
-Dissolve in 250 mLs H2O
Incubation Buffer (500 mL)
4.383 g NaCl
0.735 g CaCl2*2H2O
3.0285 g Tris Base
0.5 g NaN3 (or 5 mLs of 5% w/v aqueous NaN3)
-Dissolve in 500 mL ddH2O, adjust pH to 7.8-8.0
Running Buffer (2.0 L)
28.83 g Glycine
6.00 g Tris Base
2.00 g SDS
-Dissolve in 2000 mL H2O
Sample Buffer
Ordered from BioRAD.
Gelatin Zymograms
Supplied by Invitrogen, compatible with BOLT electrophoresis system.
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Protein Extraction for Zymography:
Remember to always keep your samples containing enzyme on ice! Also work
quickly because you are trying to preserve the enzymatic activity of the
metalloproteinases.
1.

Add 10 uL of homogenization buffer per slice to each sample tube.

2.

Homogenize on ice using an electric pestle 3 x 5 sec.

3.

Centrifuge samples at 13,000 rpm for 15 minutes.

4.

Collect and measure the amount of supernatant.

5.

Prepare a Bradford assay and measure protein concentration (instructions can
be found in the Western Blotting Protocol) of the supernatant.

6.

Remove the gelatin zymogram from the plastic wrapper and load into the
electrophoresis tank, allow to equilibrate in running buffer for a short time (about
5 min) and wash the inside of the lanes with running buffer using a 200 uL
pipette.

7.

Calculate how much supernatant you will need in order to load 15 ug of protein
per lane.

8.

Add 30 uL of sample buffer to a new centrifuge tube for each sample.

9.

Add dd H2O to the sample buffer so that:
(x uL protein + 30 uL sample buffer + x uL H2O)= 40 uL

10.

Add extracted protein sample (supernatant) to sample buffer + water.

11.

Load your prepared samples into the gelatin zymogram.

12.

Run the gel at 75 volts for ~2 hours or until the samples are completely
separated. Running at low voltage for a long time works the best because you do
not want the gel to heat up too much, which can degrade the protein samples.

13.

Remove gel from the tank and cassette and place into a box containing
renaturing buffer.

14.

Incubate while on a rocker at room temp for 40 min.

15.

Decant the renaturing buffer of the gel and rinse with incubation buffer.

16.

Pour off the incubation buffer and add fresh incubation buffer to cover the
zymogram.

17.

Incubate gel at 37°C for 5 days.
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a. Depending on the amount of MMP-2/9 in the sample, the gel may take
less time to incubate at 37°C. If the amount of MMP-2/9 in your sample is
unknown, check after 24, 48, or 72 hrs for bands of gelatinolytic activity.
18.

Decant the incubation buffer off of the gel and stain in Coomassie Blue for 1
hour.

19.

De-stain the gel using a solution containing 4% methanol/ 8% acetic acid. Check
the gel every 15 minutes for gelatinolytic bands (clear bands signifying degraded
gelatin or “potential proteolytic activity”), add new de-staining solution as needed,
until the bands appear.

20.

Image on the LICOR Odyssey Clx and analyze signal intensity of bands using
ImageStudio Lite.
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In Situ Zymography Protocol
1.

Make brain tissue slices and maintain in perfusion dish until desired collection
time.

2.

Collect tissue using a flat spatula and paintbrush at specified time points, with or
without drug treatment.

3.

Place in mold filled with OCT media and freeze on dry ice immediately.

4.

Store in -80C until ready to section.

5.

Make MMP activity/development buffer (NaCl 100 mM, CaCl2 10 mM, Tris-HCl
100 mM, 0.05% Brij-35, ph 7.5 (George et al., 2010)
To make 500 mLs:
a) NaCl=

2.922

g

b) CaCl2=

0.5549 g

c) Tris HCl=

6.057

d) Brij-35 (30% stock)

833

g
uL

Fill to 500 mL with ddH20 and pH to 7.5.
6.

Prepare DQ-Gelatin media:
a) Prepare a 1.0 mg/mL stock solution of the DQ-Gelatin by adding
1.0 mL of MMP buffer (diluted 1:10) directly to one of the five
vials containing the lyophilized substrate. It may be necessary to
agitate the sample in an ultrasonic water bath for ~5 minutes
and heat to 50°C to facilitate dissolution.
b) Protect from light at store at 4°C for up to 2 months.

7.

Section tissue using the Leica Cryostat (-20°C) to a thickness of 10 m.

8.

Draw around sections with a hydrophobic pen.

9.

Dilute stock DQ-Gelatin substrate 1:50 in MMP buffer to obtain a working
concentration of 20 ug/mL.

10.

Place ~300 uL of substrate on each slide.

11.

Place damp tissue paper onto the bottom of a dark color slide box.

12.

Place up to 8 slides in the box, balancing the slides on the plastic slide
separators.

13.

Place in 37 °C oven/incubator overnight.
182

14.

Wash three times for one minute in 1X PBS.

15.

Mount sections using coverslips and drop of Vectashield with DAPI.

16.

Image slides on a fluorescent inverted or confocal microscope that contains a
488 nm laser and analyze the signal intensity (mean grey value) using ImageJ
Fiji.

Note: Always include a slide to serve as a negative control that has 4% PFA,
BiPS, EDTA, or TIMP protein as a negative control. Can also Include a negative
control with absence of DQ-Gelatin substrate.
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Immunohistochemistry of Thin Sections on Slides Protocol
Tissue preparation of freshly harvested brain tissue:
1.

Thaw 4% PFA, treat slices with PFA for 15 minutes at room temp, on shaker.

2.

30% Sucrose/PBS treatment at RT for ~30 minutes or until tissue sinks to bottom
of vial.

3.

Cryo-protect in O.C.T. medium (on dry ice) and note orientation of brain slice.

4.

Proceed to cryosectioning or store at -80°C.

5.

Using the Leica Cryostat set at -20°C, section tissue at 10 µm (thickness of
tissue will depend on what protein you wish to detect) and mount onto Histobond
slides.

6.

Air dry for 30 minutes at room temperature. Slides can be stored at -80°C for
several months.

General Immunostaining Protocol (each slide holds about 300-500 µL):
1.

When staining cryostat sections stored in the -80°C freezer, thaw the slides at
room temperature in the fume hood (to maintain sterility and provide air flow) for
10-20 minutes.

2.

Surround the tissue with a barrier using a pen containing hydrophobic compound.

3.

Add 4% PFA to the tissue slices and fix for 10 minutes at 4°C.

4.

Wash slides at room temperature with 1X PBS, 3 X 5 minutes with gentle
agitation.

5.

Block tissues by incubating in blocking buffer (10% Normal Goat Serum or BSA,
0.5% Triton-X in 1X PBS) for 30 minutes at room temperature. The composition
of the blocking buffer is dependent on the antibody used. Check manufacturer
specifications to aid selection of blocking buffer.

6.

Apply primary antibodies diluted in blocking buffer (5% Normal Goat Serum or
BSA, 0.25% Triton-X in 1X PBS) at room temperature for X hours or overnight at
4°C (to be determined by specific antibody, generally 1:500-1:1000).

7.

Wash slides at room temperature three times for 15 minutes each in 1X PBS with
gentle agitation.
184

8.

Apply secondary antibody diluted in blocking buffer (5% Normal Goat Serum or
BSA, 0.25% Triton-X in 1X PBS) at room temperature, X hours (to be determined
by specific antibody, generally 1:1000).

9.

Wash slides at room temperature three times for 15 minutes each in 1X PBS with
gentle agitation.

10.

Coverslip with VectaSheild mounting media containing DAPI.

11.

Image slides on an inverted or confocal microscope.
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Colocalization Using Coloc 2 ImageJ Analysis Protocol
1.

Open 60X image files corresponding to green and red channels gathered from
confocal microscope.

2.

Set image scale to 0.4125 µm.

3.

Merge the image to color code the images and then split these so that there are
two color channels, noting which channel corresponds to the primary/seconday
antibody labeling scheme.

4.

Open simple neurite tracer (Longhair et al 2011). This will allow us to load
previously analyzed traces of astrocyte cells onto their corresponding image to
create a region of interest. We will look for colocalization of GFAP an Betadystroglycan on the astrocyte.

5.

Load the trace file for whichever cell will be analyzed in this image. A powerpoint
file should be included labeling cell numbers on each image. Be sure to load
correct image number and cell number trace files on the correct image.

6.

Use the ROI freehold tool to outline the edges of the loaded cell trace on one of
the images. Try to keep this ROI as close to the outline of the cells as possible so
we minimize background noise. This can be done by clicking analyze → tools →
ROI manager, or by simply clicking “control” and “M” This ROI will continue in the
same position throughout the z-stack. Be sure to outline the ROI based on the
outermost endpoint of the astrocyte tracing. Once the ROI is obtained, you may
close out of Simple Neurite Tracer.

7.

Click on the new ROI, then on the other image. Then click “control” + “shift” + “E”
to apply this same ROI to the other image. Since we are only interested in
colocalization on the astrocyte and not on other neuron cells, this will give us the
most accurate estimation of colocalization on astrocyte extensions.

8.

Make sure to convert the image you loaded the trace file onto back to 16-bit.

9.

Launch Coloc 2. This program will measure the pixel intensity correlation over
the ROI and use our selected statistical analysis to quantify.

186

10.

Choose the two-color ROI channels that we just made. Select ROI in channel 1
for mask. Threshold regression → bisection. Do not check of the excess
statistical analysis, Pearson’s test will run automatically.

11.

Choose to run Pearson’s coefficient test (GET REFERENCE), a multipurpose
test for measuring the statistical association between two variables with a value
ranging from -1 to +1. This will show linear correlation of colocalization between
the two regions of interest, without being affected by background fluorescence in
the images. This is a general analysis, if results are promising after Pearson’s
test, there are other tests that can be run using Coloc 2 to classify colocalization.

12.

Click “OK” to run the analysis.

13.

A window will pop up with values and one will pop up with a picture, close the
picture window and save the data.

14.

Save these results as a PDF file. Name the PDF: (Image #) Cell (#) Pearson

187

Simple Neurite Tracer and Sholl Analysis Protocol
Adapted from Tavares et al., 2017 and the Simple Neurite Tracer (SNT) online
tutorial provided by ImageJ (NCBI).

1.

Note where files are located in your lab notebook.

2.

Make sure to note in your lab notebook which file you are analyzing for that day
and where on the computer you have saved your information. Additionally, if not
already created, create a “Final Results” Excel document that will combine your
data for later analysis.

3.

Open the software program ImageJ-Fiji, located on the desktop.

4.

Open the two files you wish to analyze, one should be the DAPI (405nm) channel
and the other channel should correspond to the wavelength the glial cell was
labeled (i.e., 488 nm = green or 561 nm = red). Note in your notebook the
magnification used to capture your images.

5.

Merge the two channels together (Image ColorMerge Channels…) and
identify glial cells that have nuclei.

6.

Scroll through the image, determine how many cells can be analyzed from it,
where the center of the cells are located and record the number of cells on an
Excel document.

7.

Close both images and re-open the black and white image containing the glia.

8.

Set the scale by clicking (Image🡪Properties🡪and set the length to:

9.



0.4125 uM for a 40X image taken with the Olympus confocal.



0.2310 uM for a 60X



0.1605 uM for a 100X image

Click Plugins Segmentation Simple Neurite Tracer, a window will pop up,
select “Yes” and Click “Ok”.

10.

Place your cursor over the center of the nuclei and click to start a path. This will
be the origin of the first branch (path) and the center of all other paths that all
primary branches of the glial cell originate.
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11.

Starting with the longest branch first, place your cursor over the start of the glial
branch and click. You’ve now created one path. Use the keyboard shortcut [Y] to
confirm the segment.

12.

As you are extending the segment, you can go back to the original Z-stack of
images and scan throughout them to confirm the position and direction of the
branching. This is also helpful to determine if a branch is a part of the current cell
you’re analyzing or an entirely different glia cell.

13.

Continue along filapodia, pressing [Y] as you’re extending the branch, when you
reach the end of the branch, press the keyboard shortcut [F] to finish.

14.

Select the “(0)” path in the Path List and make sure it is highlighted in green.

15.

Now, the rest of the branches (paths) you trace should connect to the center of
the first path. To create a new path from the same origin, hold [Ctrl]+[Shift] and
click on the origin.

16.

Identify another primary branch and click on where it meets the soma of the cell
and press [Y].

17.

Continue tracing the branch and press [F] when finished.

18.

Complete for all primary branches, in sequence of longest to shortest primary
branch.

19.

To add a secondary branch to one of the primaries, make sure the primary
branch of interested in selected in the path window and highlighted in green on
your image.

20.

Select the start of the secondary branch and trace.

21.

Continue until the whole cell is traced.

22.

Save the traces file by clicking “File” “Save Traces File”. Save the file name as
“Traces file_ [Full Image Name].

23.

Select all the paths.

24.

Click the “Fill out” button.

25.

Hit “Pause” in the dialog box that opens.

26.

Click around all the paths until you get a satisfactory fill volume. Meaning that
the extent of the green coloring matches the correct pixel density on your image.
Setting the transparent fill display helps see through the bright green fill volumes
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that have now appeared. You can also zoom in to help and scroll through the Z
stack of images to ensure that each layer of the cell is correctly filled in with
green coloring.
27.

Click Save fill and save the file name as “Fill Volume_[Full Image Name]”.
Additionally, copy and paste the information into a “Final Results” excel
document.

28.

Create a CSV file by clicking [Export as CSV]. This gives the volume of the cell
in a CSV.

29.

Click on the center point and make sure the correct path is selected (a blue dot
should appear).

30.

Double check the Preview Plot (by clicking corresponding buttons) and visually
confirm that your intersections (y axis) and length measurements (X axis)
represent the cell you traced. The Sholl Image may or may not be helpful, but
it’s a heat map/visual representation of the frequency of intersections as the
concentric circles are drawn around the cell.

31.

Save Sholl profile. File name= ““Sholl Profile_ [Full Image Name]”.

32.

Run Analyze profile.

33.

Save the files for each of the windows that pop up in their corresponding folders
(Location= Analyzed TracesGroup #. Save as:


“Sholl Results_ [Full Image Name]” complete results for the cell
traced. Add the Sholl Results to your “Final Results” excel
document.



“Tracings_ [Full Image Name]”: complete list of lengths for each
branch traced.



“Loglog_ [Full Image Name]”: file contains log intersections vs.
length plot.



“Linear_ [Full Image Name]”—the linear graph, contains Rcoefficient
 If there are multiple cells for each image name, include Cell
# right before the image name in the file name. i.e.,
“Linear_Cell 1_[Full Image Name]”—
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 For each cell traced there should be seven files saved.
 Celebrate because you just traced a glial cell! Continue with
the next cell and images. Making sure to update the Excel
file the analysis for each file is completed.

Tips: If you are not 100% sure that a branch belongs to one cell or another, do not
include it. To maintain consistency, we will only draw tracings that we are positive
belong to the cell.
Take notes of any images that are odd or you have questions about.
To readjust the position of a trace that you loaded on a new image or old image: The
simplest way would be to export your tracings as SWC, then re-import using “File> Load
Traces/(e)SWC…”, selecting the “Apply offset to SWC file co-ordinates” option and
specifying the X, Y and Z offsets.
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Astrocyte Soma Cell Body Fill Volume Protocol
Goal: To measure the fill volume in um of the astrocyte’s soma only.

1. Open ImageJ Fiji. Open the image file you wish to analyze.
2. Go to properties and set the unit of length as um, and the pixel height, width, and
depth as .4125. Click the box titled “global” so this scale will stay for all
subsequent confocal images you analyze.
3. Open the Simple Neurite Tracer plug-in and load onto the image the trace of the
cell which you are about to analyze.
4. Scroll through the Z-stack to make sure you have loaded the correct trace file
onto the correct portion of the image.
5. Making sure to start a new path that is not connected with any of the previous
path traces, make a single segment that goes across the longest portion of the
cell body. Once this segment is completed, click on it and rename it as “Soma”.
6. Save this new trace file under folder “Soma Volume Trace File,” being sure to
include file code and cell number. (i.e. “B15Cell1Trace”)
7. Select ONLY the new path you have made and select “Fill Out”. Then, select
transparent fill display and click pause, this will help you get a more accurate fill
volume.
8. Click on the edges of the soma, going throughout the Z-stack, to make sure you
have the most accurate and precise fill volume for the soma. If needed, you can
adjust the brightness and contrast of the image to check the fill for accuracy.
9. Once you have selected the best fill volume fit for the cell, click save fill and then
export as CSV. Save this in the Soma Fill Volume Folder, as “File#Cell#Fill”
10. Do this for all astrocytes and then condense each fill volume file into a single
excel sheet.
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